CLINICAL STUDY PROTOCOL
Study Title: A Phase 1b, Randomized, Blinded, Placebo -Controlled 
Dose -Escalation Study of the Safet y and Biological Activity of 
GS-9620 in HIV -1 Infected, Virologically Suppressed Adults
Sponsor: Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
IND Number :
EudraCT Number :
Clinical Trials.gov Identifier :122452
Not Applicable
[STUDY_ID_REMOVED]
Indication: HIV-1 Infection
Protocol ID: GS-US-382-1450
Clinical Program Manager : Name:
Telephone:
Fax:
Gilead Medical Monitor : Name:
Telephone:
Fax:
Mobile :
Gilead Study Director: Name:
Telephone:
Fax:
Mobile:
Protocol Version/Date: Amendment 7: 16 January 2019
Amendment 6: 07 June 2018
Amendment 5: 18October 2017
Amendment 4: 13 October 2016
Amendment 3: 29June 2015
Amendment 2: 15 December 2014
Amendment 1: 14November 2014
Original: 16September 2014
CONFIDENTIALITY STAT EMENT
The information contained in this document, particularly unpublished data, is the property or under
control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, potential 
investigator, or consultant, for review by you, your staff, and an applicable Institutional Review Board or 
Independent Ethics Committee. The information is only to be used by you in connection with authorized 
clinical studies of the investigational drug described in the protocol. You will not disclose any of the 
information to others without written authorization from Gilead Sciences, Inc., except to the extent 
necessary to obtain informed consent from those persons to whom the drug may be administered.
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD(rJ GILEAiJ 
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 2 16 January 2019TABLE OF CONTENTS
TABLE OF CONTENTS .............................................................................................................................................. 2
LIST OF IN- TEXT TABLES ........................................................................................................................................ 5
LIST OF IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOC OL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 19
1. INTRODUCTION .............................................................................................................................................. 23
1.1. Background ............................................................................................................................................ 23
1.2. GS-9620 ................................................................................................................................................. 24
1.2.1. General Information ............................................................................................................. 24
1.2.2. Preclinical Pharmacology and Toxicology ........................................................................... 25
1.2.3. Clinical Trials of GS -9620 ................................................................................................... 27
1.3. Rationale for This Study ........................................................................................................................ 31
1.4. Rationale for Dose Selection/Dosing Interval ........................................................................................ 32
1.5. Rationale for Biomarker Testing ............................................................................................................ 33
1.6. Com pliance ............................................................................................................................................ 34
2. OBJECTIVES ..................................................................................................................................................... 35
3. STUDY DESIGN ................................................................................................
................................................ 36
3.1. Endpoints ............................................................................................................................................... 36
3.2. Study Des ign.......................................................................................................................................... 36
3.3. Study Treatments ................................................................................................................................... 38
3.4. Duration of Treatment ............................................................................................................................ 39
4. SUBJECT POPULATION .................................................................................................................................. 40
4.1. Number of Subjects and Subject Selection ............................................................................................ 40
4.2. Inclusion Criteria (All Cohorts) ............................................................................................................. 40
4.3. Exclusion Criteria (All Cohorts) ............................................................................................................ 42
4.4. Other Protocol Restrictions .................................................................................................................... 43
5. INVESTIGATIONAL MEDI CINAL PRODUCTS ........................................................................................... 44
5.1. Randomization, Blinding and Treatment Codes .................................................................................... 44
5.1.1. Procedures for Breaking Treatment Codes ........................................................................... 44
5.2. Description and Handling of GS -9620 and Placebo to match ................................................................ 45
5.2.1. Form ulation .......................................................................................................................... 45
5.2.2. Packaging and Labeling ....................................................................................................... 45
5.3. Dosage and Administration of GS -9620 ................................................................................................ 45
5.3.1. Fasting and food/liquids Requirement .................................................................................. 45
5.3.3. Storage and Handling ........................................................................................................... 47
5.4. Prior and Concomitant Medications ....................................................................................................... 48
5.5. Accountability for GS -9620 ................................................................................................................... 50
5.5.1. Investigational Medicinal Product Return or Disposal ......................................................... 50
6. STUDY PROCEDURES .................................................................................................................................... 51
6.1. Subject Enrollment and Treatment Assignment ..................................................................................... 51
6.2. Pretreatment Assessments Screening Visit (all cohorts) ........................................................................ 51
6.2.2. Pre-Baseline/Day -13 Assessments (all Cohorts) ................................................................. 53
6.2.3. Baseline/Day 1 Assessments (all C ohorts) ........................................................................... 54
CCI-
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 3 16 January 20196.3. Treatment Assessments (Cohorts 1 to 3) ................................................................................................ 56
6.3.1. Treatment Assessments on Non Dosing Days 3, 5, 11, 17, 19, 25, 31, 33, 
39, 45, 47, 53, 59, 61, 67, 73, 75 and 81 .............................................................................. 56
6.3.2. Treatment Assessments on Non Dosing Days 8, 22, 36, 50, 64 and 78 ............................... 57
6.3.3. Treatment Assessments on Dosing Days 15, 29, 43, 57 and 71 ........................................... 57
6.4. Treatment Assessments (Cohorts 4 to 9) ................................................................................................ 59
6.4.1. Treatment Assessments on Non Dosing D ays 2, 58 and 128 ............................................... 59
6.4.2. Treatment Assessments on Non Dosing Days 3, 59 and 129 ............................................... 60
6.4.3. Treatment Assessments on Non Dosing Days 8, 22, 36, 50, 64, 78, 92, 
106, 120 and 134 .................................................................................................................. 60
6.4.4. Treatment Assessments on Dosing Days 15, 29, 43, 57, 71, 85, 99, 113 
and 127 ................................................................................................................................. 61
6.4.5. Treatment Assessments on Non Dosing Days 31, 45, 73, 87, 101 and 115 
(For Cohorts 5 to 9 only) ...................................................................................................... 63
6.5. Post-treatment Assessments ................................................................................................................... 64
6.5.1. End of Study Visit (all Cohorts) ........................................................................................... 64
6.5.2. Early Study Drug Discontinuation Visit (all Cohorts) ......................................................... 65
6.6. Criteria for Discontinuation of Study Treatment .................................................................................... 66
6.8. Prolo nged Viremia ................................................................................................................................. 67
6.8.1. Management of Prolonged Viremia ..................................................................................... 67
7. ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 68
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ................................. 68
7.1.1. Adverse Events ..................................................................................................................... 68
7.1.2. Serious Adverse Events ........................................................................................................ 68
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events ......................................................................... 69
7.2. Assessment of Adverse Events and Serious Adverse Events ................................................................. 69
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 69
7.2.2. Assessment of Severity ........................................................................................................ 70
7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to Gilead ...............................................................
........................................................ 70
7.4. Gilead Reporting Requirements ............................................................................................................. 72
7.5. Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or 
Serious Adverse Events .......................................................................................................................... 72
7.6. Toxicity Management ............................................................................................................................ 73
7.6.1. Management of Dose -Limiting Toxicities (DLTs) ............................................................... 73
7.6.2. Management of Other Toxicities .......................................................................................... 74
7.7. Special Situations Reports ...............................................................
....................................................... 75
7.7.1. Definitions of Special Situations .......................................................................................... 75
7.7.2. Instructions for Reporting Special Situations ....................................................................... 76
8. STATISTICAL CONSIDER ATIONS ................................................................................................................ 78
8.1. Analysis Objectives and Endpoints ........................................................................................................ 78
8.1.1. Analysis Objectives .............................................................................................................. 78
8.1.2. Primary Endpoint ................................................................................................................. 78
8.1.3. Secondary Endpoint ............................................................................................................. 79
8.1.4. Other Endpoints of Interest .................................................................................................. 79
8.1.5. Exploratory Endpoints .......................................................................................................... 79
8.2. Analysis Conventions ............................................................................................................................. 79
8.2.1. Analysis Sets ........................................................................................................................ 79
8.3. Data Handling Conventions ................................................................................................................... 80
8.4. Dem ographic Data and Baseline Characteristics ................................................................................... 80
CCI
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 4 16 January 20198.5. Efficacy Analysis ................................................................................................................................... 81
8.5.1. Primary Analysis .................................................................................................................. 81
8.5.2. Secondary Analyses ............................................................................................................. 81
8.6. Safety Analysis ....................................................................................................................................... 81
8.6.1. Extent of Exposure ............................................................................................................... 81
8.6.2. Adverse Events ..................................................................................................................... 81
8.6.3. Laboratory Evaluations ........................................................................................................ 82
8.7. Pharm acokinetic Analysis ...................................................................................................................... 82
8.8. Sample Size ............................................................................................................................................ 83
8.9. Safety Evaluation Committee ...............................................................
.................................................. 83
8.10. Analysis Schedule .................................................................................................................................. 83
9. RESPONSIBILITIES ................................
.......................................................................................................... 84
9.1. Investigator Responsibilities .................................................................................................................. 84
9.1.1. Good Clinical Practice .......................................................................................................... 84
9.1.2. Institutional Review Board (IRB) Review and Approval ..................................................... 84
9.1.3. Informed Consent ................................................................................................................. 84
9.1.4. Confidentiality ...................................................................................................................... 85
9.1.5. Study Files and Retention of Records .................................................................................. 85
9.1.6. Case Report Forms ............................................................................................................... 86
9.1.7. Investigational Medicinal Product Accountability and Return ............................................. 87
9.1.8. Inspections ............................................................................................................................ 87
9.1.9. Protocol Compliance ............................................................................................................ 87
9.2. Sponsor Responsibilities ........................................................................................................................ 87
9.2.1. Protocol Modifications ......................................................................................................... 87
9.2.2. Study Report and Publications ............................................................................................. 87
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 88
9.3.1. Payment Reporting ............................................................................................................... 88
9.3.2. Access to Information for Monitoring .................................................................................. 88
9.3.3. Access to Information for Auditing or Inspections .............................................................. 89
9.3.4. Study Discontinuation .......................................................................................................... 89
10. REFERENCES ................................................................................................................................................... 90
11. APPENDICES .................................................................................................................................................... 92
Appendix 1. Investigator Signature Page .................................................................................................... 93
Appendix 2. Study Procedures Table .......................................................................................................... 94
Appendix 3. Management of Clinical and Laboratory Adverse Events .................................................... 105
Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities ............. 106
Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................. 129
Appendix 6. Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines) ........................... 132
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 5 16 January 2019LIST OF IN -TEXT TABLES
Table 1-1. Estimated Margins of GS -9620 Follow ing Oral Administration at the Highest 
Anticipated Human Dose ....................................................................................................... 27
Table 5-1. Fasting and food/liquids Requirement .................................................................................... 46
Table 5-2
. Recommended Moderate -Fat Meal ........................................................................................ 47
Table 5-3. Prohibited Concomitant Medications ..................................................................................... 49
LIST OF IN -TEXT FIGURES
Figure 3-1. High -Level Study Schema ...................................................................................................... 38
Figure 3-2. Cohort 6 Visit Schema ............................................................................................................ 38
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 6 16 January 2019PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Study Title : A Phase 1b, Randomized, Blinded, Placebo -Controlled 
Dose -Escalation Study  of the Safet y and Biological Activity  of 
GS-9620 in HIV -1 Infected, Virologicall y Suppressed Adults
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:122452
Not Applicable
[STUDY_ID_REMOVED]
Study Centers Planned: Multiple centers in North America
Objectives: The primary  objectives are :
To evaluate the safet y and tolerab ility of escalating, 
multiple dosesof GS -9620 in HIV - 1 infected virologicall y 
suppressed adults on antiretroviral therapy  (ART )
To evaluate the virologic effect of GS
-9620 as measured by 
changes in plasma HIV -1 RNA
The secondary  objectives are:
To evaluate the plasma pharmacokinetics (PK) of GS-9620
To evaluate the pharmacody namics (PD) of GS -9620 as 
measured b y changes in interferon -stimulat ed genes (ISGs)
and serum cy tokines in whole blood compared to placebo
To evaluate effects of GS -9620 on whole blood immune cell 
activation (T cell, B cell, NK cell) 
The explora tory objectives are:
 
 
 
CCII 
I 
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 7 16 January 2019 
 
 
 
Study Design: This is a randomized, double -blinded, multi -cohort
dose-escalation s tudy with dose cohorts: Cohort 1 (1mgDose), 
Cohort 2 (2 mg Dose), Cohort 3 (4mgDose) ,Cohort 4
(6mgDose) , Cohort 5 (8 mg Dose) , Cohort 6 
(three administrations of
10 mg Dose ,followed b y
seven administrations of12 mg Dose ;SEC review of the 10mg 
safet y dat awill be required prior to dose escalating to 12mg ), and 
optional Cohort 7  
 
 
 
 
Two additional optional 
adaptive cohorts, Cohort 8 
 
and Cohort 9 
 
 
 
For each c ohort, eight subje cts will be randomized in a 6:2 ratio 
to receive GS -9620 or placebo. 
Subjects will receive a total of either 6doses in Cohorts 1 to 3 ,
10doses in Cohorts 4 to 6,  
of their assigned study  treatment administered once every  
other week. For all subject sin Cohort 6, Dose 4 (Day  43) will 
CCI
CCI
CCI
CCI
CCII 
-
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 8 16 January 2019occur after SEC review has been completed. If dose escalation is 
approved b y the SEC, subje cts in Cohort 6 will receive 12 mg of 
GS-9620 or placebo from Doses 4 to 10; if dose escalation is not 
approved b y the SEC, subj ects will continue receiving 10 mg of 
GS-9620 or placebo fro m Doses 4 to 10.
Enrollment will initially  be opened for Cohort 1 only . ASEC will 
review stud y progress, safety and virology results of enrolled 
subjects. After all subjects in a cohort have received at least 
three doses (Cohorts 1 to 3, and 6) or five do ses (Cohorts 4 
and5), the SEC will review safety  data from that cohort, 
including adverse events (AEs) and clinical laboratory  results 
(including plasma HIV -1 RNA) before approving the next dose 
escalation.  
A cohort may be suspended if 
≥
2 out of 6 subjects receiving GS -9620 experience one ormore 
dose-limiting toxicities (DL Ts) considered related to study  drug.
Number of Subjects 
Planned:Approximately  up to 72 subjects total ( 6 GS -9620; 2 placebo per 
cohort )
Subjects who discontinue study  participation before completion 
of dosing for rea sons other than stud y treatment -related AEs may  
be replaced
Target Populati on: HIV
-1 infected male and non- pregnant, non -lactating female 
adults who have been virologicall y suppressed 
(HIV-1RNA < 50 copies/mL ) on ART for 
12consecutive months prior to screening
Main Eligibility  Criteria: HIV-1 infection
Aged 18 years at Pre- Baseline/Day  -13
On antiretroviral (ARV) treatment for
12consecutive months prior to Pre
-Baseline/Day -13
The following agents are allowed as part of the current 
ARV regimen: NRTIs, raltegravir, dolutegravir, 
rilpivirine, and maraviroc
The following agents are NOT allowed as part of the 
current ARV regimen: HIV protease inhibitors 
(including low dose ritonavir), cobicistat- containing 
regimens, elvitegravir, efavirenz, etravirine ,and 
nevirapine
CCI
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 9 16 January 2019A change in ARV regimen 45days prior to 
Baseline/Day  1for reasons ot her than virologic failure 
(eg,tolerabilit y, simplification, drug -drug interaction 
profile) is allowed
Plasma HIV -1 RNA < 50 copies/mL  at screening
Documented plasma HIV -1 RNA levels < 50copies/mL  
(according to the local assay being used) for 12months 
preceding the screening visit (measured at least twice using a 
licensed assay  with a lower limit of quantitation of at least 
40copies/mL ) 
Unconfirm ed virologic elevations of ≥ 50 copies/mL  
(transient detectable viremia, or “blip”) prior t o screening 
are acceptable. (If the lower limit of detection of the local 
HIV-1 RNA assay  is< 50 copies/mL , the plasma HIV -1 
RNA level cannot exceed 50 copies/mL  on two 
consecutive HIV -1 RNA tests)
If ARV regimen is changed ≥ 45 day s prior to 
Pre-Baseline/Day  -13, plasma HIV -1RNA <50 copies/mL  
at Pre -baseline/Day  -13 visit is required.
No documented history  of resistance to any  components of the 
current ARV regimen
Availability  of a fully  active alternative ARV regimen, in the 
opinion of the I nvestigator, in the event of discontinuation of 
the current ARV regimen with development of resistance.
Hgb 11.5
g/dL (males) or 11 g/dL (females)
WBC 4000 cells/ μ L
Platelets 150,000/mL
ANC 1500 cells/ μ
L
CD4 count  400cells/ μL
Albumin 3.9 g/dL
ALT and AST 2 ×ULN
Estimated glomerular filtration rate 60mL/min
No autoimmune disease( e.g. lupus ery thematosus, rheumatoid 
arthritis, inflammatory  bowel disease, sarcoidosis, moderate 
or severe psoriasis)
No evidence of current HBV infection
Positive anti -HBs antibody  and negative HBsAg results 
are acceptable
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 10 16 January 2019No evidence of current HCV infection
Positive anti -HCV antibody and negative HCV PCR 
results are acceptable
No documented history of pre -ART CD4 nadir < 200cells/μL
Unknown pre -ART CD4 nadir is acceptable
No history  of Class C AIDS -Defining Condition
No acute febrile illness within 35 day s prior to 
Pre-Baseline/Day  -13
Study  Visits and 
Procedures:Visit Schedule:
The main study  phase consists of a screening period of up to 
35days, a pre-treatment period of 14 Days 
(from Day -13toDay 1), treatm ent period of 71days (Cohorts 1 
to 3),127 day s (Cohorts 4 to 6), 
 and a follow -up period of 30 daysafter the last dose of study  
drug is taken . Enrolled sub
jects will undergo the following 
scheduled stud y visits: 
Cohort 1 to Cohort 3
Day -13 ( Pre-Baseline )
Day 1 (Baseline/ Dose 1 ), Day  3, Day  5, Day  8, Day  11
Day 15 (Dose 2 ), Day  17, Day  19, Day  22, Day  2
5
Day 29 (Dose 3 ), Day  31, Day  33, Day  36, Day  39
Day 43 (Dose 4), Day  45, Day  47, Day  50, Day  5 3
Day 57 (Dose 5), Day  59, Day  61, Day  64, Day  67
Day 71 (Dose 6), Day  73, Day  75, Day  78, Day  81
Day 101 ( End of Study)
Cohort 4
Day -13 ( Pre-Baseline )
Day 1 (Baseline/ Dose 1 ), Day  2, D ay 3, Day  8
Day 15 (Dose 2 ),Day 22
Day 29 (Dose 3 ), Day  36
Day 43 (Dose 4), Day  50
Day 57 (Dose 5), Day 58, Day  59, Day  64
Day 71 (Dose 6), Day 78
Day 85 (Dose 7), Day  92
CCII 
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 11 16 January 2019Day 99 (Dose 8), Day  106
Day 113 ( Dose 9), Day  120
Day 127 ( Dose 10 ), Day  128, Day  129, Day 134
Day 157
(End of Study )
Cohort s 5 to 9
Day -13 ( Pre-Baseline )
Day 1 (Baseline/ Dose 1 ), Day  2, Day  3, Day  8
Day 15 (Dose 2 )
,Day 22
Day 29 (Dose 3 ), Day 31,Day 36
Day 43 (Dose 4 ), Day 45,Day 50
Day 57 (Dose 5 ), Day  58, Day 59, Day  64
Day 71 (Dose 6 ), Day 73,Day 78
Day 85 (Dose 7 ), Day 87, Day 92
Day 99 (Dose 8 ), Day 101, Day  106
Day 113 ( Dose 9 ), Day 115, Day  120
Day 127 ( Dose 10 ), Day  128, Day 129, Day  134
Day 157 ( End of Study)
Subjects who prematurely discontinue stud y drug will be r equired 
to complete an Early  Study  Drug Discontinuation Visit within 
30daysafter their last dose of study  treatment .
The Pre -Baseline/Day  -13 visit has an allowable window of 
±
3days.
Visits scheduled for 2, 4, 7, or 10 days after a Dosing visit, 
except forDay 2, 3, 58, 59, 128 and 129 have an allowable 
window of ± 1day.
The Day  101 and 157 visits
have an allowable window of 
± 3days.
Non-dosing visits may  occur at the investigator site or at other 
location agreed b y the subject andmobile nurse vendor .
Screening Procedures:
Screening procedures include: complete ph ysical examination, 
vital signs, height, weight, medical history  (including route and 
estimated duration of HIV infection, pre -ART viral set point, and 
complete ARV history ), HIV -1 RNA, ARV trough PK, 
hematol ogy, serumchemistry , serum pregnancy  test, urinaly sis, 
HBV andHCV serologies, eGFR, and electrocardiogram (ECG). 
Pre-ART CD4 nadir and historica l genoty pe will be collected 
ifavailable.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 12 16 January 2019In order to establish eligibility , Investigators may  repeat screening 
procedures or laboratory  assessments for subjects who have an 
acute illness or abnormal laboratory  value that is expected to 
resolve without sequelae within the screening window.
On-Study Procedures:
Dosing:
For Cohorts 1 to 3 , dosing visits will occur at Day  1, Day 15, 
Day 29, Day 43, Day 57, and Day  71. For Cohorts 4 to 9 , dosing 
visits will occur at Day  1, Day  15, Day  29, Day 43, Day 57, 
Day 71, Day  85, Day  99, Day  113 and Day  127.
 
For Cohorts 1 to 4
, subjects will fast for at least 
2hours before dosing. For Cohorts 5 to 8, subjects will fast 
overnight (at least 8 hours) before dosing. 
 
The Investigator will verify  the subject’s continued 
eligibility  for dosing at post -Baseline dosing visits, including the 
absence of dose -limiting toxicities (DL Ts) and (for females of 
childbearing potential) a negative urine pregnancy test, prior to 
dosing. All doses will be directly  administered by  blinded site 
staff. Subjects will fast for 2 hours after dosing for all cohorts. 
After Dose 1, subjects will remain on site for 12 hours after 
dosing for safet y assessment and phlebotomy .
Safety:
Solicitation of AEs and concomitant medications and 
symptom -directed phy sical examination at every  visit.
Hematology , serum chemistry , and urinal ysis weekly  for 
Cohorts 1 to 3. For 
Cohorts 4 to 9these labs will be collected on 
dosing day s, seven day s post dose (starting from Dose 4) , at end 
of study,and ESDD .For Cohorts 6  these labs will also be 
collected on Day  2 and two day s post dose (starting from Dose 5).
 
Urine pregnancy  test (for females of childbearing potential) prior 
to each dose.
Vital signs (blood pressure, pulse, respiration rate 
andtemperature) at all dosing visits.
Subjects 
will be instructed to contact the sit e immediatel y if an y 
flu-like sy mptoms are noted (e g,fatigue, py rexia, chills, my algia, 
joint pain or headache).
CCI
CCI
CCI
CCI-
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 13 16 January 2019Pharmacokinetics:
Plasma GS -9620 concentrations will be collected at the following 
time points for all cohorts :
Pre-dose ( ≤5 minutes prior to dosing), 0.5, 1, 2, 4, 6, 8, 10, 
and 12 hours post dose at Day 1; then one sample 48hours 
post dose at Day 3
If the SEC approves 
the dose escalation to 12 mg in 
Cohort 6, starting from Dose 4 and onwards , plasma 
GS-9620 concentrations will also be collected on Day 43
(Dose 4) : Pre-dose ( ≤5 minutes prior to dosing), 0.5, 1, 2, 4, 6, 
8, 10, and 12 hours post dose
; then one sample 48 hours 
post dose at Day  45
 
A single trough ARV PK sample will be collected at 
Pre-Baseline/Day  -13 ( Cohorts 1 to 3) or at Screening, Day 29, 
Day 57, Day  85 and Day 99 (Cohort 5), or at Screening, Day 57 
and Day  99(Cohorts 6
 
The timing of the ARV 
trough collection is to be 20 -24 hours fol lowing the subject’s 
previous QD regimen dose and before next ARV dose (and, for 
any subject on a regimen containing a BID component, the trough 
collection must also occur 8-12 hours following the subject’s 
previous dose of that BID component and before ne xt ARV dose). 
These samples may be analy zed to assess interim ART adherence .
Pharmacodynamics:
Whole blood I SG mRNA panel: For Cohorts 1 to3, immediately  
before and 2 days and 7 day s after each dose of study  drug, and at 
the end of the stud y (Day 101). For Cohorts 4 to 9, immediately  
before and 1 day , 2 day s and 7 day s after doses 1, 4 (only  if 
Cohort 6 subjects receive 12 mg starting at Dose 4 ), 5 and 10.  
TLR7 genot yping: at Pre-Baseline/Day  -13
CCI
CCI
CCI
CCI
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 14 16 January 2019Virology:
Plasma HIV -1 RNA: at every  visit except Pre -Baseline (Day -13).
Cell-associated HIV -1 RNA/DNA ( CAVR/ CAVD) , and plasma 
HIV
-1 RNA by  Single Copy  Assay  (SCA) will be collected 
immediately before and two day s post Doses 1, 4, 6 and at end of 
the study  (Cohort 1 to 3) ;immediately  before and two day s post 
Doses 1, 5, 10 and at end of the study  (Cohorts 4 to 9).  
 
HIV
-1 reservoir measurements :at Pre -Baseline/Day -13 and at 
the end of the stud y (Cohorts 4 to 9).
 
 
Immunology:
Peripheral blood immune cell numbers for T/B/NK/pDC/mDC 
including: CD4 and CD8 
populations, C D4/CD8 ratio, CD4% and 
lymphocy te activation (T, B and NK cells) by  flow cy tometry will 
be collected immediatel y before and two days post Doses 1, 3, 
and 6 
(Cohorts 1 to 3 ), and immediately  before, one and twodays 
post Doses 1, 5 and 10 (Cohorts 4 to 9) . 
 
FoxP3+ Treg cells b y flow cy tometry will be collected
immediately  before Doses 1, 3, and 6 ( Cohorts 1 to 3) , and 
immediately  before Doses 1, 5 and 10 ( Cohort 4 to 9). 
 
 
Changes in the levels of antiviral cytokines and inflammatory  
markers b y chemiluminescence :immediatel y befor e and 2 days 
and 7 days after each dose ,and at the end of the study  (Cohorts 1 
to 3). For subjects in Cohorts 4 to 9, immediately  before, 
post dose day s 1, 2 and 7 after Doses 1, 4 (onl y if Cohort 6
subjects receive 12 mg at Dose 4), 5 and 10.
PBMC I ntracellular cy tokine staining (ICS) for Treg cells:
immediately before and 2 day s after Doses 1 and 6 for subjects in 
Cohorts 1 to 3.
CCI
CCI
CCI
CCI
CCI
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 15 16 January 2019HIV-specific T- cell responses by  ELISPOT will be collected at 
Pre-Baseline/Day -13, immediately  before Dose 6 and at the end 
of study  for subjects in Cohorts 1 to 3. 
For subjects in Cohorts 4 to 9, HIV-specific poly functional T cell 
Intracellular Cy tokine Staining (I CS) and HIV -specific T- cell 
responses b y ELISPOT will be collected at Pre -Baseline/Day -13 
and at the end of the study.
 
Stool sample will be obtained for microbiome analy sis.(Day 1 
and Day  157 for Cohorts 5 to 9 ).  
 
 
 
 
 
 
Additional End of Study Procedures:
Symptom -directed phy sical examinatio n, review of AEs and 
concomitant medications, weight, eGFR, hematology , serum 
chemistry
, urinal ysis, urine pregnancy  test (for females of 
childbearing potential, if not performed within the previous 
30days).
Early Study Drug Discontinuation Visit Procedur es:
Symptom -directed phy sical examination, review of AEs and 
concomitant medications , weight, eGFR, HIV -1 RNA, 
hematology , serum chemistry , whole blood ISG mRNA panel, 
serum cy tokine/soluble biomarker studies, urinal
ysis, urine 
pregnancy  test.
Procedure De finitions and Specifications :
HIV -1 RNA will be performed by  a licensed assay with a lower 
limit of quantitation of at least 20 copies/mL .
Hematology panel includes: complete blood count (CBC) with 
differential and platelets, CD4+ cell count, CD8+ cell count, 
CD4/CD8 ratio, and CD4%.
CCI
CCI
CCI
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 16 16 January 2019Serum chemistry panel includes: alkaline phosphatase, AST, 
ALT, total and direct bilirubin, total protein, albumin, 
bicarbonate, BUN, calcium, chloride, creatinine, glucose, 
phosphate, magnesium, potassium, sodium, CPK, and uric acid.
Urinalysis includes dipstick. Serum and urine pregnancy tests
are performed only  on female subjects of childbearing potential.
Phlebotomy  volume limits will be maintained in accordance with 
American Red Cross blood donation guidelines, which limit 
blood donation to 473 mL every  56 day s. Subj ects will undergo 
periodic phlebotomy  over a 149 -day period and will provide no 
more than 473 mL every  56 day s. Subjects will be prohibited 
from blood donation in excess of that required for clinical care 
within 30 day s prior to screening and 30 days after study  ends.
Study Treatment:
Investigational 
Medicinal Products:GS-9620: 1 mg, 2 mg, 4 mg , 6 mg (administered as three 2 mg 
tablets), 8 mg (administered as two 4 mg tablets) , 10mg 
(administered as five 2 mg tablets ), 12 mg (administered as
six2mg tablets ,or three 4mg tablets ) dose administered orall y 
once every  other week. 
Reference Treatment: Placebo- to-match GS -9620, administered orall y once every  other 
week. 
Duration of Treatment: The treatment duration is 71 day s (Cohorts 1 to 3), 127 days
(Cohort s
4to 6),  
Other Treatment: Subjects will continue their existing ARV regimen (as currentl y 
prescribed and supplied) for the duration of stud y participation.
Criteria for Evaluation:
Safety : AEs and clinical laboratory  tests will be collected at every  visit 
and summarized through Day  101 or Day  157 (30days after the 
last dose of GS -9620 or placebo).
The following are DLTs:
ALT elevation defined as:
ALT ≥ 10 × ULN OR
confirmed ALT elevation (i .e. grade shift or 2 ×previous 
value) with evidence of worsened hepatic function 
(e.g. total bilirubin > 2mg/dL above Baseline, serum 
albumin > 1g/dL decrease from Baseline)
A confirmed ≥ Grade 3 AE considered by  the investigator to 
be study  drug - related
CCI
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 17 16 January 2019A confirmed ≥ Grade 3 lab abnormalit y considered by the 
investigator to be stud y drug -related and clinically significant
A persistent ( ≥ 72 hours) ≥Grade 2 flu- like sy mptom 
(egpyrexia, fatigue, m yalgia, arthr algia, headache, chills) 
considered b y the investigator to be study  drug -related
A post -dose increase in plasma HIV -1 RNA that fails to 
resolve to < 50copies/mL within 1 0daysin Cohorts 1 to3
A post -dose increase in plasma HIV -1 RNA that fails to 
resolve to < 200copies/mL within 10 day s in Cohort s 4to9
The Investigator will notify  the SEC within 24 hours of an yDLT. 
The SEC may  unblind the treatment assignment for a subject 
experiencing a DLT.
Study drug dosing for a subject may be discontinued if the 
subject receives GS -9620 and experiences one or more DLTs 
considered to be related to study  drug .
A Dose Cohort may be discontinued if ≥ 2 out of 6 subjects 
receiving GS -9620 experience one or more DLTs considered 
related to stud y drug.
Statistical Methods:
Safety : To evaluate overall safe ty, the incidences of treatment-emergent 
AEs and treatment -emergent laboratory  abnormalities will be 
summarized by  treatment group.
The proportion of subjects in each treatment group with an AE 
leading to premature discontinuation of s tudy drug and proportion 
of subjects with serious adverse events (SAEs) will be 
summarized by  treatment group.
Virology : The change in plasma HIV -1 RNA and the incidence of 
detectable plasma HIV -1 RNA at each visit will be summarized 
by treatment group.
The change in plasma HIV -1 RNA SCA from pre-dose to 2 days 
post-dose may be explored .
The c hange in cell (PBMC) associ ated HIV -1 RNA from 
pre-dose to2days post-dose may be explored .
The change in HIV
-1 reservoir measured b ycell ( PBMC )
associated HIV -1 DNA from pre -dose to 2 day s post -dose,and in 
Cohorts 4 to 9 by  use of second aryassay s using stored PBMC 
samples may  be explored
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 18 16 January 2019PK: Exposure parameters of GS- 9620 will be summarized using 
descriptive statistics by active treatment . 
PD: The c hange from baseline in the levels of serum cy tokines will be 
summarized using descriptive statistics by  treatment group. The 
post-baseline change and fold induction in mRNA for ISGs will 
be summarized using descriptive statistics by  treatment group.
Immun ology : The post -baseline change in peripheral blood immune cell 
numbers for T/B/NK/pDC/mDC including: CD4 and CD8 
populations , CD4/CD8 ratio, CD4 % and ly mphocy te activation 
(T, B and NK cells) will be summarized using descriptive 
statistics by  treatment group.
The post -baseline change i n magnitude and pol y-functionality
(Cohort s 4 to 9) of the HIV-1-specific T cell immune response 
may be explored.
TLR7 genot ype may be reported and its association with key  
pharmacod ynamic and virologic parameters may be explored.
Sample Size : This is an exploratory  study  to characterize the safety  and efficacy  
of GS -9620; therefore, no power calculation was performed. 
Sample size is determined based on empirical considerations. A 
total of up to 54subjects (6 per cohort) receiving GS -9620 will 
provide a reasonable preliminary  assessment of safety .
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 19 16 January 2019GLOSSARY OF ABBREVIAT IONS AND DEFINITION OF TERMS
C degree(s) Celsius
F degree(s) Fahrenheit
ACTG AIDS Clinical Trials Group
AE adverse event
AIDS Acquired Immune Deficiency Syndrome
ALT alanine aminotransferase (SGPT)
ANOVA analysis of variance
ART antiretroviral therapy
AST aspartate aminotransferase (SGOT)
ATI analytical treatment interruption
AUC 0-t area under the plasma concentration -time curve from zero
AUC 24h area under the plasma concentration -time curve in 24 hours
AUC tau area under the plasma concentration versus time curve over the dosing 
interval (tau)
BID bis in die (two
-or twice-a- day)
BLQ below  the limit of quantitation
BUN blood urea nitrogen
CAVR/ CAVD Cell-associated HIV -1 RNA/DNA
CBC complete blood count
CDC Center for Disease Control and Prevention
CFR Code of Federal Regulations (United States)
Clast last observed quantifiable concentration of the drug
CL cr creatinine clearance
Cmax maximum observed concentration of drug
CNS central nervous system
CPK creatine phosphokinase (= creatine kinase, CK)
CSR clinical study report
Ctau observed drug concentration at the end of the dosing interval (tau)
CYP 3A cytochrome P450
dL deciliter(s)
DLT dose- limiting toxicities
DNA deoxyribonucleic acid
DTG dolutegravir
EC ethics committee
EC 50 50% effective inhibitory concentration
ECG Electrocardiogram
EDC Electronic data capture
eCRF electronic case report form(s)
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 20 16 January 2019eGFR estimated glomerular filtration rate
ESDD Early Study Drug Discontinuation
EudraCT European Union Drug Regulating Authorities Clinical Trials
FDA Food and Drug Administration (United States)
FSH Follicle stimulating hormone
FTC emtricitabine
ET early termination
G Gram
GCP Good Clinical Practice (Guidelines)
GGT gamma -glutamyl transferase (= gamma -glutamyl transpeptidase, GGTP)
GSI Gilead Sciences, Inc.
HBV hepatitis B virus
HCV hepatitis C virus
HBsAg hepatitis B virus surface antigen
HLT high level term
HLGT high level group term
HPF high-power field
HIV human immunodeficiency virus
hr Hour
ICH International Conference on Harmoni zation
ICS intracellular cytokine staining
IC50 50% inhibitory concentration
IEC Institutional Ethics Committee
IFN Interferon
IFN- interferon -alpha
IND Investigational New Drug (Application)
IP-10 interferon γ –inducible protein -10
IRB Institutional Review Board
ISGs interferon -inducible genes
IUD intrauterine device
IU international unit
kg Kilogram
LLN lower limit of the normal range
LLOD lower limit of detection
LLT lower level term
LRA latency reversal agents
MAD multiple ascending dose
MedDRA Medical Dictionary for Regulatory Activities; MedDRA®
mg Milligram
g Microgram
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 21 16 January 2019min Minute
mDC conventional (myeloid) dendritic cell
mL Milliliter
mRNA messenger ribonucleic acid
NK natural killer (cell)
NDA New  Drug Application
NOAEL no observed adverse effect level
NRTI Nucleoside Reverse ‑Transcriptase Inhibitors
PEG pegylated interferon
PBMC peripheral blood mononucleated cell
PCR polymerase chain reaction
PD pharmacodynamics(s)
pDC plasmacytoid dendritic cell
PK pharmacokinetic(s)
POC Proof of concept
PT prothrombin time
PT preferred term
PVE Pharm acovigilance and Epidemiology , Gilead Sciences
PXR pregnane X receptor
QD quaque die (one-or once -a-day)
QOD every other day (dosing)
qPCR quantitative PCR
RBC red blood cell (count)
RNA ribonucleic acid
SAD single ascending dose
SADR serious adverse drug reaction
SAE serious adverse event
SCA single copy assay
SD standard deviation
SEC Safety Evaluation Committee
SIV Simian immunodeficiency virus
SOC System  Organ Class
SUSAR Suspected Unexpected Serious Adverse Reaction
T1/2 estimate of the terminal elimination half -life of the drug, calculated by 
dividing the natural log of 2 by the terminal elimination rate constant ( z)
Th1/Th2 /Th17 T helper cells (1, 2 , 17)
Tr1 Type 1 T regulatory cells
Tlast time (observed time point) of C last
Tmax time (observed time point) of C max
Treg T regulatory (cells)
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 22 16 January 2019TBD to be determined
TFV tenofovir
TLR toll-like receptor
ULN upper limit of the normal range
US United States
USA United States of America
vs versus
WHO World Health Organization
wt weight
z terminal elimination rate constant, estimated by linear regression of the 
terminal elimination phase of the concentration of drug versus time curve
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 23 16 January 20191. INTRODUCTION
1.1. Background
Human immunodeficiency virus type-1 (HIV -1) infection is a life -threatening and serious 
disease that is of major public health interest around the world. Th ere are approximately  
2.4million people in North America and Western and Central Europe living with HIV -1 and 
36million people worldwide 
{Joint United Nations Progra mme on HIV/AIDS (UNAIDS) 
2016}. Untreated infection leads to deterioration in immune function anddeath. The availabilit y 
of antiretroviral therap y (ART) hasbeen associated with a dramatic decrease in acquired im mune 
deficiency  syndrome (AIDS) -related 
morbidity  and mortality {Mocroft 1998, Palella 1998 , 
Sterne 2005
}.
While ART effectivel y suppresses HIV replication, HIV infection remains incurable. 
Persistent viral reservoirs fuel rebound viremia when treatment ceases. Despite the availability  of 
chronic treatment, morbidity  and mortali ty due to HIV infection remain high due to the latent 
HIV reservoir, which may  contribute to ongoing inflammation- driven disease. Current therap y is 
associated with challenges with tolerability , long -term adherence and safet y, drug -drug 
interactions, and e xpense. Persistent HIV infection may also be associated with psy chosocial 
stigma. Thus, the discovery  and development of therapeutic interventions that can eradicate or 
control HIV reservoirs, leading to long- term ART -free remission or HIV cure, is a major
priority .
Following entry  into a target cell, HIV -1 stably  integrates into the host genome, thus establishing 
the basis for latent infection and the main barrier to HIV cure. Neither the host immune sy stem 
nor ART can eliminate transcriptionally  inactive virus. Therefore, adjunctive therapies that 
efficientl y reactivate (“kick”) virus out of this latent reservoir to enable its destruction (“kill”) 
may be required for viral eradication. This “kick and kill” strategy  to cure or induce long -term 
HIV remission has been tested in clinical trials of latency  reversal agents (LRA) such as histone 
deacety lase inhibitors (HDACi). While short -term treatment with HDACi such as romidepsin 
appears to be safe and may  activate viral transcription in individuals virological ly suppressed on 
ART, the size of the latent viral reservoir as measured b y total peripheral blood mononuclear cell 
(PBMC) -associated HIV -1 DNA or quantitative viral outgrowth assay  (QVOA) appears to be 
unchanged {Sogaard 2015 }. However, a TLR9 agonist has been dosed in HIV- 1 positive 
participants on ART in a single
-arm open -label study  demons trating increases in plasma IFN -α 
levels, transcriptional (messenger ribonucleic acid [mRNA] induction of interferon stimulated 
genes ( ISGs ), activation of pDCs, activation of cytotoxic natural killer (NK) and CD8+ T cells 
with trans ient increases in plasma HIV -1 RNA in a subset of individuals {Vibholm 2017}. I t is 
postulated that a combination of therapies exerting 
viral latency  reversing activity and 
engagement of the host immune sy stem will be necessary tohave a demonstrable effect on 
reducing the HI V-1 reservoir. To date there is no fully  validated biomarker for the latent HIV - 1
reservoir . Therefore, measurement of the time to viral rebound and/or new viral load set -point s
following analy tical treatment interruption (ATI) is the most accurate endpoint to evaluate the 
efficacy  of “kick and kill” interventions. The AIDS Clinical Trials Group (ACTG) has reported 
that ATI can be conducted safel y in patients {Bar 2016 , Li 2016} and that certain measures of 
the HIV reservoir may  be correlated with time to viral rebound {Li 2016 }.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 24 16 January 2019GS-9620 is an orall y-administered toll -like receptor (TL R) 7 agonist currently  in clinical 
development for the treatment of HIV. In vitro, GS -9620 appears to mediate both HIV-1 “kick” 
and “kill” activity .In a rhesus macaque model of chronic SIV infection, treatment with GS -9620 
or its close analog GS -436986 has also demonstrated the ability  to both “k ick” and “kill”: 
treatment resulted in transient detection of plasma viremia within 24 -72 hours of dosing, 
decreases in ex vivo SI V production from T-cell receptor stimulated PBMC cultures or immune 
cell isolates of peripheral ly
mph nodes comparing pre -treatment to post -dosing samples and 
a~0.5 log 10lower viral load set -point after discontinuation of ART {Lim 2018 }.Most 
importantly , in a subset of animals, there was a lac k of detectable plasma virus (< 50 SIV 
RNA copie s/mL) for > 2 y earsafter discontinuation of ART. 
During the off ART phase ,
twoanimals from one of the studies hadno viral rebound after administration of antibodies 
depleting NK and CD8+ ly mphocy tes or transfer of viral infection after infusion of mononuclear 
immune cells from lymph node and peripheral blood into naïve animals ; imply ing a substantial 
reduction in viral reservoir .The administration of multiple doses of GS -9620 has been shown to 
be safe in clinical studies of health y subjects (single dose s up to 12 mg) ,and hepat itisB virus 
(HBV) -infected subjects (multiple doses up to 4 mg) . This study  will therefore investigate the 
safet y and efficacy of GS -
9620 in HIV -infected individuals who are virologically  suppressed on 
ART.
1.2. GS-
9620
1.2.1. General Information
GS-9620 is an orall y-administered TL R7 agonist in development for the treatment of HIV 
infection.
Data in- vitro have shown that GS-9620 is a potent and selective TLR7 receptor agonist with a 
> 30- fold selectivity  for TL R7 (32 -fold based on EC 50and 81- fold based on minimum 
effective concentration) over toll -like receptor 8 (TL R8), with no detectable stimulation of other 
human TL Rs at concentrations up to 100 μM (PC -243- 2031).
Nonclinical data in mice and in chimpanzees chronically  infected with 
HBV demonstrated that 
oral administration of GS -9620 induce a t ype I IFN dependent innate response in the liver, as 
measured b y induction of interferon -stimulated genes (ISGs ), in the absence of concomitant 
serum detectable levels of IFN -α (i.e. a pre -systemic response) {Fosdick 2013, Lanford 2013 }. 
The induction o f typeI IFN-
dependent innate immune responses without the induction of 
detectable systemic IFN-α has been confirmed in healthy  human subjects (GS -US-320- 0101) and 
patient s affected b y chronic hepatitis C (GS -US-
243-0102) o r by chronic hepatitis B 
(GS-US-283-0102 ,GS-US-283-0106 , GS-US-283- 1059, and GS-US-283- 1062 ).
For further informat ion on 
GS-9620, refer to the investigator’s brochure for GS- 9620 .
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 25 16 January 20191.2.2. Preclinical Pharmacology and Toxicology
Preclinical in vivo pharmacology  studies in different non- human primate species have 
consistently  demonstrated that GS - 9620 induces IFN- α,multiple cy tokines, chemokines, 
peripheral blood mononuclear cell (PBMC) derived I SG mRNAs and peripheral immune cell 
activation in a dose -dependent manner .Ofnote, with escalating doses of GS -9620 cy nomolgus 
monkey s were s hown to have an exaggerated IFN-α response both in vitro and in vivo compared 
to other species (mice, chimpanzees, and humans).
In in vitro PBMC cultures, GS -9620 stimulated markedl y higher maximal levels of secreted 
IFN-α in cy nomolgus monkey  PBMC compared to human PBMC cultures; the in vitro mean 
peak IFN-αwas 9105 pg/ mLand 1552 pg/mLin cynomolgus monkey  and human PBMCs, 
respectivel y.
Similarly , the mean peak IFN-αconcentration in serum following a single oral dose in vivo was 
notably higher in cy nomolgus monkey s than healthy  human volunteers at an equivalent dose; at 
0.5mg/kg (human equivalent dose 9.6 mg) the mean peak of serum IFN-α was 4859 pg/mLin 
cynomolgus monkey  versus 93.7 pg/ mLin human healthy  volunteers receiving 12 mgdose 
[study GS-US-243- 0101] (human equivalent dose was calculated using a conversion factor 
of0.32 for cy nomolgus monkey  and ass uming a human body  weight of 60 kg {U. S. Department 
of Health and Human Services (DHHS) 2005 }).
Single oral doses of GS -9620 given in preclinical studies in cy nomolgus monkey s 
(0.05 to0.5mg/kg, human equivalent dose 1 
– 9.6 mg) and mice (0.3 m g/kg, 
human equivalent dose 1.4 mg) human equivalent dose was calculated using a conversion factor 
of 0.08 for mice and assuming a human bod y weight of 60 kg {U. S. Department of Health and 
Hum an Services (DHHS) 2005}) have shown that GS -9620 can induce an innate immunity  gene
expression signature, e.g. up-regulation of interferon-stimulated genes (ISG) in the absence of 
detectable serum IFN -α concentrations. These observations are consistent with the concept of a 
pre-system ic response elicited by  oral GS -
9620.
Body temperature increases were noted in the cardiovascular/respiratory  safet y pharmacology 
study  in cy nomolgus monkey s (≥ 0.5 mg/kg) at C maxexposures that were approximately  
equivalen t to the C max at the highest dose tested in HBV infected patients 
(4mg;study GS-US-283-0102). Increases in heart rate were observed concurrentl y with the 
increases in body  temperature and with the peak of IFN
-αlevels. Of note, body  temperature and 
heart rate increase were not seen at the 4- mg dose in the human clinical studies. I ncreases in 
body  temperature and heart rate are well-described side effects of exogenous IFN-α
administration in humans {Vial 1994 }and in nonhuman primates {Kubicek 1958, Vial 1994 }
and may  reflect the seq uelae of elevated IFN -α in the 
cynomolgus monkey s.
In an in vitro elect rophysiology  assay GS- 9620 inhibited the human ether - à-go-go-related gene 
(hERG) -mediated current at an I C50 (50% inhibitory concentration) value that was 
150-foldhigher than the C maxat the highest dose used in HBV infected patients
(4mg;study GS-US-283-0102). These margins are likely  even higher once adjusted for protein 
binding.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 26 16 January 2019No adverse cardiovascular effects were noted in cy nomolgus monkey s at C maxexposures up to 
1.7-fold higher than projected C max(11.97 ng/mL) for a 12 mg dose of GS - 9620, the highest dose 
planned to be used in this clinical study . No notable effects on the central nervous or respiratory  
systems were seen in the safet y pharmacology studies. Safet y pharmacology studies did not 
identify  any major effects that would impede the 
use of GS -9620 in human subjects.
Preclinical toxicology studies were conducted in single dose and multiple dose settings in 
different animal species.
Single Dose Toxicology Studies
Single oral doses of GS -9620 were well tolerate d at up to 30 mg/kg and up to 2mg/kg in mice 
and cy nomolgus monkeys, respectivel y. At higher doses , mortality  was noted in single dose oral 
studies in mice at 100 mg/kg (TX -243- 2008) or greater (AD - 243-2017) and in a single 
woodchuck administered 10 mg/kg orall y (AD -243-2014). Addi tionally , mortality  was observed 
following intravenous administration of 3 mg/kg to rhesus monkey s
(AD-243-2034). These 
deaths were attributed to high systemic exposure to GS -
9620 (≥ 21- fold higher t han the 
AUC 0
-24in HBV infected patients [study  GS-US-283-0102] ; 44.3 pg•h/ mLat 4mg).
Multiple Dose Toxicology Studies
Oral administration of GS-9620 every -other -day (QOD) was well tolerated in the 
4-week and6-week studies in mice, with the highest doses of 5 and 3 mg/kg QOD, respectivel y, 
being the no observed adverse effect levels (NOAEL s) (Table 1-1).
In cy nomolgus monkey s, GS -9620 was well tolerated in the 4 -week stud y with the highest dose 
of 1.5 mg/kg QOD being the NOAEL ( Table 1-1).
In the 26 -week cy nomolgus monkey  toxicity  study , GS-9620 administration at 
≤
0.15 mg/kg/dose was well tolerated. Administration of 0.50 mg /kg every  other day  
(reduced to0.3 mg/kg every  other day  at Week 11) resulted in morbidity /mortality  of 3 animals 
beyond
8weeks of QOD dosing. In this study  the pharmacod ynamic effects appeared to increase 
over time and w ere associated with high levels of circulating IFN -α. Cynomolgus monkey s were 
the most sensitive toxicology  species and have an apparent exaggerated IFN-α response to 
GS-9620 ( Table 1-1). The observed mortalities in cy nomolgus monkey s are consistent with data 
obtained from the New Drug Application (NDA) a
pprovals of peginterferon alpha 2a(Pegas ys®) 
and peginterferon alpha 2b (Peg- Intron®) showing that r epeated high doses of IFN -α or PEG 
cause a similar spectrum of effects in cy nomolgus monk eys as those observed in the 26- week 
toxicology  study  with GS -9620 {European Medicines Agency  (EMA) 2006 , Pilaro 2000}. The 
margins of exposure in the preclinical species ,based on IFN-α stim ulation ,range from 0.33 to 
122-fold depending on the duration of exposure due to GS -9620 dosing every  other day . Less 
frequent administration
, once every  other week, in the clinical setting would be expected to 
minimize chronic IFN -α exposure side -effects .
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 27 16 January 2019Table 1-1. Estimated Margins of GS-9620 Following Oral Administration at the 
Highest Anticipated Human Dose
Species DurationDose
(mg/kg/dose)AUC 0-taua
ng•h/ mLCmaxa
ng/mLMean 
Peak 
IFN -α 
pg/mLMargin of Exposure
AUC infbCmaxbIFN-αc
MouseQOD x 4weeks5
(NOAEL)43.5 13.4 237 0.3x 1.1x 2.4x
QOD x26weeks3
(NOAEL)15.8 6.64 60.7 0.1x 0.6x 0.6x
Cynomolgus 
MonkeyQOD x 4weeks1.5
(NOAEL)73.8 86.7 11900 0.5x 7.2x 1 22x
QOD x26weeks0.15
(NOAEL)0.171 0.077 32 0. 001x 0.006x 0.33
0.5/0.3 1.82d0.504d2085d0.013x 0.04x 21x
a Males and females combined, Week 4 or Week 26 as applicable
b Margins of exposure were calculated using clinical GS - 9620 C maxand AUC infat 12 mg of 12.0 ng/mL and 140 ng•h/mL, 
respectively (GS-US -243-0101)
c Margins of exposure were calculated using the mean peak for IFN - α (97.3 pg/mL) from healthy subjects dosed with 12 mg 
GS-9620 (GS-US-243-0101)
d Week 17 at 0.3 mg/kg
Source: Studies TX -243- 2005, TX -243- 2011, TX -243- 2004 , TX-243- 2012
Monotherapy Proof -of-Concept Stud iesin Monkeys
In a rhesus macaque model of chronic SIV infection, treatment with GS -9620 or its close analog 
GS-436986 has also demonstrated the ability  to both “kick” and “kill ”. Treatment resulted in 
transi ent detection of plasma viremia within 24- 72 hours of dosing, decreases in ex vivo SI V 
production from T -cell receptor stimulated PBMC cultures or immune cell isolates of peripheral 
lymph nodes comparing pre -treatment to post -dosing samples and a ~0.5 log 10lower viral load 
set-point after discontinuation of ART {Lim 2018 }. Most importantly , in a subset of animals, 
there was a lack of detectable plasma virus (< 50 SIV RNA copie s/mL) for > 2 y ears after 
discontinuation of ART. During the off ART phase two animals from one of the studies had no 
viral rebound after administration of antibodies depleting NK and CD8+ l ymphocytes or transfer 
of viral infection after infusion of mononu clear immune cells from l ymph node and peripheral 
blood into naïve animals; imply ing a substantial reduction in viral reservoir.
1.2.3.
Clinical Trials of GS-9620
As of 27 March 2018, 4 Phase 1 clinical studies, 1 Phase 2 clinical study , and 1 registry  study  
have been completed in which 55 health y subjects, 42 HCV infected subjects, and 230 subjects 
with chronic hepatitis B(CHB) (
189virologically  suppressed and 41 treatment naive subjects) 
were dosed with GS -9620. In addition, a Phase 2 clinical trial ( GS-US- 283-1059) in virologically  
suppressed CHB subjects has completed dosing and a Phase 1 clinical trial ( GS-US-382- 3961) in 
HIV
-1 infected controllers on ART is currentl y on- going. In these studies, single dos es ranged 
from 0.3 mg to 12 mg in healthy  volunteers, and from 0.3 mg to4mg in HCV -and 
HBV -infected subjects. Multiple doses (two doses oneweek apart and up to 12 doses one week 
apart ) were assessed in HCV- infected and HBV -infected subje cts and ranged from 0.3 mg to 
4mg.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 28 16 January 2019In HIV -infected subjects, multiple doses of GS -9620 ranging from 1 mg to 6 mg were assessed, 
with the 8 mg dosing cohort currentl y in progress.
1.2.3.1. GS-US-
243-0101
Study  GS
-US-243- 0101 was a first -in-human, ra ndomized, double -blind, placebo -controlled, 
single ascending dose (SAD) study of GS -9620 in 75 healthy  male and female subjects. The 
primary  objective of the study  was to evaluate the safet y and tolerability of GS -9620 and the 
secondary  objectives were to characterize the plasma PK/PD p rofile of G S
-9620. Doses used 
were: 0.3, 1, 2
, 4, 6, 8, and 12 mg.
The treatment was generally  well tolerated. There were no Grade 4 AEs or serious adverse 
events (SAEs) reported, and most AEs were mild. No individual subject discontinued due to AEs 
orlaboratory  abnormalities. Treatment -emergent Grade 3 AEs included pyrexia in 2 subjects 
who received GS -9620 12 mg. A higher incidence of flu -like s ymptoms was also reported in 
subjects administered the higher doses (8 and 12 mg). Myalgia and headache wer e reported b y 
subjects in both the 8 and 12 mg cohorts, while pyrexia and chills were only reported b y subjects 
in the 12 mg cohort.
Plasma concentrations of GS -9620 peaked between 1.5 and 6 hours after dosing and dec lined 
gradually over 48 hours. The mean maximum plasma concentration (C max) ranged from 
184.2 pg/mL at the 0.3 mg dose to 11.97 ng/mL at the 12 mg dose. Exposure swere higher in the 
faste d state than in the fed state. After the 1 mg, 2 mg, and 4 mg dose s, GS -9620 was detectable 
at 48 hours afte r dosing and had a median terminal half-life between 17.16 and 26.96 hours.
Three ISGs were anal yzed: ISG15, MX -1 and OA S-1. Significant ISG induction was observed at 
the 2
-mgdose and above . ISG15 mRNA expression showed the h ighest induction compared to 
MX-1 andOAS-1. Serum IFN -α was detected transiently  in subjects who received the 
8
or 12 mg doses , and only  the 12 mg cohort had a >2 -fold mean change in serum IFN -αfrom 
baseline . A dose -dependent induction was observed for serum I P -10 but not for IFN-α or TNF -α. 
Dose -dependent T cell activation was also observed at the 2 mg dose and above.
In summary , single doses of GS -9620 up to 12 mg were well tolerated, with significant ISG 
induction and T cell activation at doses of 2, 4, and 6 mg in the absence of detectable 
serum IFN-α or sy stemic AEs .
1.2.3.2. Other Phase 1 studies
The following studies have also demonstrated good tolerability  of GS -9620 (see IB for details):
GS-US-243- 0102: A Phase 1b ascending, single and multiple -dose study  evaluating the 
safet y, PK, PD
, and antiviral activity  in treatment -naive HCV subjects.
GS-US-283-0102: A Phase 1b ascending, single and multiple -dose study  evaluating the 
safet y, PK/PD, and antiviral activity in virologically -suppressed HBV subjects.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 29 16 January 2019GS-US-283- 0106: A Phase 1b ascendi ng, single and multiple -dose study  evaluating the
safet y, PK/PD, and antiviral activity in treatment
-naive HBV subjects.
GS-US-283- 0110: An observational registry  study of subjects who did not achieve loss of
HBsAg and sustained HBV viral load reduction be low the 
level of quantitation in 
Gilead- Sponsored trials of GS -9620 in subjects with chronic HBV infection.
1.2.3.3. GS-US-283-1059
GS-US-
283-1059 was a Phase 2, randomized, double- blind, placebo- controlled multi -center 
study  to evaluate the safety  and efficacy  of GS-9620 in HBV -infected subjects who are 
virologicall y suppressed. In this study , approximately  162 subjects receive dweekl y dosing with 
GS-9620 (1, 2
or 4mg) or placebo for a total of 4 (Cohort A) , 8(Cohort B) or 12 (Cohort C)
weeks. The efficacy  of GS -9620 was evaluated b y assessing t he change from baseline to 
Week 24 in HBsAg levels. Overall, once -weekl y dosing of GS -9620 1, 2, or 4 mg for 4, 8, or 
12weeks was generall y well tolerated in virologically
-suppressed subjects with CHB on OAV. 
Most subjects had Grade 1 (mild) AEs and, except for the Cohort C 4 mg group in which a 
higher proportion of subjects had Grade 2 (moderate) and 3 (se vere) AEs compared with 
Cohorts A and B. No other dose -related or treatment duration- related safety  findings were 
observed. No Grade 4 (life threatening) AEs were repor ted in an y of the cohorts. Four subjects 
had SAEs, 3 of these subjects had AEs that led to discontinuation of study  drug, and 3 of the 
4subjects had study  drug interrupted due to AEs. No deaths occurre d in any  study  participant.
Two subjects interrupted study  treatment after having experienced SAEs due to an overdose 
caused b y a dispensing error at the stud y site. One of these subjects randomized to 2 mg
GS-9620 mistakenly received 10 mgand one subject randomized to 4 mgmistakenly received
20mg. These 2 subjects experienced transient Grade 3 
AEs of flu- like s ymptoms, , and decline 
in lymphocy tes count; the subject who received 10 mg experienced Grade 3 AEs of py rexia, 
chills and hot flush, all SAEs th at were assessed as related to study  drug by the investigator. The 
subject who received 20mgexperienced SAEs of Grade 3 AE of tremor and Grade 2 
hypotension requiring hospitalization . This subject also experienced additional Grade 2 AEs of 
abdominal pain , diarrhea, and vomiting, and an increase in ALT value. For both subjects, each of 
the AEs 
resolved within 24 hours after overdose. A meeting of the Data Monitoring Committee
reviewed these events and determined them to be due to the overdose of GS -9620 with expected
effects of interferon -alpha induction and cy tokine release and allowed for the study  to proceed as
planned. The other two subjects with SAEs were in Cohort C (cataract, which was reported in 
one subject with a medical history  of cataract, and cholecy stitis, which was reported in the other 
subject). The subject who experienced cholecy stitis also withdrew from study  drug and the 
study .
Most AEs reported were Grade 1 or Grade 2 in severity . No Grade 4 (life threatening) AEs 
occurred in an y of the cohorts. For Cohort A, 1 subject in each group had Grade 3 AEs. None of 
the Grade 3 AEs led to withdrawal from stud y drug and none occurred in more than 1 subject. 
All of the Grade 3 AEs resolved. Excluding the 2 overdosed subjects discussed above , 2subjects 
(placebo and GS -9620 1 mg) experienced transient Grade 3 AE of anxiety  and diarrhea, 
respectivel y, during the treatment period with GS -9620/placebo; both AEs resolved within 
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 30 16 January 201924hours. For Cohort B, no subjects had Grade 3 AEs. For Cohort C, 6 subjects had Grade 3 
AEs: 2 subjects in the GS -9620 1 mg group, 1 subject in the GS -9620 2 mg group, 2 subjects in 
the GS -9620 4 mg group, and 1 subject in the placebo group. Two subjects, both in the GS-9620 
4mg group, with Grade 3 AEs (cholecy stitis [discussed above] and panic attack) withdrew from 
the study  and stud y drug.
Overall, patients from both the GS-9620- treated and placebo groups experienced a similar 
number of treatment emergent AE s(TEAEs) (68% study  drug vs. 70% placebo ). Upon 
assessment of relation to study  drug, 37% of patients treated with GS-9620 reported at leastone 
AE compared to 50% of placebo patients, all of which were mild to moderate in severit y. No 
dose-dependency  for AEs was observed across cohorts. The most commonly  reported related 
AEs (for ≥2 or more patients) in Cohort A were fatigue (4 of 16 [25.0%] subjects) and diarrhea, 
headache, orophary ngeal pain, pruritus, and py rexia (ea ch of which occurred in 2 of 16
patients 
[12.5%]) (1-mg group); headache (4 of 15 [26.7%] subjects), fatigu e (3 of 15 [20.0%] patients) 
and chills (2 of 15 [13.3%] patients) (2- mg group); and fatigue and py rexia (each in 3 of 16 
[18.8%] patients) and headache (2 of 16 [12.5%] patients) (4- mg group). In Cohort B, headache 
(6 of 18 [33.3%] patients), nausea (3 of 18 [16.7%] patients) and acne, dizziness, fatigue, 
insomnia, and orophary ngeal pain (each in 2 of 18 [11.1%] patients) (1 -mg group); headache and 
dizziness (each in 2 of 17 [11.8%] patients) (2
-mg group) ; and headache (4 of 17 
[23.5%] patients) and fatigue, influenza -like illness, and rhinorrhea (each in 2 of 17 [11.8%] 
patients) (4- mg group) were most common. In Cohort C, headache, fatigue, influenza -like illness 
(each in 4 of 16 [25.0%] patients) and asthenia, p yrexia and somnolence ( each in 2 of 16 [12.5%] 
patients) (1-mg group); abdominal pain upper and headache (each in 3 of 17 [17.6%] patients) 
and fatigue (2 of 17 [11.8%] patients) (2- mg group); and asthenia (5 of 14 [35.7%] patients), 
headache, influenza -like illness, and py rexia (each in 3 of 14 [21.4%] patients) and myalgia (2 of 
14 [14.3%] patients) (4 -mg group). Headache wa s the most commonly  reported placebo group 
AE (40 -50% of patients).
Among the patients dosed with GS -9620, treatment -emergent graded ALT elevations were see n 
in 5subjects ( 4subjects with Grade 1 and one subject with Grade 2). All grade 1 elevations were 
transient (1 placebo, 1 GS -9620 2 mg, and 2 GS -9620 4 mg) and the grade 2 elevation occurred 
22days after the last dose of GS-9620 4 mg and reduced to grad e 1 elevation 3 days later.
Please refer to the current GS -9620 I nvestigator’s Brochure for the treatment of 
chronic hepatitis 
B virus infection for additional information regarding the above studies.
1.2.3.4. GS-US-283-1062
This Phase 2, randomized, double
-blind, placebo -controlled study  is being conducted to evaluate 
the safet y and efficacy of administering either 1 mg, 2 mg or 4 mg of GS -9620 orally  once a 
week (every  7 day s) for 12 doses (Weeks 0- 11) in adult subjects with CHB who were not 
currentl y on treatment for CHB. 192subjects were randomized i n a 1:2:2:2 ratio to 1 of the 
4treatment arms (placebo, GS -9620 1 mg, 2 mg, or 4 mg) for weekl y dosing for a total of 
12doses and stratified b y HBeAg status (positive versu s negative) and ALT (> versus 
≤ 19 IU/mL for female; > versus ≤ 30 IU/mL for male). All subjects were also treated with TDF 
300 mg oral daily  for 48 weeks.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 31 16 January 2019Preliminary  interim safety  results from Week 48 show that overall, once-weekl y dosing of 
GS-
9620 1, 2, or 4 mg was generally well tolerated. 65% of subjects overall had at least 1 AE 
during the stud y and most of the reported AEs were Grade 1 (mild) or 2 (moderate) in severit y. 
Overall, the majorit y of subjects had Grade 1 (mild) or moderate (Grade 2) AEs. Six subjects 
experienced Grade 3 (severe) AEs. No Grade 4 (life threatening) AEs were reported in an y of the 
treatment groups. 
Four subjects had treatment -emergent SAEs: a nSAE of laceration (deep laceration on the right 
foot) on Day 133 which resolved on Day 252, a n SAE of asthma (worsening of asthma) on 
Day 257 which resolved on Day 288, an SAE of breast cancer on Day 422 continuing at the time 
of the interim data cut, and a
n SAE of abdominal pain (exacerbation of chronic generalized 
abdominal pain) on Day 71 which resolved on Day 85. All SAEs were considered b y the 
investigator to be unrelated to study  drugs or to study  procedures. No action was taken with 
study  drugs, wit h the exception of TDF dose interruption for the abdominal pain case and dose 
withdrawn for the breast cancer case. No deaths occurred.
Six subjects overall (3.1%) discontinued study  drug due to an AE, all of which were considered 
related to stud y drugs b ythe investigator.
Across the treatment groups, most laboratory  abnormalities were Grade 1 or 2 in severit y. 
Five subjects had ALT ≥ 10x ULN and thirty had AL T between 3x ULN and < 10xULN and 
>
2xnadir.
1.2.3.5. GS-US-382-3961
This ongoing Phase 1b, 
randomized, double - blind, p lacebo -controlled study is being conduct ed
to evaluate the safety and efficacy  ofGS-9620 in antiretroviral treated HIV -
1 infected 
controllers
. The stud y isconducted in two periods. I n Period 1, up to 30 subjects will be 
randomized 2:1 to receive GS -9620 or placebo -to-match . All subjects will receive up to 10doses 
of their assigned stud ytreatment administered orally  every  14 day s.Subjects will continue to 
take their pr escribed ART during Period 1. In Period 2, all subjects will disco ntinue ART and be 
monitored for rebound in HIV -1 plasma viremia. Enrollment is ongoing and several subjects 
have completed dosing (4-6 mg) and are undergoing ART interruption (Period 2) .
1.3. Rationale for This Study
Despite the extensive advances made in the t reatment of chronic HIV -1 infection, eradication of 
the latent HIV -1 reservoir is still needed to achieve a cure that abrogates the requirement for 
lifelong ART. To this end, “kick and kill” strategies to reactivate and target latent virus have 
been tested in a number of clinical trials, but none have resulted in lasting virologic remission. 
GS-9620 is a promising candidate for this approach given the demonstration of both SI V 
reactivation (as measured by  transient plasma viremia in the presence of ART), de crease in SIV 
reservoir (as measured by proviral DNA in PBMCs, ly mph node and colon), and ~0.5 log 
reduction in SIV set point relative to pre -ART plasma viral load set point following ART 
interruption in studies of SI V
-infected rhesus macaques treated with GS-436986, a close analog 
of GS -9620. In a second study  in SIV -infected rhe sus on ART the TL R7 agonists GS -9620 or 
GS-436986 administered for 10 or 19 doses produced tra nsient plasma viremia within 
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 32 16 January 201924-72 hours after dosing. Sampling PBMCs and immune cell isolates from ly mph node biopsies 
prior to TL R7 agonist administration and after completing all doses demonstrated a decrease in 
the amount of SIV production following T -cell receptor stimulation. I nterestingly , two of these 
animals, one from the GS -
9620 dosing group and one from the GS -436986 dosing group had no 
detectable ex vivo SIV production from both PBMCs and isolated immune cells from ly mph 
node biopsies. Most importantly , after ART discontinuation these same two animals had no 
detectable plasma vir us (< 50 SIV RNA copies/mL) rebound which has been sustained for at 
least 
twenty  four months. These results suggest the possible use of TL R7 agonists in 
combination with ART toward reduction of HIV reservoirs and ultimatel y finite therapies for 
HIV-1 infec tion. In addition, GS -9620 appears to be safe in health yand HBV -infected subjects.
1.4. Rationale for Dose Selection/Dosing Interval
In 50 HCV and in 100 HBV patients, doses of up to 4 mg of GS- 9620 were evaluated, either as a 
single dos e or two doses one week apart. Safet y data from th esestudies demonstrated that 
GS-
9620 iswell-tolerated with no evidence of dose dependent adverse events or laboratory 
abnormalities that are consistent with sy stemic immune activation such as flu -like sy mptoms, 
hematologic reductions or increases in liver enz ymes including transaminases. In the majorit y of 
patients there was no detectable IFN -α in serum, consistent with the mechanism of action of 
pre-systemic innate immune sy stem activation in the GALT and /or in the liver. Evidence of 
biological activity  was observed in a dose dependent manner in these studies, with maximal 
induction of I SG15 occurring within 48 hours and return to baseline levels of expression within 
168 hours (7 day s). In addition, the sa fety of a weekly  dosing interval was supported by  the 
observed elimination half -life (median range 8 to25hours for 1, 2, or 4 mg doses in HBV- or 
HCV -infected subjects) and that no accumulation of GS -9620 occurred following once-weekl y 
dosing.
A dosing schedule of once every  2 weeks is planned for this protocol in order to verify  the 
resolution of GS -9620-induced HIV-1 viremia prior to additional dosing. This schedule is more 
conservative than the weekly  administrations used in the Phase 1 evaluations a cross the 
above -referenced studies in chronic hepatitis B and C patients.
In the current study  GS-US-
382-1450, approximately  32 HIV-1- infected subjects have received 
biweekl y dosing with GS -9620 (1, 2 and 4 mg) or placebo for a total of 6 doses
,and GS-9620 
6mg or placebo for a total of 10 doses . No safet y issues including dose -limiting toxicities were 
identified; however, pharmacod ynamic and virologic eff ects were limited. The protocol
-defined 
safet y evaluation committee (SEC) recommended proceeding with enrollment of the 6 mg cohort 
on February  7, 2017. In the 6 mg dose cohort (Cohort 4) of this study , 6 subjects experienced 
treatment -emergent AEs. Three of these subjects had AEs which were considered to be related to 
study  drug b y the investigator: one s
ubject had decreased concentration, vivid dreams, sweats, 
and fatigue; another subject had headache and increased p eripheral neuropathy ; the third subject 
had fatigue, m yalgia, and nasal congestion. All of these AEs were grade 1 or 2 and all resolved 
during the dosing period. There have been no grade 3 or 4 AEs, AEs leading to stud y drug 
discontinuation, SAEs or deaths. The protocol -defined SEC revie wed blinded safet y data from 
the 6 mg cohort on 25 September 2017 and recommended procee ding with the addition of the 
8mg cohort (Cohort 5).In the 8 mg dose cohort (Cohort 5) of this study ,a total of 8 subjects 
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 33 16 January 2019have been enrolled and are currentl y being dosed with study  drug. At the time of the interim 
safet y data cut ( 30 April 2018 ), all subjects hadcompleted 5 out of 10 doses, and3subjects had 
completed 6 doses. There have been no grade 3 or 4 AEs, AEs leading to study  drug 
discontinuation, SAEs or deaths. Three subjects have had mild AEs considered related to study  
drug b y the investigator. These AEs include chills and malaise in one subject, py rexia and 
myalgia in another subject ,and headache in the last subject. All resolved within one day  and 
have not recurred after Dose 3, thus far. If the SEC recommends proceeding with the10mgdose
escalation of GS -9620, C ohort 6 will be opened for enrollment with the potential to escalate to 
the 
12 mg dose of GS -9620 , starting with dose 4 ( out of 10 total doses of GS -9620). In Cohort 6, 
the SEC will review blinded safet y data after all subjects have completed three doses of 
10mgof 
GS-9620 or placebo. D ose escalation to 12 mg of GS -9620 within Cohort 6will only be initiated 
ifSEC approval is obtained
.
The highest GS -9620 dose planned to be assessed in this clinical study may be up to 12mg. 
Dose selection has been based on the results from the study  in health y volunteers 
(GS-US-243- 0101) that showed dose -dependent ISG mRNA induction from 0.3 mg up to 12 mg
in the absence of dose -dependent induction in serum IFN -
α. As described above, d ose escalation 
toCohort 6 (GS -9620 10 mg) for the proposed study  is also based on interim safet y data from the
ongoing 8mg cohort (Cohort 5)as described above.  
 
With regard to the proposed adaptive cohorts, f ood affects absorption of GS -9620 and 
administration of GS -9620 4 hours post -inges tion of a high fat meal in S tudy GS
-US-243-0101 
resulted in approximately 30% reduc tionof systemic exposures of GS - 9620, minimal effect on 
PD biomarkers and improved tolerability . Dosing GS -9620 with an acidic solution may  improve 
the solubility  and absor ption of the compound. 
 
 
 
 
1.5.
Rationale for Biomarker Testing
It is hy pothesized that t he mechanism of action of GS- 9620 is partly  due to the initial activation 
of theinnate immun e systemvia TL R7 positive pDCs, promoting activation and maturation of 
pDCs and the release of antiviral cy tokines and chemokines including IFN-α. The
matured pDCs 
present HIV antigens to HIV-specific CD4 and CD8 T cel ls, thereb y enhancing the HIV -specific 
adaptive response (cy totoxic CD8 T cell s). These multifaceted effector mechanisms 
(cytotoxic CD8 T cells, NK cells, and antiviral cy tokines ) together strengthen the lymphocy te 
anti-HIV immune response and may  lead to lowering the vi ral set point.
CCI
CCI
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 34 16 January 2019To provide proof of concept on the mechanism of action of GS- 9620 in HIV -1 infected patients, 
several exploratory immunological biomarkers will be e xamined and listed below. The testing 
outlined below is based upon the current state of scientific knowledge. It may be modified during 
or after the end of the study  to remove tests no longer indicated and/or to add new tests based on 
the growing state of the art knowledge. The following samples and biomarkers will be examined :
Whole blood samples will be collected for interferon stimulated gene (ISG) mRNA 
measurements 
Whole blood samples will be collected , mononuclear cells isolated, and frequency  and 
phenoty pe (activation, maturation, exhaustion) of ly mphocy te populations will be 
enumerated b y flow cy tometry .
Whole blood samples will be collected, mononuclear cells isolated and thefrequency of 
HIV-specific T- cells will be quantitated b y ex vivo IFN -γELIS POT assay and 
poly-functional ICS .
Levels of cy tokines, chemokines, and inflammatory  markers will be quantified by  
immunoassay s.
Stool samples will be collected in Cohorts 5 to 9 for testing of the fecal microbiome and 
exploratory  anal ysis
1.6. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 35 16 January 20192. OBJECTIVES
The primary  objective of this study  is:
To evaluate the safet y and tolerability  of GS -9620 at escalating, multiple doses of GS -9620
in HIV -1 infected virologically  suppressed adults on ART
To evaluate the virologic effect of GS
-9620 as me asured b y changes in plasma HIV -1RNA
The secondary  objectives of this study  are:
To evaluate the plasma pharmacokinetic s (PK) of GS-9620
To evaluate the pharmacody namics (PD) of GS -9620 as me asured by  changes in 
interferon -stimulat edgenes (ISGs) and serum cy tokines in whole blood compared to placebo
To evaluate effects of G S-9620 on whole blood immune cell activation (T cell, Bcell, 
NKcell)
The exploratory  objectives of this study  are:
 
 
 
 
 
CCII 
I 
I 
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 36 16 January 20193. STUDY  DESIGN
3.1. Endpoints
The primary  safet y endpoint of this study  is:
Incidence of treatment -emergent SAEs and all tr eatment -emergent adverse events
The primary virology endpoint of this study  is:
Maximum change from baseline in plasma HIV-1 RNA at an y post -dose time point
The secondary  endpoints of this study  are:
Change from baseline in plasma HIV-1 RNA at post -baseline visits 
Proportion of subjects with plasma HIV -1 RNA > 50 copies/mL  at any post -dose timepoint
The exploratory  endpoints of thi s study are:
 
 
 
 
3.2. Study Design
This protocol describes a randomized, double -blind, multi -cohort dose escalation study that will 
evaluat ethe safet y and efficacy of 1 mg , 2 mg , 4 mg ,6 mg ,8 mg , 10mg and12 mg of GS - 9620 
or placebo administered orally  every  other week for 71 day s(for Cohor ts1 to 3) , 127 days 
(forCohorts 4 to 6), in HIV -1 infected , ARV - treated,
virologicall y suppressed adults. For each cohort, subjects will be randomized in a 6:2 ratio to 
receive GS -9620 or placebo. For Cohorts 5, 6  eight unique subjects per cohort will receive 
GS-
9620 or placebo after an overnight fast. 
All subjects will receive a total of 6 doses (for Cohor ts1 to 3) , 
10doses ( for Cohort s 4to 9) of their assigned study  treatment admin istered once every  other 
week. For all subjects in Cohort 6, Dose 4 (Day  43) will occur after SEC review has been 
CCI
CCI
CCI
CCII 
I I 
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 37 16 January 2019completed. If dose escalation is approved by  the SEC, subjects in Cohort 6 will rec eive 12 mg of 
GS-9620 or placebo from Doses 4 to 10; if dose escalation is not approved by  the SEC, subjects 
will continue receiving 10 mg of GS -9620 or placebo from Doses 4 to 10 .  
 
Subjects will continue their 
ARV regimen for the entire study  duration.
Subjects will return for an end of study visit 30days after the last dose of study  drug is taken .
Enrollment will initially  be opened for Cohort 1 only . The S E C will review study  progress,
safet y and virology  data of enrolled subjects. After all subjects in a cohort have received at least 
three doses (Cohorts 1 to 3, and 6 ) or five doses (Cohorts 4 to 5), the S EC will review safety data 
from that cohort, i ncluding adverse events
,clinical laboratory  results and plasma HIV -1 RNA, 
before approving the next dose escalation .  
A 
cohort may be suspended if ≥ 2 out of 6 subjects receiving GS -9620 experience one or more 
DLTsconsidered related to study  drug . The S EC will consist of members not directly  involved 
with the conduct of the study . Please refer to the SECCharter for additional details.
CCI
CCI
CCIGS-9620 
Protocol GS-US-382-1 450 Final 
Gilead Sciences , Inc. Amendment 7 
Figure 3-1. High-Level Study Schema 
Cohort 1: GS-0020 1mg : placebo (6:2) 
1 2 
Cohort 2: GS-9620 2mg : placebo (6:2) 
s - , 
Cohort 3: GS-9620 4mg : placebo (6:2) 
Cohort 5 : GS-8620 3mg : placebo (6:2) 
Dose. : 123.t5 6789 10 
< ,. __ .,Cohort 6: GS-9620 10mg with possible esca lation 
to 12mg : placebo (6:2) 
' 2 3 i45G7 891 0 
~J cohort s: GS-9620 12mg : placebo (6:2) I 
Dose-: 45678910 
Figure 3-2. Cohort 6 Visit Schema 
D&y-13 
Ser@'l?nlng Druil! 1 Dose 2 DosE< 3 Dose 4- Dose S 
Dav I Day 15 Day 29 Day 43 Day· 57 
12 mgdos in~ 
3.3. Study Treatments 
CONFIDENTIAL IJ<>,e 6 
Day71 
Notes: Dose 7 Dos.e 8 Dose 9 Dose 10 
Dav 85 Dav 99 Oe,y 113 Day 121 
Cohort 6 will con,ist of S ,ubject. (3:l). Preliminary/(i FL) 
safety data of 8 subjects up to Dose 3 Day29 will be 
reviewed by the protooo l-defin ed SEC. Dose esca lation 
to 12m g (Dose 4-10) wit hin t he cohort will be initiat ed 
only ofter SEC opprovol. 
Page 38 End oi Study Day 
157 
16 Januruy 2019 
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 39 16 January 2019For each cohort, 8 subje cts will be randomized in a 6:2 ratio to receive GS - 9620 or placebo. All 
subjects will receive a total of 6 doses (for Cohor ts1 to 3) , 10 doses (for Cohorts 4 to 6),  
of their assigned st udy treatment administered once every  other 
week. Subjects will continue their existing ARV regimen for the entire study  duration.
Cohort 1 (n=8) : GS- 9620 1 mg (n=6) or placebo -to-match (n= 2 )
Cohort 2 (n=8) : GS- 9620 2 mg (n=6) or placebo -to-match (n= 2 )
Cohort 3 (n=8) : GS- 9620 4 mg (n=6) or placebo -to-match (n= 2 )
Cohort 4 (n=8): GS -9620 6 mg (n=6) or placebo -to-match (n=2)
Cohort 5 (n=8): GS- 9620 8 mg (n=6) or placebo- to-match (n=2) administered following
overnight fasting 
Cohort 6 (n=8): GS-9620 10mgwith potential to escalate to 12 mg (n=6) or placeb o-to-match 
(n=2) administered following overnight fasting
 
 
 
 
3.4. Duration of Treatment
The treatment duration is 71 day s (Cohorts 1 to 3 ),127 day s
(Cohorts 4 to 6),  
 
CCI
CCI
CCI-
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 40 16 January 20194. SUBJECT POPULA TION
4.1. Number of Subjects and Subject Selection
Approximately  up to seventy  two (72) subjects who meet the i nclusion/ exclusion criteria will be 
enrolled. Subjects who discontinue study  participation before completion of dosing for reasons 
other than study -treatment related adverse events may  be replaced.
4.2. Inclusion Criteria (All Cohorts)
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study .
1)The ability  to understand and sign a written informed consent form, which must be obtained 
prior to initiation of study procedures
2)HIV-1 infected male s and non -pregnant, non -lactating females ≥ 18 y earsat 
Pre-Baseline/ Day 
-13
3)Onantiretroviral (ARV) regimen for ≥ 12 consecutive months prior to Pre-Baseline/ Day -13
a)The following agents are allowed as part of the current ARV regimen: NRTIs, raltegravir, 
dolutegravir, rilpivirine, andmaraviroc
b)The following agents are NOT allowed as part of the cu rrent ARV regimen: 
HIVprotease inhibitors (including low dose ritonavir), cobicistat- containing regimens, 
elvitegravir ,efavir enz, etravirine, and nevirapine
c)A change in ARV regimen ≥ 45 day sprior to Baseline/Day  1 for reasons other than 
virologic failure (e.g. tolerability , simplification , drug -drug interaction profile ) is allowed
4)Plasma HIV -1 RNA levels < 50 copies/mL  at screening
5)Documented plasma HIV -1 RNA levels < 50 copies/mL  (according to the local assay  being 
used) for ≥ 12 months preceding the screening visit (measured at least twice using a licensed 
assay  with a lower limit of quantitation of at least 40 copies/mL ) 
a)Unconfirmed virologic elevations of ≥ 50 copies/mL  (transient detectable viremia, or
“blip”) prior to screening are acceptable. (If the lower limit of detection of the local 
HIV-1 RNA assay  is < 50 copies/mL , the plasma H IV-1 RNA level cannot exceed 
50copies/mL  on two consecutive HIV -1 RNA tests)
b)If AR Vregimen is changed ≥ 45days prior to P re-Baseline/Day  -13, plasma HIV - 1RNA 
<50copies/mL at Pre -baseline/Day  -13 visit is required.
6)No documented history  of resistance to any  components of the current ARV regimen
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 41 16 January 20197)Availability  of a fully  active alternative ARV regimen, in the opinion of the Investigator , in 
the event of discontinuation of the current ARV regimen with development of resistance
8)Hemoglobin ≥ 11.5 g/dL (males) or ≥ 1 1g/dL (females)
9)White blood cell ≥ 4000 cells/L
10)Platelets ≥ 150,000/mL
11)
Absolute Neutrophil Count ≥ 1500 cells/ L
12)CD4 count 
≥ 400 cells/ L
13)Albumin ≥ 3.9 g/dL
14)Alan ine aminotransferase (ALT) and aspartate aminotransferase (AST)  2 × upper limit of 
normal (ULN)
15)Estimated GFR ≥ 60 mL /min according to the Cockcroft -Gault formula for creatinine 
clearance {Cockcroft 1976 }:
i.Male: (140 –age in years) (wt in kg) CLcr (mL /min)
72(serum creatinine in mg/dL)
ii.Female: (140 –age in years) (wt in kg) 0.85  CLcr (mL/min)
72(serum creatinine in mg/dL)
16)All subjects must agree to utilize male or female condoms during sexual activity , or practice
sexual abstinence for the duration of the study.
17) Females of childbearing potential must agree to utilize highly effective contraception 
methods (as described in Appendix 5) orbe non -heterosexually  active or practice sexual 
abstinence from screening through the duration of study  treatment and for 36days following 
the last dose of study  drug.
a)Female subjects who utilize hormonal contraceptive as one of their b irth control methods 
must have used the same method for at least three months prior to study  dosing
b) Female subjects who have stopped menstruating for ≥ 12 months but do not have 
documentation of ovarian hormonal failure must have a serum follicle stimulating 
hormone (FSH) level at screening within the post- menopa usalrange based on the 
Central Laboratory  reference 
18)Male subjects must agree to utilize a highl y effective method of contraception during 
heterosexual intercourse (as described in Appendix 5) orbe non -heterosexually  active, or 
practice sexual abstinence from screening throughout the study  period and for 90 days 
following discontinuatio n of investigational medicinal product
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 42 16 January 20194.3. Exclusion Criteria (All Cohorts)
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study .
1)A new AIDS -defining condition diagnosed within 90 days prior to scree ning 
(refer toAppendix 6)
2)Hepatitis B surface antigen (HBsAg) positive
a)Positive anti -HBs antibody  and negative HBsAg results are acceptable
3)Hepatitis C antibody  (HCVAb) positive
a)Positive anti -HCV antibody and negative HCV 
PCR results are acceptable
4)Documented history  of pre -ART CD4 nadir < 200 cells/L
a)Unknown pre -ART CD4 nadir is acceptable
5)History  of autoimmune disease (e.g. lupus ery thematosus, rheumatoid arthritis, 
inflammatory  
bowel disease, sarcoidosis, moderate or severe psoriasis)
6)Acute febrile illness within 35 day s prior to Pre -Baseline/ Day -13
7)Participation in any  other clinical trial (including observational trials) without prior approval 
from the sponsor is prohibited while participating in this trial
8)Current alcohol or substance use judged b y the Investigator to potentiall y interfere with 
subject study  compliance
9)History  or presence of allergy  or intolerance to the study  drug or their components
10)Any vaccinat
ion or immunomodulatory  concomitant medication within 30 day s prior to
Pre-Baseline/Day  -13. Elective vaccination (e.g. flu shot, hepatitis A or B vaccine) during the
course of the stud y will require prior approval from Sponsor.
11)Use of an y other prohibited concomitant medications as described in Section 5.4within 
14days prior to Baseline/Day  1 visit . Refer to the current Prescribing Info rmation for the 
medications that are contraindicated with the current ARV regimen
12)Any other clinical condition or prior therapy  that, in the opinion of the I nvestigator, would 
make the subject unsuitable for the stud y or unable to comply with dosing requir ements.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 43 16 January 20194.4. Other Protocol Restrictions
Subjects will be encouraged to avoid strenuous or prolonged exercise, as well as saunas, 
steam baths, and sunbathing or other prolonged UV exposure, (eg in a tanning salon) from the 
screening evaluation until completion of end of study  procedures, as these activities are known to 
affect certain clinical laboratory  test parameters, (eg CPK) and may  provide false indicators of a 
potentially  treatment -related toxicity .
Subjects will also be prohibited from blood donation (in excess of that required for clinical care) 
within 30 days prior to Screening and 30 day s after end of study .
Smokers and other current tobacco users should keep their tobacco use relatively  consistent 
while enrolled in the study . Non -smokers or ex- smoker s should not start or resume smoking.
Other restrictions include all illegal or illicit drug use and use of prescription drugs outside the 
care of the prescribing phy sician.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 44 16 January 20195. INVESTIGA TIONAL  MEDI CINAL  PRODUCTS
5.1. Randomization, Blinding and Treatment Codes
Therandomization will be performed via an Interactive Web Response Sy stem (I WRS), whereby  
study  treatment will be assigned to subjects according to the randomization schedule.
The subject number assignment may  be performed up to 3 days prior to the in -clinic
Pre-Baseline/ Day -13 visit ,provided that all other screening procedures have been completed 
and subject eligibility  has been confirmed. Once a subject number has been assigned, it will not 
be reassigned to any  other subject.
Eligible subjects (n = 72, 8 per cohort ) will be randomized in a 6:2ratio to receive GS- 9620 
1mgor placebo (Cohort 1) , 2 mg or placebo (Cohort 2) , 4mgor placebo (Cohort 3), 6 mg or 
placebo (administered as three 2 mg tablets ) (Cohort s 4  8 mg or placebo (administered as 
two4 mg tablets) (Cohort 5) , 10 mg or placebo (Cohort 
6)(administered as five 2 mg tablets) , 
with the 
potential to escalate to 12mg or placebo (administered as six 2 mg tablets , orthree 4 mg 
tablets) with prior approval from SEC, 
Clinical Packaging & Labeling for purposes of managing blinded labeling and Clinical Supply  
Management for purposes of inventory  management will remain unblinded throughout the stud y 
to prepare and manage thestudy  drug. The Pharmacoki netics File Administrator, or designee, 
who facilitates data transfer of PK files between Gilead and vendors, will remain unblinded.
5.1.1. Procedures for Breaking Treatment Codes
In the event of a medical emergency  where breaking the blind is required to provide medical care 
to the subject, the investigator may  obtain treatment assignment directly  from the IWRSsystem 
for that subject. Gilead recommends but does not require that the investigator contact the 
Gilead medical monitor before breaking the blind. Treatment assignment should remain blinded 
unless that knowledge is necessary  to determine subject emergency  medica l care. The rationale 
for unblinding must be clearl y explained in source documentation and on the electronic case 
report form (eCRF), along with the date on which the tre atment assignment was obtained. The 
investigator is requested to contact the Gilead me dical monitor promptly  in case of an y treatment 
unblinding .
Blinding of stud y treatment is critical to the integrity  of this clinical trial and therefore, if a 
subject’s treatment assignment is disclosed to the investigator, the subject may have study  
treatment discontinued at SEC discretion . All subjects will be followed until study  completion 
unless consent to do so is specificall y withdrawn by the subject.
Gilead Pharmacovigilance andEpidemiology (PVE ) may  independently  unblind cases for 
expedited repor ting of suspected unexpected serious adverse reactions (SUSARs).
CCI
CCI-
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 45 16 January 2019The SEC may  also recommend unblinding of treatment assignments for one or more subjects to 
help determine if dosing can be resumed in subjects or cohorts where dosing has been suspended.
5.2. Description and Handling of GS-9620 and Placebo to match
5.2.1. Formulation
GS-9620 is available as 1 mg, 2 mgor 4mgstrength tablets. The tablets are round, biconvex, 
plain- faced, and film-coated white. Total tablet weight is 100 mg.
GS-9620 tablets contain lactose, microcry stalline cellulose, c roscarmellose sodium, 
magnesium stearate, pol yethylene gl ycol, pol yvinyl alcohol, talc, and titanium dioxide in 
addition to the active ingredient.
Placebo- to-match GS -9620 tablets are round, biconv ex, plain -faced, and film-coated white.
Total tablet weight is 100 mg.
Placebo tablets contain lactose, microcry stalline cellulose, croscar mellose sodium, 
magnesium stearate, pol yethylene gl ycol, pol yvinyl alcohol, talc, and titanium dioxide .
5.2.2. Packaging and Labeling
GS-9620 tablets and placebo -to-match GS -9620 tablets are packaged in white, high densit y 
polyethylene bottles. Each bottle contains 
5tablets, silica gel desiccant, and poly ester packing 
material. E ach bottle is capped with a child -resistant poly propylene screw cap fitted with an 
induct ion seal, aluminum- faced liner.
Study  drug(s) to be distributed to centers in the US shall be labeled to meet applicable 
requirements of the United States Food and Drug Administration (FDA) and/or other local 
regula tions.
5.3. Dosage and Administration of GS-9620
A blinded study  staff member will utilize the I WRS sy stem to obtain bottle numbers and 
dispense blinded GS -9620 or placebo -to-match tablets from these bottles to randomized subjects 
in the planned cohorts on their dosing day s.Up to six bottles of study  drug (5 tablets perbottle) 
may be assigned by  the IWRS for each subject at randomization.
All subjects must remain on the same formulation throughout the duration of treatment. Subjects 
will be given their dose in the clinic once every  two weeks, and will not take the study  
medication with them.
5.3.1. Fasting and food/liquids Requirement
Thefollowing fasting guidelines should be followed by  subjects on alldosing day s
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 46 16 January 2019Table 5-1. Fasting and food/liquids Requirement
Cohort Fasting Period Water/liquids Permitted Water/liquids at Dosing
1 to 4 At least 2 hours prior to and after dosinga 1 hour prior to and 2 hours 
after dosing240mL o f water
5, 6,  Overnightb (at least 8hrs before dosing for 
Cohorts 5, 6  
 and at least 2 hours after dosing1 hour prior to and 2 hours 
after dosing240mL o f water
a If subjects eat prior to the 2 hour fasting period before study drug dosing, no more than a light meal should be eaten 
(asdescribed in the PK Sample Collection, Processing, Storage , and Shipment Manual).
b If subjects did not fast overnight, plasma GS -9620 Intensive PK must not be completed. The subject should be counseled 
regarding proper fasting requirement and asked to return for the Intensive PK collection.
For Cohorts 1 to 4, GS -9620 or placebo should be taken b y subject swith approximately  
240mLof water on an empty  stomach. Food will not be permitted between at least 2hours prior 
to and until 2 hours after dosing. Aside from the 240 mL  of water provided at dosing, 
water/liqui ds will not be permitted from 1 hour prior to until 2 hours after dosing. If subjects eat 
prior to the 2 hour fasting period before study  drug dosing, no more than a light meal should be 
eaten (asdescribed in the PK Sample Collection, Processing, Storage, and Shipment Manual).
For Cohort s
5, 6 , GS-9620 or placebo should be administered with 
240mL of water after an overnight fast (nothing but water for ≥ 8 hours prior to dosing).
 
 
 
[Note: For all cohorts, other than the water or cranberry  juice provided with dosing, water and 
other fluids will be prohibited for 1 hour before and 2 hours after dosing.]
 
 
 
 
CCI
CCI
CCI
CCI
CCI
CCI
CCI-
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 47 16 January 2019 
 
 
 
 
 
5.3.3. Storage and Handling
GS-9620 and placebo -to-match tablet s should be stored at controlled room temperature of 
25 °C (77°F); excursions are permitted between 15 °C and30 °C (59 °F and86°F).Storage 
conditions are specified on the label.
Until needed for IMP dispens ation to the subjects, b ottles of GS -9620 and placebo -to-match 
should be stored in a securely  locked area, accessible only  to authorized site personnel. To 
ensure the stability  of the tablets and proper product identification, the drug products should be 
stored in the containers in which they  are supplied until needed. Keep the bottles tightly  closed.
CCI
CCI
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 48 16 January 2019Consideration should be given to handling, preparation, an d disposal through measures that 
minimize drug contact with the body . Appropriate precautions should be followed to avoid direct 
eye contact or exposure through in halation when handling GS-9620.
5.4. Prior and Concomitant Medications
No clinical drug -drug inter action studies have been conducted with GS- 9620. GS -9620 is 
predominantly  metabolized by  CYP3A with minor contribution of CYP2C8 and CYP2D6 in 
vitro, and was shown to be a substrate of P -gp and BCRP in vitro. GS-9620 plasma exposure 
may increase or decrease on co -administration with CYP3A /P-gp/BCRP inhibitors or inducers. 
ARV agents known to inhibit or induce CYP3A /P-gp/BCRP are excluded from use in this 
protocol. 
The following agents are NOT allowed as part of the current ARV regimen: HIV 
protease inhibitors (including low dose ritonavir), cobicistat -containing regimens, elvitegravir , 
efavirenz, etravirine, and nevirapine.
Concomitant use of herbal/natural supplements with GS -9620 may  result in pharmacokinetic 
interactions resulting in alterations in exposure of GS -9620. Administration of GS- 9620 with 
grapefruit juice or Seville orange juice may result in higher exposures to GS -9620. Subjects will 
refrain from consumption of grapefruit juice, grapefruits, and Seville orange juice throughout
participa tionin the study .
Subjects are restricted from receiving therap y with any medication listed inTable 5-3. 
Administration of any  of the disallowed medications listed in 
Table 5-3must be discontinued at 
least 14days prior to the Baseline/Day  1 visit and through completion of 
treatment or the 
EarlyStudy  Drug Discontinuation Visit. Any medications not on the list must be reviewed 
with the Sponsor prior to randomization and during the study treatment period. Vitamins 
and/or acetaminophen and/or ibuprofen and/or hormonal contraceptive medications are 
exception sand are allowed during the study period. No immunomodulatory  concomitant 
medicati ons are allowed for at least 30 days prior to Pre -Baseline/Day -13.
Subjects’ ARV regimens must be used in accordance with their Prescribing Information.
At clinically  achieved plasma concentrations, GS-9620 is not expected to be a perpetrator of 
systemic drug
-drug interactions. GS-9620 conc entrations estimated to be achie ved in the gut at 
the 
≥10 mg GS -9620 doses may  transientl y inhibit intestinal P -gp and increase s ystemic 
exposures of the drugs that are known P -gp substrates
. It is recommended that oral P -gp 
substrates are administered with caution in combination with GS -9620 ≥10 mg doses .
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 49 16 January 2019Table 5-3. Prohibited Concomitant Medications
Drug Class Agents DisallowedUse Discouraged and To be Used 
with Caution
Acid Reducing Agents Proton Pump Inhibitors H2-receptor antagonistsa
ACAT inhibitor Avasimibe
ACE Inhibitors Captopril
Analeptic Modafinil
Angiotensin II inhibitors Telmisartan
Anti-anginals Ranolazine
Anti-arrhythmics Amiodarone, Dronedarone, Quinidine
AntibioticsAzithromycin, Clarithromycin, Erythromycin, 
Nafcillin, TelithromycinCiprofloxacin, Trimethoprim
AnticonvulsantsCarbamazepine, Phenytoin, Phenobarbital, 
Oxcarbazepine
AntidepressantsNefazodone , Venlafaxine, Ziprasidone, 
Paroxetine
Antidiabetics Pioglitazone
Anti-epileptics Divalproex
Antiemetics Aprepitant, Casopitant
AntifungalsCaspofungin, Ketoconazole, Itraconazole, 
Voriconazole, Posaconazole, Fluconazole
Antimycobacterials Rifampin, Rifampentine, Rifabutin, Isoniazid
Antiretroviral AgentsHIV Protease Inhibitors (including low dose 
Ritonavir), Cobicistat -containing regimens, 
Elvitegravir, Efavirenz, Etravirine and 
Nevirapine
Beta-Blockers Carvedilol, Talinolol
Calcium Channel BlockersDiltiazem, Felodipine Mibefradil, Nicardipine, 
Nifedipine, Nitrendipine, Verapamil
Diuretics Conivaptan
Endothelin Receptor Antagonists Bosentan
Herbal/Natural Supplements*St. John’s Wort, Echinacea, Gingko, Milk 
thistle, Chinese he rb shosaiko -to 
(orXiao -Shai -Hu-Tang)
HMG -Coa Reductase Inhibitors AtorvastatinPitavastatin , Pravastatin, 
Rosuvastatin , Lovastatin, Fluvastatin, 
Simvastatin
ImmunosuppressantsCyclosporine, Rapamycin, Sirolimus, 
Tacrolimus
Systemic Corticosteroids All agents, including dexamethasoneUse of Prednisone a s a steroid burst 
(≤ 1 week of use) should be 
monitored appropriately
Systemic Chemotherapeutic 
(antineoplastic) AgentsAll agents
a Dose not to exceed 20 mg famotidine or equivalent and dose should b e administered not less than 24 hours prior to dosing 
with GS -9620 and not less than 12 hours after dosing with GS -9620.
* Use of complementary or alternative medicines is prohibited at least 14days prior to Baseline (Day 1) through the end of the 
follow -up
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 50 16 January 2019Should subjects have a need to initiate treatment with any  concomitant medication, the 
Gilead Medical Monitor must be consulted prior to initiation of the new medication. In instances 
where a medication is initiated prior to discussion with the Sponsor, the I nvestigator must notify  
Gilead as soon as he/she is aware of the use of the medi cation.
5.5. Accountability for GS-9620
The investigator is responsible for ensuring adequate accountability  of all used and unused study  
drug. This includes acknowledgement of receipt of each shipment of study  drug
(quantity andcondition).
GS-9620 accountabi lity records will be provided to each stud y site to:
Record the date received and quantity  of study  drug bottles
Record the date, subject number, subject initials, the study  drug bottle number the pills were 
dispensed from .
Record the date, quantity of use d and unused study  drug returned or destroy ed, along with 
the initials of the person recording the information.
5.5.1. I nvestigational M edicinal Product Return or Disposal
Gilead recommends that used and unused IMP supplies be returned to the shipping facility  from 
which it came for eventual destruction. The stud y monitor will provide instructions for return. If 
return is not possible, the study  monitor will evaluate each study  center’s IMP disposal 
procedures and provide appropriate instruction for destruction of unused IMP supplies. I f the site 
has an appropriate standard operating procedure (SOP) for drug dest ruction as determined b y 
Gilead QA, the site may  destroy  used (empt y or partially empty) and unused I MP supplies in 
accordance with that site’s approved SOP. A copy of the site’s approved SOP will be obtained 
for central files. 
If IMP is destroyed on site, the investigator must maintain accurate records for all IMP 
destroy ed. Records must show the identification and quantity  of each unit destroy ed, the method 
of destruction, and the person who disposed of the I MP. Upon study  completion, copies of the 
IMP accountability  records must be filed at the site. Another copy  will be returned to Gilead. If 
drug is destro yed on site, the investigator must maintain accurate records for all study  drug
bottles destroy ed. Records must show the identification and quantity  of each unit destroy ed, the 
method of destruction, and person who disposed of the drug. All study  drug records must be 
maintained at the site and copies must be submitted to Gilead Sciences at the end of the stud y.
The study  monitor will review IMP supplies and associated records at periodic intervals.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 51 16 January 20196. STUDY  PROCEDURES
The study  procedures to be conducted for each subject enrolled in the study  are presented in 
tabular form in Appendix 2and desc ribed in the text that follows.
The investigator must document an y deviation from protocol procedures and notify  the sponsor 
or contract research organization (CRO).
6.1. Subject Enrollment and Treatment Assignment
It is the responsibility  of the investigator to ensure that subjects are eligible to participate in the 
study prior to enrollment. Each study  candidate must sign an Informed Consent Form prior to the 
conduct of an y screening procedures, in accordance with regulatory  and local 
Institutional Review Board requirements. Once consent has been obtained, all screeni ng tests and 
procedures have been completed, and study  eligibility  has been confirmed, subjects will be 
randomized using an IWRS . Subjects will receive study  drug within their assigned treatment 
group as described in 
Section 5.1. With Gilead Medical Monitor approval, c andidates who fail to 
meet eligibility  criteria by  screening evaluations may  be re -screened if there is a reasonable 
expectation that t he candidate will be eligible after repeat screening. The Medical Monitor must 
approve all re -
screening requests.
Retests of screening labs are permitted only  if there is reason to believe the retest value will be 
within accepted parameters, if the initial value was either due to a sample processing error or due 
to an extenuating circumstance (e.g. intercurrent infection). Reasons for any  re- tests should be 
documented.
6.2. Pretreatment Assessments Screening Visit (all cohorts)
Subjects will be screened within 35 day sbefore randomization to determine eligibility  for 
participation in the study . The following will be performe d and documented at screening:
6.2.1.1. Obtain written informed consent
6.2.1.2. Obtain medical history including history  of HIV -1 disease -related events and 
prior medications within 35 day s of the screening visit
6.2.1.2.1. Collect ARV history  for at least 12 months 
6.2.1.2.2. Collect pre-ARV viral set point, pre -ARV CD4 nadir and historical genot ype(s), 
if available
6.2.1.3. Complete phy sical examination including vital signs (blood pressure, pulse, 
respiration rate and temperature) , body  weight, and height. Urogenital/anorectal 
exams will be performed at the discretion of the Investigator
6.2.1.4. 12- lead ECG performed supine
6.2.1.5. Obtain urine collection for urinal ysis
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 52 16 January 20196.2.1.6. Obtain blood samples for:
6.2.1.6.1. Serum pregnancy test (female s ofchildbearing potential only ). If the test is 
positive, th e subject will not be enrolled
6.2.1.6.2. Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, 
uricacid
6.2.1.6.3. Estimated GFR ≥ 60 mL /min according to the Cockcroft -Gault formula for 
creatinine clearance :
Male: (140 –age in years) (wt in kg) CLcr (mL /min)
72(serum creatinine in mg/dL)
Female: (140 –age in years) (wt in kg) 0.85  CLcr (mL/min)
72(serum creatinine in mg/dL)
6.2.1.6.4. Hematology  profile: complete blood count (CBC) with differential and platelet 
count
6.2.1.6.5. CD4+ cell count
6.2.1.6.5.1. C D8+ cell count, CD4/CD8 ratio and CD4 % (for Cohort s 5to 9only)
6.2.1.6.6. Plasma HIV -1 RNA ( TaqMan®v2.0)
6.2.1.6.7. Hepatitis B virus surface antigen serology  
6.2.1.6.8.
Hepatitis C virus serology
6.2.1.6.9. Plasma ART trough PK (for Cohort s 5to 9only)
6.2.1.7. Record an y serious adverse events and al l adverse event srelated to protocol 
mandated procedures occurring after signing of the consent form.
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic within 35 day s after the screening visit for t he Pre-Baseline/Day -13study  visit.
From the time of obtaining informed consent through the first administration of investigational 
medicinal product, record all serious adverse events (SAEs), as well as any adverse events 
related to protocol -mandated procedures on the adverse events electronic case report form 
(eCRF). All other untoward medical occurrences observed during the screening period, including 
exacerbation or changes in medical history are to be capture d on the medical history  eCRF. 
See S ection7Adverse Events and Toxicity  Management for additional details.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 53 16 January 20196.2.2. Pre-Baseline/Day -13 Assessments (all Cohorts)
The following evaluations are to be completed at the Pre-Baseline/Day  -13visit. The 
Pre-Baseline/Day  -13visit is to be completed within ± 3 day s of the protocol specified visit date.
6.2.2.1. Review of Inclusion/Exclusion criteria to confirm subject eligibility
6.2.2.2. Review of AEs and changes in conco mitant medications
6.2.2.3. Review medical history
6.2.2.4. Symptom -directed phy sical examination as needed
6.2.2.5. Blood sample collection for the following laboratory  anal yses:
6.2.2.5.1. PBMC for HIV specific T cell response b y ELISPOT  
 
6.2.2.5.2. TLR7 genot yping
6.2.2.5.3. Pharmacokinetic Blood Collection -Details of pharmacokinetic blood sampling 
procedures and sample management for all PK samples in the study  will be 
documented in the Pharmacokinetic Sample Collection, Processing, Storage, and 
Shipment Manual.
6.2.2.5.3.1. Pharmacokinetic assessments (for Cohort s1 to 3 only ) - Plasma ARV 
concentrations: a single troug h PK sample will be collected. The timing of the 
ARV trough collection is to be 20 -
24hours following the subject’s previous QD 
regimen dose (and, for any  subject on a regimen containing a BID component, the 
trough collection must also occur 8 -12hours fol lowing the subject’s previous 
dose of that BID component).
6.2.2.5.5. HIV specific pol yfunctional T cell ICS ( for Cohort s 4 to 9).  
 
6.2.2.5.6. HIV
-1reservoir measurement s (for Cohort s
4to 9).  
 
6.2.2.5.7. Blood sample collection for future biomarker and virology studies (for Cohort s 4
to 9).  
CCI
CCI
CCI
CCI
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 54 16 January 20196.2.2.6. Obtain subject number and randomize the subject via I WRS. The subject number 
assignment and randomization may  be performed up to 3 days prior to the 
in-clinic Pre-Baseline/ Day -13 visit provided that all screening procedures have 
been completed and subject eligibility  has been confirmed.
6.2.2.7. Subjects should be reminded to come in for Day  1 visit in an overnight fasted 
state for Cohorts 5 to 9. 
6.2.3. Baseline /Day 1 Assessments (all Cohorts)
Subjects are to arrive in a fasting state for the Baseline/Day  1 visit . Initiation of the treatment 
with the study  drug must take place in the clinic and will be administered by blinded study  staff .
Fasting requirement and food/liquids consumption requirement is shown in Table 5-1.
For all cohorts, s
ubjects will remain on-site for 12 hours after the first dose for safety 
assessments and phlebotomy. The following evaluations are to be completed at the 
Baseline/Day  1 Vis it:
6.2.3.1. Review medical history
6.2.3.2. Review of AEs and changes in concomitant medication
 
 
6.2.3.4. Symptom -directed phy sical examination as needed
6.2.3.5. Vital signs (blood pressure, pulse, respiration rate and temperature)
6.2.3.6. Weight
6.2.3.7. VAS Adherence Questionnaire to be completed by  the subject. Subject is to read 
questionnaire b y himself/herself and write/mark answers directly  onto 
questionnaires. (Cohorts 5 to 9only)
6.2.3.8. Urine collection for the following laboratory  procedures:
6.2.3.8.1. Urinaly sis 
6.2.3.8.2. Urine pregnancy  test (females of childbearing potential only ). If the uri ne 
pregnancy  test is positive at Baseline/Day  1, study drug will not be dispensed. 
The positive result will be confirmed with a serum pregnancy  test. If the serum 
pregnancy  test is positive, the subject will not be able to participate
CCI-
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 55 16 January 20196.2.3.9. Blood sample collection for the following laboratory  anal yses:
6.2.3.9.1. Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, mag
nesium, potassium, sodium, 
uricacid
6.2.3.9.2. Estimated glomerular filtration rate according to th e Cockcroft -Gault formula for 
creatinine clearance
6.2.3.9.3. Hematology  profile: complete blood count (CBC) with differential and platelet 
count
6.2.3.9.4. Plasma HIV -1 RNA ( TaqMan®v2.0)
6.2.3.9.5. CD4+ cell count
6.2.3.9.5.1 CD8 +cell count, CD4/CD8 ratio and CD4 % (Cohort s 5to 9 only )
6.2.3.9.6. Serum for cy tokine/soluble biomarker studies
6.2.3.9.7. Whole blood ISG mRNA panel
6.2.3.9.8. Cell-associated HIV -1 RNA/DNA (CAVR/CAVD) with stored PBMC .
6.2.3.9.9. Plasma HIV - 1RNA Single Copy  Assay  with stored plasma 
6.2.3.9.10. Whole blood for immune cell activation (T, B, NK) and FoxP3+ Treg level
6.2.3.9.11. PBMC intracellular cy tokine staining (ICS) for Treg cells (for Cohort s1 to 
3only)
6.2.3. 9.12. Pharmacokinetic Blood Collection
Intensive PK sampling will occur at the following time points
Pre-dose ( ≤5 minutes prior to dosing), 0.5, 1, 2, 4, 6, 8, 10, and 12 hours post dose at 
Baseline/Day  1;
Then one sample on Day 3 at time = 48 hours post dose.
Details of pharmacokinetic blood sampling procedures and sample management for all PK 
samples in the study  will be documented in the Pharmacokinetic Sample Collection , Processing, 
Storage, and Shipment Manual.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 56 16 January 20196.2.3.10. Stool sample collection before dosing for microbiome anal ysis (if subject is able 
to provide) (Cohorts 5 to 9).
 
6.2.3.11. In-Clinic Dosing
Dose GS-9620 or placebo with 240 mL  of water ( All Cohorts ,
6.3. Treatment Assessments (Cohort s1 to 3)
6.3.1. Treatment Assessments on Non Dosing Days 3, 5, 1 1, 17, 19, 25, 31, 33, 39, 45,
47, 53, 59, 61, 67, 73, 75 and 81
All study  visits are to be scheduled relative to the Baseline/Day  1 visit. All study  visits listed
above except for Day 3 allow a visit window within ± 1 day  of the protocol specified visit date. 
The following procedures will be performed:
6.3.1.1. Review of AEs and changes in concomitant medications
6.3.1.2. Symptom -directed phy sical examination as needed
6.3.1.3. Blood sample collection for the following laboratory  anal yses:
6.3.1.3.1. Plasma HIV -1 RNA ( TaqMan®v2.0)
6.3.1.3.2. Hematology  profile: complete blood count (CBC) with differential and 
platelet count 
(Days 3, 17, 31, 45, 59 and 73 only )
6.3.1.3.3. CD4+ cell count (Days 3, 17, 31, 45, 59 and 73 only)
6.3.1.3.4. Serum for cy tokine/soluble biomarker studies (Days 3, 17, 31, 45, 59 and 
73only)
6.3.1.3.5. Whole blood ISG mRNA panel (Days 3, 17, 31, 45, 59 and 73 only)
6.3.1.3.6. Cell-associated HIV -1 RNA/DNA with stored PBMC (Day s 3, 45, and73only)
6.3.1.3.7. Plasma HIV -
1RNA Single Copy  Assay  with stored plasma (Day s 3, 45, and
73only)
CCI
CCI
CCII 
I 
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 57 16 January 20196.3.1.3.8. Whole blood for immune cell activation (T, B, NK) (Days 3, 31 and 73only)
6.3.1.3.9. PBMC I ntracellular cy tokine staining (ICS) for Treg cells (Day s 3 and 73 only)
6.3.1.3.10. GS-9620 plasma pharmacokinetic assessment (Day 3 only)
6.3.2. Treatment Assessments on Non Dosing Days 8, 22, 36, 50, 64 and 78
All study  visits are to be scheduled relativ e to the Baseline/Day  1 visit. Study  visits on 
Days
8, 22, 36, 50, 64 and 78are to be completed within ± 1 day  of the protocol specified visit 
date. The following procedures will be performed:
6.3.2.1. Review of AEs and changes in concomitant medications
6.3.2.2. Symptom -directed phy sical examination as needed
6.3.2.3. Urine collection for urinaly sis
6.3.2.4. Blood sample collection for the following laboratory  anal yses:
6.3.2.4.1. Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and 
indirect bili
rubin, total protein, albumin, CPK, bicarbonate, BUN, calcium,
chloride, creatinine, glucose, p hosphorus, mag nesium, potassium, sodium, 
uricacid
6.3.2.4.2. Hematology  profile: complete blood count (CBC) with differential and 
platelet count
6.3.2. 4.3. Plasma HIV -1 RNA ( TaqMan®v2.0)
6.3.2.4.4. CD4+ cell count
6.3.2.4.5. Serum for cy tokine/soluble biomarker studies
6.3.2.4.6. Whole blood I SGmRNA panel
6.3.3.
Treatment Assessments on Dosing Days 15, 29, 43, 57 and 71
On dosing day s, GS -9620 or placebo should be taken by  subject with approximately  240 mLof 
water on an empty  stomach. Food will not be permitted between at least 2 hours prior to and 
until 2 hours after dosing. Aside from the 240 mL of water provided at dosing, water/liquids will 
not be permitted from 1 hour prior to until 2 hours after dosing. If subjects eat prior to th e 2hour 
fasting period before study  drug dosing, no more than a light meal should be eaten
(asdescribed in the PK Sample Collection, Processing, Storage, and Shipment Manual) .
These fasting guidelines should be followed b y subjects on all dosing day s.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 58 16 January 2019Prior to the subject being administered the in -clinic dose the I nvestigator must verify the 
subject’s continued eligibility for in -
clinic dosing, including the absence of Dose Limiting 
Toxicities (DLTs) described in Section 7.6.1.
All doses will be directly administered to the study subject by blinded site staff.
6.3.3.1. Review of AEs and changes in concomitant medication
6.3.3.2. Symptom -directed phy sical examination as needed
6.3.3.3. Vital signs (blood pressure, pulse, respiration rate and temperature)
6.3.3.4. Urine collection for the following laboratory  procedures:
6.3.3.4.1. Urinaly sis 
6.3.3.4.2. Urine pregnancy  test (females of childbearing potential only ). If the urine 
pregnancy  test is positive at a dosing visit, study  drug will not be dispensed. The 
positive result will be confirmed with a serum pregnancy  test. If the serum 
pregnancy  test is positive, the subject will be discontinued from the study
6.3.3.5. Blood sample collect ion for the following laboratory  anal yses:
6.3.3.5.1. Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and 
indirect bili
rubin, total protein, albumin, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, mag
nesium, potassium, sodium, 
uricacid
6.3.3.5.2. Hematology  profile: complete blood count (CBC) with diffe rential and 
platelet count
6.3.3.5.3. Plasma HIV -1 RNA ( TaqMan®v2.0)
6.3.3.5.4. CD4+ cell count
6.3.3.5.5. Cell-associated HIV -1 RNA/DNA with stored PB MC (Days 43 and 71 only)
6.3.3.5.6. Serum for cy tokine/soluble biomarker studies collected pre -dose
6.3.3.5.7. Whole blood I SGmRNA panel collected pre -dose
6.3.3.5.8. Plasma HIV - 1RNA Single Copy  Assay  with stored plasma collected pre- dose 
(Days 43 and 71 only)
6.3.3.5.9. Whole blood for immune cell activation (T, B, NK,) and FoxP3+ Treg level 
collected pre -dose (Days 29 and 
71only)
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 59 16 January 20196.3.3.5.10. PBMC for ELISPOT collected pre -dose (Day 71only)
6.3.3.5.11 PBMC I ntracellular cy tokine staining (ICS) for Treg cells (Day 71 only)
6.3.3.6. The Investigator will verify  the subject ’s continued eligibility  for in -clinic dosing, 
including the absence of DL Ts described in Section 7.6.1.
6.3.3.7. In-Clinic Dosing
6.4. Treatment Assessments (Cohort s
4to 9)
 
6.4.1. Treatment Assessments on Non Dosing Days 2, 58 and 128
All study  visits are to be scheduled relative to the Baseline
/Day 1 visit. The following procedures 
will be performed :
6.4.1.1. Review of AEs and changes in concomitant medications 
6.4.1.2. Symptom -directed phy sical examination as needed
6.4.1.3. Urine collection for urinaly sis(Day 2 only)
6.4.1.4. Blood sample collection for the following laboratory  anal yses:
6.4.1.4.2. Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, 
uricacid (Day 2 only)
6.4.1.4.3. Hematology  profile: complete blood count (CBC) with differential and platelet 
count (Day 2 only)
6.4.1.4.4. Plasma HIV -1 RNA ( TaqMan®v2.0)
6.4.1.4.5. Serum for 
cytokine/soluble biomarker studies
6.4.1.4.6. Whole blood I SG mRNA panel
6.4.1.4.7. Whole blood for immune cell activation (T, B, NK) 
CCI
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 60 16 January 20196.4.2. Treatment Assessments on Non Dosing Days 3, 59 and 129
All study  visits are to be scheduled relative to the Baseline/Day 1 visit. The following procedures 
will be performed:
6.4.2.1. Review of AEs and changes in concomitant medications 
6.4.2.2. Symptom -directed phy sical examination as needed
6.4.2.3. Urine collection for urinaly sis (Days 59and 129 only)
6.4.2.4. Blood sample collection for the following lab oratory  anal yses:
6.4.2.4.1. Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium,
uricacid (Days 59 and 129 only)
6.4.2.4.2. Hematology  profile: complete blood count (CBC) with differential and platelet 
count (Days 59 and 129 only)
6.4.2.4.3. Plasma HIV -1 RNA (TaqMan® v2.0)
6.4.2.4.4. Serum for cy tokine/soluble biomarker studies
6.4.2.4.5. Whole blood I SG mRNA panel 
6.4.2.4.6. Cell-associated HIV -1 RNA/DNA with stored PBMC 
6.4.2.4.7. Plasma HIV -1 RNA Single Copy  Assay  with stored plasma 
6.4.2.4.8.
Whole blood for immune cell activation (T, B, NK) 
6.4.2.4.9. GS-9620 plasma pharmacokinetic assessment (Day  3 onl y)
6.4.3. Treatment Assessments on Non Dosing Days 8, 22, 36, 50, 64, 78, 92, 106, 120 
and 134
All study  visits are to be scheduled relative to the Baseline
/Day 1 visit. Study  visit s on 
Days 8, 22, 36, 50, 64, 78 , 92, 106, 120 and 134 are to be completed within ± 1day of the 
protocol specified visit date. The following procedures will be performed:
6.4.3.1. Review of AEs and changes in concomitant medications
6.4.3.2. Symptom -directed phy sical examination as needed
6.4.3.3. Urine collection for urinaly sis(Day s50, 64, 78, 92, 120 and 134 only)
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 61 16 January 20196.4.3.4. Blood sample collection for the following laboratory  anal yses:
6.4.3.4.1. Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and 
indirect bili
rubin, total protein, albumin, CPK, bicarbonate , BUN, calcium,
chloride, creatinine, glucose, phosphorus, mag nesium, potassium, sodium, 
uricacid (Day s50, 64, 78, 92, 120 and 134 only)
6.4.3.4.2. Hematology  profile: complete blood count (CBC) with differential and 
platelet count (Day s50, 64, 78, 92, 120 and 134 only)
6.4.3.4.3. Plasma HIV -1 RNA ( TaqMan®v2.0)
6.4.3.4.4. CD4+ cell count (Day s50, 64, 78, 92, 120 and 134 )
6.4.3.4.4.1 CD8+ cell count, CD4/CD8 ratio and CD4 % (Days50, 64, 78, 92, 120 and 134 
for Cohorts 5 
to 9 only)
6.4.3.4.5. Serum for cy tokine/soluble biomarker studies (Days 50, 64 and 134only)
6.4.3.4.6. Whole blood I SG mRNA panel (Days 50, 64 and 134only)
6.4.4.
Treatment Assessments on Dosing Days 15, 29, 43, 57, 71, 85, 99, 113 and 127
Subjects are to arrive in a fastin g state for the Dosing Day s 15, 29, 43, 57, 71, 85, 99, 113 and 
127and to follow fasting and food/liquids consumption requirement shown in 1. Initiation of the 
treatment with the study  drug must take place in the clinic and will be admini stered by  blinded
study  staff.
For all subjects in Cohort 6, Dose 4 (Day 43) will occur after SEC review has been completed. 
Prior to the subject being administered the in -
clinic dose the Investigator must verify the 
subject’s continued eligibility for in -clinic dosing, i ncluding the absence of Dose Limiting 
Toxicities (DLTs) described in Section 7.6.1.
All doses will be directly administered to the study subject by blinded site staff.
6.4.4.1. Review of AEs and changes in concomitant medication
6.4.4.2. Symptom -directed phy sical examination as needed
6.4.4.3. Vital signs (blood pressure, pulse, respiration rate and temperature)
6.4.4.4. Observe , if possible, and record t he exact tim e that subject start s consuming 
the 
meal, the time that (s)he finishes the meal, and what (if an ything) is not eaten and 
how much is consumed (Cohort 9 only )
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 62 16 January 20196.4.4.5. VAS Adherence Questionnaire to be completed by  the subject. Subject is to read 
questionnaire b y himself/herself and write/mark answers directly  onto 
questionnaires. (Day s 29, 57, 99 and 127 for Cohorts 5 to 9only)
6.4.4.6. Urine collection for the following laboratory  procedures:
6.4.4.6.1. Urinaly sis 
6.4.4.6.2. Urine pregnancy  test (females of childbearing potential only ). Ifthe urine 
pregnancy  test is positive at a dosing visit, study  drug will not be dispensed. The 
positive result will be confirmed with a serum pregnancy  test. If the serum 
pregnancy  test is positive, the subject will be discontinued from the study
6.4.4.7. Blood sam ple collection for the following laboratory  anal yses:
6.4.4.7.1 Plasma ART trough PK 
(Day s29, 57, 85 and 99 for Cohort 5;Days57 and 99
for Cohorts 6 
6.4.4.7.2. Chemistry  profile: alkaline phosphatase , AST, ALT, total bilirubin, direct and 
indirect bili
rubin, total protein, albumin, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, 
uricacid
6.4.4.7.3. Hematology  profile: complete blood count ( CBC ) with differential and 
platelet count
6.4.4.7.4. Plasma HIV -1 RNA (TaqMan®v2.0)
6.4.4.7.5. CD4+ cell count
6.4.4.7.5.1 CD8+ cell count, CD4/ CD8 ratio and CD4 % ( Cohort s 5to 9only)
6.4.4.7.6. Cell-associated HIV -1 RNA/ DNA (CAVR/CAVD) with stored PBMC ( Days 57 
and 127 only)
6.4.4.7.7. Serum for cy tokine/soluble biomarker studies collected pre -dose (Day 43 for
Cohort 6 subject swho receive 12 mg at Dose 4; Days 57 and 127 for all subjects)
6.4.4.7.8. Whole blood I SG mRNA panel collected pre -dose (Day 43 for Cohort 6 subject s
who receive 12 mg at Dose 4; Days57 and 127 for all subjects)
6.4.4.7.9. Plasma HIV - 1RNA Single Copy  Assay  with stored plasma collected pre- dose 
(Days 57 and 127 only)
6.4.4.7.10. Whole blood for immune cell activation (T, B, NK,) and FoxP3+ Treg level 
collected pre -dose 
(Days 57 and 127 only)
CCI-
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 63 16 January 20196.4.4.7.11. Pharmacokinetic Blood Collection (only if the SEC approves the dose 
escalation to 12 mg in Cohort 6, starting from Dose 4 and onwards ) 
Intensive PK sampling will occur at the following time points
Pre-dose ( ≤5 minutes prior to dosing), 0.5, 1, 2, 4, 6, 8, 10 , and 12 hours post dose at Day 43;
Then one sample on Day 45 (48 hours post dose)
Details of pharmacokinetic blood sampling procedures and sample management for all PK 
samples in the study  will be documented in the Pharmacokinetic Sample Collection, Processing, 
Storage, and Shipment Manual. 
6.4.4.8. The Investigator will verify  the subject ’s continued eligibility  for in -clinic dosing, 
including the absence of DL Ts described in Section 7.6.1.
6.4.4.9. In-Clinic Dosing
6.4.5. Treatment Assessments on Non Dosing Day s31, 45, 73, 87, 101 and 115 
(For Cohort s
5to 9only)
All study  visits are to be scheduled relative to the Baseline/Day  1 visit. Study visits on Day 31, 
Day 45, Day  73, Day 87, Day  101 and Day  115 Day are to be completed within ± 1day of the 
protocol specified visit date. The following procedures will be performed:
6.4.5.1. Review of AEs and changes in concomitant medi cation
6.4.5.2. Symptom -directed phy sical examination as needed
6.4.5.3. Urine collection for urinaly sis (Days 73, 87, 101 and 115 only)
6.4.5.4.
Blood sample collection for the following laboratory  anal yses:
6.4.5.4.1. Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric 
acid ( Days 73, 87, 101 and 115 only)
6.4.5.4.2. Hematology  profile: complete blood count (CBC) with differential and platelet 
count ( Days
73, 87, 101 and 115 only)
6.4.5.4.3. Plasma HIV -1 RNA ( TaqMan®v2.0)
6.4.5.4.4. Serum for cy tokine/soluble biomarker studies (Day 45 , only  if the SEC approves 
the dose escalation to 12 mg in Cohort 6 starting from Dose 4
)
6.4.5.4.5. Whole blood I SG mRNA panel (Day 45, only if the SEC approves the dose 
escalation to 12 mg in Cohort 6 starting from Dose 4 )
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 64 16 January 20196.5. Post-treatment Assessments
6.5.1. End of Study Visit (all Cohorts)
30daysafter the last administration of study  drug, subjects will return to the study  center to 
complete an end of study visit . For the purpose of scheduling the end of study  visit, a ± 3days 
window may  be used. 
The following evaluations and/or procedures will be performed at the 
endof study  visit for all cohorts, unless otherwise specified :
6.5.1.1. Review of AEs and changes in concomitant medication
6.5.1.2. Symptom -directed phy sical examination as needed
6.5.1.3. Weight
6.5.1.4. Urine collection for the following laboratory  procedures:
6.5.1.4.1. Urinaly sis 
6.5.1.4.2. Urine pregnancy  test (females of chi ldbearing potential only ,if not done within 
the previous 30 day s ). 
6.5.1.5. Stool sample collection for microbiome anal ysis (if subject is able to provide) 
(Cohort s 5 to 9only) .  
6.5.1.6. Blood sample collection for the following laboratory  anal yses:
6.5.1.6.1. Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and 
indirect bili
rubin, total protein, albumin, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, 
uricacid
6.5.1.6.2. Estimated glomerular filtration rate according to the Cockcroft -Gault formula for 
creatinine cleara nce
6.5.1.6.3. Hematology  profile: complete blood count (CBC) with differential and 
platelet count
6.5.1.6.4. Plasma HIV -1 RNA ( TaqMan®v2.0)
6.5.1.6.5. CD4+ cell count
6.5.1.6 .5.1 CD8+ cell count, CD4/CD8 ratio and CD4 % (Cohort s 5to 9only)
6.5.1.6.6. Cell-associated HIV -1 RNA/DNA (CAVR/CAVD) with stored PBMC 
CCI
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 65 16 January 20196.5.1.6.7. Plasma HIV - 1RNA Single Copy  Assay  with stored plasma 
6.5.1.6.8. PBMC for HIV specific T cell response b y ELISPOT  
 
6.5.1.6.9. Serum for cy tokine/soluble biomarker studies (Cohort s 1to 3only)
6.5.1.6.10. Whole blood I SG mRNA panel (Cohort s 1to 3 only)
6.5.1.6.11. HIV specific pol y -functional T cell ICS ( Cohort s 4 to 9).  
 
6.5.1.6.12. HIVreservoir measurements (Cohorts 4 to 9).  
 
6.5.1.6.13.  
6.5.2. Early Study 
Drug Discontinuation Visit (all Cohorts)
Subjects who prematurely discontinue stud ydrug will be required to complete an Earl y Study  
Drug Discontinuation Visit (ESDD) within 30 days after their last dose of study  treatment.
If a subject discontinues study  dosing (for example, as a result of an AE) every  attempt should be 
made to keep the subj ect in the study  and continu e to perform the required study -
related 
follow -up and procedures .
At the ESDD Visit, any evaluations showing abnormal results indicating that there is a 
possible or probable causal relationship with the study drug , should be rep eated weekly 
(oras often as deemed prudent by the Investigator ) until the abnormality is resolved, 
returns to baseline, or is otherwise explained.
The following evaluations are to be completed at the Early Study Drug Discontinuation Visit for 
all cohorts, unless otherwise specified :
6.5.2.1. Review of AEs and changes in concomitant medication
6.5.2.2. Symptom -directed phy sical examination as needed
6.5.2.3. Weight
CCI
CCI
CCI
CCI
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 66 16 January 20196.5.2.4. Urine collection for the following laboratory  procedures:
6.5.2.4.1. Urinaly sis 
6.5.2.4.2. Urine pregnancy  test (females of childbearing potential only ). 
6.5.2.5. Stool sample for microbiome anal ysis (if subje ct is able to provide) 
(Cohorts 5to9).  
 
6.5.2.6.
Blood sample collection for the following laboratory  anal yses:
6.5.2.6.1. Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, CPK, bicarbo nate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, mag nesium, potassium, sodium, 
uricacid
6.5.2.6.2. Estimated glomerular filtration rate according to the Cockcroft -Gault formula for 
creatinine clearance
6.5.2.6.3. Hematology  profile: complete blood count (CBC) with differential and 
platelet count
6.5.2.6.4. Plasma HIV -1 RNA ( TaqMan®v2.0)
6.5.2.6.5. CD4+ cell count
6.5.2.6.5.1 CD8 +cell count, CD4/CD8 ratio and CD4 % (Cohort s 5to 9only)
6.5.2.6.6. Serum for cy tokine/soluble biomarker studies
6.5.2.6.7. Whole blood I SG mRNA panel
6.6. Criteria for Discontinuation of Study Treatment
Study  medication may  be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical s
tatus to a significant degree 
Unacceptable toxicity , ortoxicity  that, in the judgment of the investigator, compromises the 
ability  to continue study -specific treatment and/or procedures or is considered to not be in the 
subject ’s best interest
Subject receives GS -9620 and experiences one or more DLTs (at discretion of SEC )
CCI
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 67 16 January 2019Subject request to discontinue for an y reason
Subject noncompliance
Pregnancy  during the study ; refer to Appendix 5
Discontinuation of the study at the request of Gilead, a regula tory agency  or an 
institutional review board (I RB)
 
 
 
 
 
 
 
6.8. Prolonged Viremia
Subjects will be considered to have prolonged viremia if they  have two consecutive plasma 
HIV-1RNA levels ≥
200copie s/mL  during a single dosing period .
6.8.1. Management of Prolonged Viremia
If plasma H IV-
1RNA level is ≥ 200 copies/mL  at any visit post - dose, viral load will be tested at 
next scheduled visit or retested within 4 day s. The next dose will be withheld and only  given 
after viral load of ≤ 200 copies/mL  is achieved. The study  procedure schedule will be reset 
relative to the next dose of study  drug. 
If HIV -1 RNA viral load ≥
200copies/mL  is confirmed during a single dosing period, then this 
subject will be considered to have prolonged viremia and blood samples from this visit will be 
used for HIV -1 genot ype/phenoty pe testing with assay s corresponding to the antiretroviral
medications the subject is taking.
If primary  resistance mutations to the subject’s existing ART regimen are ident ified, a new ART
regimen will be configured at the discretion of the I
nvestigator and the subject will be 
discontinued from the study . If the genot yping/phenoty ping assay  fails to provide results or no 
drug resistance mutations are identified, a new ART re gimen may  be configured at the discretion
of the Investigator. Subjects who start a new ART regimen will not be allowed to receive further
doses of study  drug, but can be monitored for the study  duration at the discretion of the study
Investigator. Subjects who remain on their current ART regimen must show confirmed HIV -1 
RNA levels <200 copies/mL  before resuming study  drug dosing at the discretion of the 
Investigator.
CCI
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 68 16 January 20197. ADVERSE EVENTS AND T OXICITY  MANAGEMENT
7.1. Definition sof Adverse Events , Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a medicinal product, which does not necessarily  have a causal relationship with the 
treatment. An AE can therefore be an y unfavorable and/or unintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered re lated to 
the medicinal product. AEs may  also include pre -or post -treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy , overdose ,drug abuse/misuse reports , or 
occupational exposure .Preexisting events that increase in severit y or change in nature during or 
as a consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy , tooth extraction, and transfusion. 
The condition that led to the procedure may be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
screening visit that do not worsen
Situations where an untoward medical occurrence has not occurred (e.g., hospitalization for 
elective surgery , social and/or convenience adm issions)
Overdose without clinical sequelae (see Section 7.7.1 )
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. I t is considered to be pre -existing and should be documented on the medical history  
eCRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at an y dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospitalization or prolongation of existing hospitalization
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 69 16 January 2019Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction: such eve nts may  not be immediately  
life-threatening or result i n death or hospitalization but may  jeopardize the subject or may  
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedit ed reporting rules. Examples of m edically  important e vents include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; anddevelopment of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a 
medicall y important e vent and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to IMP interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital signs) that are 
associated with signs and/or sy mptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.1 and7.1.2 .If the laboratory  
abnormality is part of a sy ndrome, record the s yndrome or diagnosis (eg, anemia), not the 
laboratory  result (ie, decreased hemoglobin).
For specific information on handling of clinical laboratory  abnormalities in this study , please 
refer to Section 7.5.
7.2.
Assessment of Adverse Events and Serious Adver se Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs an d Procedures
The investigator or qualified subinvestigator is responsible for assessing t he relationship to 
IMP therapy  using clinical judgment and the following considerations:
No:Evidence exists that the adverse event has an etiology  other than the IMP. For SAEs, an 
alternative causality must be provided (eg, pre -existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes: There is reasonable possibility  that the event may  have been caused by the 
investigational medicina l product.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 70 16 January 2019It should be emphasized that ineffective treatment should not be considered as causall y related in 
the cont ext of adverse event reporting.
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be as sessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes: The adverse event occurred as a result of protocol procedures, (eg., venipun cture)
7.2.2. Assessment of Severity
A distinction should be drawn between seriousness and severit y of AEs. An AE that is assessed 
as Grade 4 (potentiall y life -threatening) should not be confused with an SAE. Severity  is a 
category  utilized for rating the intensit y of an event; and both AEs a nd SAEs can be assessed as 
Grade 4. An event is defined as “serious” when it meets one of the predefined outcomes 
described above in Section 7.1.2.
Severity  should 
be recorded and graded according to the GSI Grading Scale for Severit y of 
Adverse Events and Laboratory  Abnormalities ( Appendix 4) For adverse events associated with 
laboratory  abnormalities, the event should be graded on t
he basis of the clinical severit y in the 
context of the underly ing conditions; this may  or may  not be in agreement with the grading of 
the laboratory abnormality .
7.3. Inve stigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead
Requirements for collection prior to study drug initiation:
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be reported on the case report form (eCRF): all serious adverse events (SAEs) and 
adverse events related to protocol- mandated procedures.
Adverse Events
Following initiation of study  medication, collect a ll AEs, regardless of cause or rela tionship, 
until 30 day s after last administration of study  IMP must be reported to the eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
Gilead Sciences may  request that certain A Es be followed bey ond the protocol defined follow up 
period.
Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur safter the subject first consents to 
participate in the study (ie, signing the informed consent) and throughout th e duration of the 
study , including the protocol -required post treatment follow -up period, must be reported to the 
eCRF database and Gilead Pharmacovigilance andEpidemiology (PVE ) as instructed. This also 
includes an y SAEs resulting from protocol- associate d procedures performed 
after informed 
consent is signed.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 71 16 January 2019Any SAEs and deaths that occur after the post treatment follow -up visit but within 4 weeks of 
the last dose of study  IMP, regardless of causalit y, should a lso be reported.
Investigators are not obligated to activel y seek SAEs after the protocol defined follow up period,
however, if the investigator learns of an y SAEs that occur after stud y participation has concluded 
and the event is deemed relevant to the use of IMP, he/she should promptly  document a nd report 
the event to Gilead PVE .
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline.
Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the e CRF database and from there transmit the SAE 
information to Gilead PVE within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If for an y reason it is not possible to record the SA E information electronically , ie, the eCRF 
database is not functioning, record the SAE on the paper serious adverse event reporting 
form and submit within 24 hours to Gilead PVE :
Gilead Sciences PVE Representative: Fax:
E
-mail:
As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eC RFdatabase has been locked, 
nofurther action is necessary .
For fatal or life -threatening events, copies of hospital case reports, autops y reports, and other 
documents are also to be submitted by  e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability  of a document to the subject identifiers.
Additional information may  be requested to ensure the timely  completion of accurate safet y 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s eCRF and the event description section of the SAE form.
PPD
PPD
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 72 16 January 20197.4. Gilead Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country -specific legislation or regulations, Gilead may  berequired to expedite to 
worldwide regulatory  agencies reports o f SAEs , serious adverse drug reactions (SADRs) ,or 
suspected unexpected serious adverse reactions (SUSARs). In accordance with the 
EUClinical Trials Directive (2001/20/EC), Gilead or a specified designee will notify  worldwide 
regulatory  agencies and the relevant IECin concerned Member States of applicable SUSARs as 
outlined in current regulations.
Assessment of e xpectedness forSAEs will be determined by  Gilead using reference safety  
information specified in the 
investigator’s brochure or releva nt local label as applicable .
All investigators will receive a safet y letter notifying them of relevant SUSAR reports associated 
with any  study  IMP. The investigator should notify  the IRB or IEC of SUSAR reports as soon as 
is practical, where this is requi red b y local regulatory agencies, and in accordance with the local 
institutional policy .
7.5. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities are usuall y not recorded as AEs o r SAEs. However, laboratory  
abnormalities (eg, clinical chemistry , hematology , urinaly sis) independent of the 
underly ingmedical condition that require medical or surgical intervention or lead to 
investigational medicinal product interruption or discontinua tion must be recorded as an AE, as 
well as an SAE, if applicable. In addition, laboratory  or other abnormal assessments 
(eg,electrocardiogram, x -rays, vital signs) that are associated with signs and/or sy mptoms must 
be recorded as an AE or SAE if they  meet the definition of an AE (or SAE) as described in 
Sections 7.1.1 and7.1.2. If the laboratory  abnormality  is part of a s yndrome, record the 
syndrome or diagnosis (ie, anemia) not the l aboratory  result (ie, decreased hemoglobin).
Severity  should be recorded and grade d according to the GSI Grading Scale for Severit y of 
Adverse Events and Laboratory  Abnormalities ( Appendix 4)For adverse events associated with 
laboratory  abnormalit ies, the event should be graded on the basis of the clinical se
verity in the 
context of the underly ing conditions; this may  or may  not be in agreement with the grading of 
the laboratory abnormality .
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 73 16 January 20197.6. Toxicity Management
7.6.1. Management of Dose -Limiting Toxicitie s (DLTs)
Prior to the subject being administered the in -clinic dose the Investigator will verify  the subjects 
continued eligibility  for dosing, including the absence of DLTs listed below:
ALT elevation as defined as:
ALT ≥ 10 × ULN OR
Confirmed ALT elevation (ie. Grade shift or 2× previous value) with evidence of 
worsened hepatic function (e.g. total bilirubin > 2mg/dL a bove Baseline, 
serum albumin > 1g/dL decrease from Baseline)
A confirmed ≥ Grade 3 AE considered drug related by the Investigator
Aconfirmed, clinically  significant ≥Grade 3 laboratory  abnormalit y considered stud y 
drug-related b y the investigator
A persistent ( ≥ 72 hours) ≥ Grade 2 flu- like sy mptom (py rexia, fatigue, myalgia, arthralgia, 
headache, chills) considered study drug-related b y the in vestigator
A post -dose increase in plasma HIV -1 RNA that fails to reso lve to < 50 copies/mL  within 
10daysin Cohorts 1 to 3 
A post -dose increase in plasma HIV -1 RNA that fails to resolve to < 200copies/mL  within 
10days in Cohort s
4to 9
The designated Safet y Evaluation Committee contact will be notified within 24 hours of the 
Investigator’s knowledge of a subject having an y of the above DLTs . Dosing must be withheld 
until the Safety  Evaluation Committee determines the appropriate next s teps, including but not 
limited to additional safety , pharmacokinetic and pharmacody namic assessments
. The SEC may  
also suspend dosing in additional subjects or cohorts.
The SEC may  hold or discontinue study  drug dosing f or a subject if they  receive GS -9620 an d 
experience one or more DL Ts. The SEC may  hold or discontinue study  drug dosing for a cohort 
if 
≥ 2 out of 6 subjects receiving GS -9620 experience one or more DLTs. 
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 74 16 January 20197.6.2. Management of Other Toxicit ies
Unless otherwise specified in Section 7.6.1, toxicities will be managed according to the 
guidelines below.
All clinical and clinicall
y significant laboratory toxicities will be managed according to 
uniform guidelines detailed in Appendix 3.
Grade 3 and 4 clinicall y significant laboratory  abnormalities should be confirmed by  repeat 
testing 
within 3 calendar day s of receipt of results and before investigational medicinal 
product (IMP) discontinuation, unless such a delay is not consistent with good medical 
practice.
Clinical events and clinically significant laboratory  abnormalities wil l be graded according to 
the Table for GSI Grading Scale for Severity  of Adverse Events and Laboratory  
Abnormalities (Appendix 4).
When restarting IMP following resol ution of the adverse event, the investigational medicinal 
product should be restarted at full dose or modified dose that is dependent upon discussion 
with the Gilead Sciences Medical Monitor.
Any recurrence of the 
Grade 3 or4 clinical or clinically  signif icant laboratory  adverse event 
following dose interruption mandates permanent discontinuation of IMP.
Any questions regarding toxicity  management should be directed to the 
Gilead Sciences Medical Monitor.
7.6.2.1. Grades 1 and 2 Laboratory  Abnormality  or Clinical Event
Continue investigational medicinal product at the discretion of the Investigator.
7.6.2.2. Grade 3 Laboratory  Abnormality  or Clinical Event
For a Grade 3 clinical event or clinicall y significant Grade 3 laboratory  abnormality  
confirmed b y repeat testing, IMP should be withheld until the toxicity  returns to Grade 2.
If a laboratory  abnormality  recurs to Grade 3 following rechallenge with IMP, then IMP
should be permanentl y discontinued and the subject managed according to local practice. 
7.6.2.3. Grade 4 Laboratory Abnormality  or Clinical Event
For a Grade 4 clinical event or clinicall y significant Grade 4 laboratory abnormality 
confirmed b y repeat testing , IMP should be withheld until the toxicity  returns to Grade 2. 
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 75 16 January 2019For a Grade 4 clinical event or clinicall y significant Grade 4 laboratory  abnormality  
confirmed b y repeat testing that is considered related to IMP, IMP should be permanently  
discontinued and the subject managed according to local practice. The subject should be 
followed as clinicall y indicated until the laboratory abnormality  returns to baseline or is 
otherwise explained, whichever occurs first. A clinically  significant Grade 4 laboratory  
abnormality  that is not confirmed by  repeat testing should be managed according to the 
algorithm for the new toxi city grade.
Investigational medicinal product may  be continued without dose interruptio n for a clinically  
non-significant (and therefore not an AE), Grade 4 la boratory  abnormality  (eg, Grade 4 CK after 
strenuous exercise, or trigl yceride elevation that is non- fasting or that can be medicall y 
managed).
7.7. Special Situations Reports
7.7.1. Definitions of Special Situations
Special situation reports includ e all reports of medication error, abuse, misuse, overdose, reports 
of adverse events associated with product complaints, occupational exposure with an AE, AE in 
an infant following exposure from breastfeeding and pregnancy  reports r egardless of an 
associa ted AE.
Medication error is an y unintentional error in the prescribing, dispensing ,or administration of a 
medicinal product while in the control of the 
health care provider , subject, or consumer.
Abuse is defined as persistent or sporadic intentional exc essive use of a medicinal product b y a 
subject.
Misuse 
is defined as an y intentional and inappropriate useof a medicinal p roduct tha t is not in 
accordance with the protocol instructions or the local prescribing information .
An overdose is defined as an ac cidental or intentional administration of a quantity  of a medicinal 
product given per administration or cumulatively  which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in case s in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribu tion of the medicinal product.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 76 16 January 20197.7.2. Instructions for Reporting Special Situations
7.7.2.1. Instructions for Reporting Pregnancies
Subjects should be instructed to notify  the investigator if they  become pregnant at an y time 
during the stud y, or if they become pregnant within 4 weeks of last study  drug dose. Subjects 
who become pregnant or who suspect that they  are pregnant during the study  must report the 
information to the investigator, and seek the investigator’s advice regarding action required with 
study  drug immediatel y. The investigator should co unsel the subject regarding the possible 
effects of prior stud y drug exposure on the fetus and the need to inform the study site o f the 
outcome of the pregnancy.
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  medication and throughout the study , including the post study  drug foll ow-up
period, to Gilead PVE using the pregnancy  report form within 24 hours of becoming aware of 
the pregnancy .
Refer to S ection 7.3and the eCRF completion guidelines for full instructions on the mechanism 
of pregnancy  reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premat ure termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported with in 24 hours as an 
SAE. The underl ying medical reason for this procedure should be recorded as the AEterm.
A spontaneous abortion is alway s considered to be an SAE and w ill be reported as described in 
the Adverse and Serious Adverse Section 7.1.1 and 7.1.2. Furthermore, an y SAE occurring as an 
adverse pregnancy  outcome post study  must be report ed to Gilead 
PVE .
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy . The outcome should be reported to Gilead PVE using the pregnancy  outcome report 
form. If the end of the pregnancy  occurs after the study  has been completed, the outcome should 
be reported directl y to Gilead PVE . Gilead PVE contact information is as follows: 
Gilead Sciences PVE Representative: Fax:
E-mail:
PPD
PPD
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 77 16 January 2019Pregnancies of female partners of male stud y subjects exposed to Gilead or other study  drugs
must also be reported and relevant information should be submitted to or Gilead PVE using the 
pregnancy  and pregnancy  outcome forms within 24 hours. Monitoring of the subject should 
continue until the conclusion of the pregnancy . If the end of the pregnancy occurs after the stud y 
has been completed, the outcome should be reported directl y to Gilead PVE , 
faxnumber  or email 
Refer to 
Appendix 5for Pregnancy  Precautions, Definition for Female of Childbearing Potential 
and Contraceptive Requirements.
7.7.2.2. Reporting Other Special Situations
All other special situation rep orts must be reported on the special situations report form and
forwarded to or Gilead PVE within 24 hours of the investigator becoming aware of the situation. 
These reports must consist of situations that involve study  IMP and/or Gilead concomitant 
medica tions, but do not apply  to non- Gilead concomitant medications.
Special situations involving non -Gilead concomitant medications do not need to be reported on 
the special situ ations report form; however, for special situations that result in AEs due to a 
non-Gilead concomitant medication, the AE should be reported on the AE form.
Any inappropriate use of concomitant medications prohibited by  this protocol should not be
reported as “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to section and the eCRF completion guidelines for full instructions on the mechanism of 
special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the symptoms and 
signs, clinical management, and outcome will be reported, when available.
Special Situations reports should be sent to Gilead Sciences PVE :
Gilead Sciences PVE Representative: Fax:
E
-mail:
PPD
PPD
PPD
PPD
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 78 16 January 20198. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary  anal ysis objectives are :
To evaluate the safet y and tolerability  of escalating, multiple doses of GS -9620 in HIV -1 
infected virologically  suppressed adults on ART
To evaluate the virologic effect of GS- 9620 as me asured b y changes in plasma HIV -1RNA.
The secondary  analy sis objectives are:
To evaluate the PK of GS-9620
To evaluate the PD of GS -9620 as measured b y changes in I SGs and serum cytokine sin 
whole blood compared to placebo
To evaluate effects of GS -9620 on whole blood immune cell activation (T cell, B cell, 
NKcell)
The exploratory  anal ysis objectives are:
 
 
 
8.1.2. Primary Endpoint
The primary  safet y endpoint is i ncidence of treatment- emergent SAEs and all 
treatment -emergent adverse events.
The primary  virology  endpoint is maximum change from baseline in plasma log 10
HIV-1RNA at any  post -dose timepoint
CCII 
I 
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 79 16 January 20198.1.3. Secondary En dpoint
The secondary  endpoints are:
Change from baseline in plasma HIV -1 RNA at post-baseline visits
Proportion of subjects with plasma HIV -1RNA > 50 copies/mL  at any  post -dose timepoint
8.1.4. Other Endpoints of Interest
Other endpoints include:
Change from baseline in the levels of serum cytokines 
Change from baseline and fold induction in mRNA for ISGs
Change from baseline in peripheral blood ly mphocy te count for T/B/NK/pDC/mDC
including: CD4 andCD8 populations, CD4/CD8 ratio, CD4 % and ly mphocy te activation 
(T,B and NK cells )
8.1.5. Exploratory Endpoints
 
 
 
 
 
8.2. Analysis Conventions
8.2.1. Analysis Sets
8.2.1.1. All Randomized
Therandomized analysis set includes all subjects who arerandomized into the study . This is the 
primary  anal ysis set for by -subject listings.
8.2.1.2. Efficacy
8.2.1.2.1 Full Anal ysis Set
CCII 
I I 
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 80 16 January 2019The full anal ysis set (FAS) wi ll include all subjects who (1) are ra ndomized into the study  and 
(2)have received at least one dose of stud y drug. Subjects wit h major eligibility  violations that 
are identifiable based on pre -randomization characteristics will be excluded.
Subjects will be grouped according to the treatment to which they  were randomized.
8.2.1.3. Safety
The safet y analysis set will include all randomized subjects who receiv ed at least one dose of 
study  drug. All the data collected up to 30 day s after subjects permanentl y discontinue their 
study  drug will be included in the safet y summaries. Subjects will be grouped according to the 
treatment they  actually  received.
8.2.1.4. Phamacokinetics
8.2.1.4.1 GS-9620 Pharmacokinetic Anal ysis Set
The GS -9620 pharmacokinetic (PK) anal ysis set will include all subjects who are randomized 
and have received at least one dose of stud y drug and for whom PK parameters of anal yte 
GS-9620 are available.
8.2.1.4.2 ARV Pharmacokinetic Analy sis Set
The ARV PK anal ysis set will include all subjects who are randomized and have received at least 
onedose of stud y drug and for whom the PK concentration of an y anal yte of the ARV is 
available.
8.2.1.5.
Biomarkers
The biomarker anal ysis set will include all subjects who are randomized and have received at 
least one dose of study drug and for whom the biomarkers are available.
8.3. Data Handling Conventions
Natural logarithm transformation for key  PK parameters, such as C max, AUC lastand AUC inf, will 
be applied for pharmacokinetic anal ysis, as appropriate .
PK concentration values below the limit of quantitation (BLQ) will be presented as “BLQ” in the 
concentr ation data listing, will be treated as zero for the determination of summary  and order 
statistics, and will be excluded for natural logarithm transformation. PK parameter values that 
are BLQ will be presented as “BLQ” in the parameter data listing and will be excluded in an y 
calculation of geometric means or ratios.
8.4. Demographic Data and Baseline Characteristics
Demographic and baseline measurements will be summarized using standard descriptive 
methods by  treatment group.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 81 16 January 2019Demographic summaries will include s ex, race/ethnicity , and age.
Baseline data including body  weight, height, bod y mass index, HI V-1 infection will be 
summarized.
8.5. Efficacy Analysis
8.5.1. Primary Analysis
The primary  virology  endpoint is the maximum change from baseline in plasma log 10
HIV-1RNA at any post -dose timepoint . It will be summarized by  treatment group. The primary  
analysis of the efficacy  will be based on the full analy sis set (FAS).
8.5.2. Secondary Analyses
The change from baseline in plasma log 10HIV-1 RNA at post -baseline visits will be summarized 
by treatment group.
The number and proportion of subjects w ith plasma HIV -1 RNA > 50copies/mL  at an y 
post-dose timepoint will be summarized by  treatment group.
8.6. Safety Analysis
All safet y anal yses will be performed using the safety  analysis set.
All safet y data collected on or after the date that study drug was fir st taken up to the date of 
lastdose of study  drug plus 30 day s will be summarized by  treatment group accordi ng to the 
study  drug received. Data for the pretreatment period and the period post the date of last dose of 
study  drug plus 30 day s will be included in data listings.
8.6.1. Extent of Exposure
A subject’s extent of exposure to study  drug will be generated from the study  drug 
administration data. Exposure data will be summar ized by  treatment group.
Duration of exposure to study  drug will be expressed as the nu
mber of weeks between the 
firstand last dose of the study  drug , inclusive, regardless of temporary interruptions in study  
drug administration and summarized by  treatmen t.
Dosing information for individual subjects will be listed.
8.6.2. Adverse Events
Clinical and laboratory  adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clinical database.
Treatment -emergent AEs are 1) any AEs with onset date on or after the study drug start date and 
no later than 30 day s after the study  drug stop dat e, or 2) an y AEs leading to study drug 
discontinuation .
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 82 16 January 2019Summaries (number and percentage of subjects) of treatment -emergent adverse events 
(bySOC and PT) will be provided by  treatment group. Additional summaries will include 
summaries for adverse events b y grade, Investigator’s assessment of relationship to study  drug, 
and effect on stud y drug dosing.
On an ongoing basis adverse events will be reviewed for events that might meet the definition of 
Category  C events that are indicative of an AIDS- Defining Di agnoses. The Gilead medical 
personnel will review the possible Category  C events and approve the events that meet the 
definition. Those events that do meet the Category C definition of an AIDS -Defining Diagnosis 
will be listed.
A listing of Category  C, AIDS-Defining Diagnosis can be found inAppendix 6.
8.6.3. Laboratory 
Evaluations
Selected laboratory  data will be summarized using onl y observed data. Absolute values and 
changes from baseline at all scheduled visits will be summarized.
Graded laboratory  abnormalities will be defined using the grading scheme defined in Grading of 
laboratory  abnormalities provided in Appendix 4.
Incidence of treatment -emergent laboratory  abnormalities, defined as va lues that increase at least 
onetoxicity  grade from baseline at an y time post baseline up to and including the date of 
lastdose of study  drug plus 30 day s, will be summarized by  treatment group. If baseline data are 
missing, an y graded abnormality  (i.e., at least a Grade 1) will be considered treatment emergent. 
The maximum toxicity  grade will be summarized by  laboratory  parameter.
Laboratory  abnormalities that occur before the first dose of study  drug or after the subject has 
been discontinued from treatment plus 30 days will be included in a data listing.
8.7. Pharmacokinetic Analysis
The concentration data of GS-9620 and ARV (trough sample s), if anal yzed, will be summarized 
by nominal sampling time using descriptive statistics. For GS -9620, pharmacokinetic parameters 
(Cmax, Tmax, Clast, Tlast, λz, AUC inf,AUC last,and t½) will be listed and summarized using 
descriptive statistics (e.g., sample size, arithmetic mean, geometric mean, coefficient of variation 
(%), standard deviation, median, minimum, and maximum). Plasma concentrations over time 
will be plotted in semi -logarithmic and linear formats as mean ± standard deviation, and median 
(Q1, Q3). For ARVs, trough sample concentrations for an individual will be descriptivel y 
compared to historical data.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 83 16 January 20198.8. Sample Size
This is an exploratory  study  to characterize the safety  and efficacy  of GS -9620; therefore, 
nopower calculation was performed. Sample size is determined based on empirica l 
considerations. A total of up to 54 subjects receiving GS -9620 will provide reasonable 
preliminary  assessment of safet y.
8.9. Safety 
Evaluation Committee
ASafet y Evaluation Committee (S EC) will review study  progress, virology  and safet y of 
enrolled subjects. The SEC will consist of members not directly  involved with the conduct of the 
study . After all subjects in a cohort have received at least three doses (Cohorts 1 to 3,and 6 ) or 
fivedoses (Cohorts 4 and5), the S EC will review safet y data from that cohort, including adverse 
events ,clinical laboratory  results, and plasma HIV -1RNA, before approving opening of 
enrollment in the next cohor t. For Cohort 6, SEC will confer once all subjec ts have completed 
3doses of 10 mg GS -9620 ,and recommend whether or not subjects may proceed with a dose 
escalat ionto 12 mg starting with Dose 4 .
 
A cohort may be suspended if ≥ 2 out of 6 subjects receiving GS -9620 
experience one or more DL Tsconsidered related to study  drug . Please refer to the SE C Charter 
for additional details.
8.10. Analy sis Schedule
Interim Unblinded Analyses
Prior to the final anal ysis, selected individuals from Gilead will be unblinded to assess the
interim safet y, virology , biomarker, 
and PK data of GS -9620 . This group may consist of at least
one representative from Clinical Research, Biostatistics, Clinical Pharmacology , 
Pharmacovigilance/Epidemiology , Biomarkers, Clinical Virology  and may include other 
personnel as necessary .
The access to individual unblinded data (safet y, virology, biomarker an
d PK) will be limited only 
to data relevant for analysisby thefunction representatives and will be summarized at the group 
level f or regulatory  documents and external submissions 
without revealing individual subject 
identification to protect study  blind atthe subject level. This group will review data (safet y, 
virology , biomarker and PK) to support development of new clinical protocols, regulatory  
documents, and conference submissions.
Final analysis
The Sponsor will conduct a final anal ysis of all data after the last subject in the study  completes
the last visit (Day  157) or prematurely  discontinues from the study .
CCI
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 84 16 January 20199. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and 
South Africa), International Conference on Harmonisation (ICH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study  subject. These standards are consistent with the European Union Clinical 
Trials Directive 2001/20/E C and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR 312, subpart D, “Responsibilities of Spons ors and Investigators,” 
21 CFR, part50, ”Protectio n of Human Subjects” , and 21 CFR, part 56, 
”Institutional Review
Boards” .
The investigator and all applicable subinvestigators will comply  with 21 CFR, Part 54, 
“Financial Disclosure b y Clinical I nvestigators” , providing documentation of their financial 
interest or arrangements with Gilead, or proprietary interests in the investigational drug under 
study . This documentation must be provided prior to the investigator’s 
(and any subinvestigators’ ) participation in the study . The investigator and sub -investiga tor agree 
to notify  Gilead of an y change in reportable inter ests during the stud y and for 1 year following 
completion of the study . Study  completion is defined as the date when the last subject completes 
the protocol -defined activities.
9.1.2. I nstitutional Revie w Board (IRB) Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject inf ormation sheets, or descriptions of the study  used to obtain 
informed consent) to an. The investigator will not begin any  study  subject activities until 
approval from the IRB has been documented and provided as a letter to the investigator.
Before implemen tation, the investigator will submit to and receive documented approval from 
theany modifications made to the protocol or an y accompan ying material to be provided to the 
subject after initial approval, with the exception of those necessary  to reduce immed iate risk to 
study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y stud y-related procedures. The 
investigator must use the most current approved consent form for documentin g written informed 
consent. Each informed consent (or assent as applicable) will be appropriately  signed and dated 
by the subject or the subject’s legall y authorized representative and the person conducting the 
consent discussion, and also by  an im partial witness if required b y.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 85 16 January 20199.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only  subject initials, date of birth, another 
unique identifier (as allowed b y local law) and an identification code will be recorded on an y 
form or biological sample submitted to the Sponsor ,or laboratory . Laboratory  specimens must 
be labeled in such a way  as to protect subject identity  while allowing the results to be recorded to 
the proper subject. Refer to specific laboratory  instructions NOTE :The investigator must keep a 
screening log showing codes, names, and addresses for all subjects screened and for all subjects 
enrolled in the trial. Subject data will be processed in accordance with all applicable regulations. 
The investigator agrees that all information received from Gilead, including but not limi ted to the 
investigator brochure, this protocol, eCRF , the IMP, and any  other study  information, remain the 
sole and exclusive property  of Gilead during the conduct of the study  and thereafter. This 
information is not to be disclosed to any  third party  (except employees or agents directl y 
involved in the conduct of the study  or as required by  law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent o f the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study  data to be su bsequently  verified. These documents should 
be classified into at least the following two categories: (1)investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, eCRF and que ry forms, and 
governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, ie, history , phy sical examination, and 
confirmation of diagnosis (to support inclusion and ex clusion criteria);
Documentation of the reason(s) a consented subject is not enrolled
Participation in study  (including study  number);
Study  discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were p erformed;
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 86 16 January 2019Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of IMP, including dates of dispensing and return;
Record of all adverse events and other safety  parameters (start and end date, and including
causality  and severity );
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of study  completion and reason for earl y discontinuation, if it occurs .
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region (ie, United States, Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH reg ion; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory 
authorities have been notified. Investigators may  be required to retain documents longer if 
specified 
by regulatory  requirements, by  local regulations, or by  an agreement with Gilead. The 
investigator must notify  Gilead before destro ying any  clinical study  records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study  site for any  or all of 
the documents, special arrangements must be made between the investigator and Gilead to stor e 
these records securel y awa y from the site so that they  can be returned sealed to the investigator 
in case of a n inspection. When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away  from the site.
9.1.6. Case Report Forms
For each subject consented, an eCRF will be completed by  an authorized study  staff member 
whose training for this function is documented according to study  procedures. eCRF should be 
completed on the day  of the subject visit to enable the sponsor to perform cent ral monitoring of 
safet y data. Subsequent to data entry , a stud y monitor will perform source data veri fication 
within the EDC sy stem. Original entries as well as any  changes to data fields will be stored in the 
audit trail of the sy stem. Prior to database lock (or any  interim time points as described in the 
clinical data management plan), the investigator will use his/her log in credentials to confirm that 
the forms ha ve been reviewed, and that the entries accuratel y reflect the information in the 
source documents. The eCRF capture the data required per the protocol sche dule of events and 
procedures. System -generated or manual queries will be issued to the investigative site staff as 
data discrepancies are identified by  the monitor or internal Gilead staff, who routinely  review the 
data for completeness, correctness, and consistency . The site coordinator is responsible for 
responding to the queries in a timely  manner, wi thin the sy stem, either b y confirming the data as 
correct or updating the original entry , and providing the reason for the u pdate 
(e.g. data entry error). At the conclusion of the trial, Gilead will provide the site with a read -only 
archive cop y of the dat a entered b y that site. This archive must be stored in accordance with the 
records retention requirements outlined in Section 9.1.5.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 87 16 January 20199.1.7. Investigational Medicinal Product Accountability and Return
Gilead recommends that used and unused IMP supplies be returned to the shipping facility  from 
which it came for eventual destruction. The stud y monitor will provide instructions for return. If 
return is not possible, the study  monitor will evaluate each study  center’s IMP disposal 
procedures and provide appropriate instruction for destruction of unused IMP supplies. I f the site 
has an appropriate standard operating procedure (SOP) for drug destruction as determined b y 
Gilead QA
, the site may  destroy  used (empt yor partially  empty ) and unused IMPsupplies in 
accordance with th atsite’s approved SOP. A cop y of the site’s approved SOP will be obtained 
for central files.
If IMP is destro yed on site, the investigator must maintain accurate records for all IMP
destroy ed. Records must show the identification and quantity  of each unit destroy ed, the method 
of destruction, and the person who disposed of the IMP. Upon study  completion , copies of the 
IMP accountability  records must be filed at the site. Another copy  will be returned to Gilead.
The study  monitor will review IMP supplies and associated records at periodic intervals.
9.1.8. Inspections
The investigator will make available all sou
rce documents and other records for this trial to 
Gilead’s appointed stud y monitors , toIRBs, or to regulatory  authorit y or health authority  
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance w ith the 
procedures and evaluations described in this protocol.
9.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by Gilead. The investigator must submi t all protocol modifications to the IRB in 
accordance with local requirements and receive documented approval before modifications can 
be implemented.
9.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulato ry agency . Gilead will 
ensure that the report meets the standards set out in the I CH Guideline for Structure and Content 
of Clinical Study  Reports (I CHE3). Note that an abbreviated report may  be prepared in certain 
cases.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 88 16 January 2019Investigators in this study  may  communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
The results of the stud y in their entiret y have been publicly disclosed by or with the consent 
of Gilead in an abstrac t, manuscript, or presentation form or the study  has been completed at 
all study  sites for at least 2 y ears
The investigator will submit to Gilead any  proposed publication or presentation along with 
the respective scientific journal or presentation forum at least 30 day s before submission of 
the publication or presentation. 
No such communication, presentation, or publication will include Gilead’s confidential 
information (see Section 9.1.4).
The investigator will comply  with Gilead’s request to delete references to its confidential 
information (other than the study  results) in any  paper o
r presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be a sked to provide services performed under this 
protocol, e.g. attendan ce at I nvestigator's Meetings. If required under the applicable statutory  and 
regulatory  requirements, Gilead will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including any  clinical trial pay ments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study mo nitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
eCRF .
The monitor is responsible for routine review of the eCRF at regular intervals throughout the 
study  to verify  adheren ce to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to an y subject records needed to 
verify  the entries on the eCRF . The investigator agrees to cooperate with the monitor to e nsure 
that any  problems detected 
through an y type of monitoring (central, on site) are resolved.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 89 16 January 20199.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of Gilead may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the Gilead medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency  or Gilead access to rec ords, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at an y time. Should 
this be necessary , both parties will arrange disc ontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies), I RBs, and IECs. In terminating the study , Gilead and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 90 16 January 201910. REFERENCES
Bar KJ, Sneller MC, Harrison L J, Justement JS, Overton ET, Petrone ME, et al. Effect of HIV 
Antibody  VRC01 on Viral Rebound after Treatment I nterruption. N Engl J Med 
2016;375 (21):2037-50.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31-41.
European Medicines Agency  (EMA). Pegas ys: EPAR – Scienti fic Discussion: 8 August 2006. 8 
Aug, 2006.
Fosdick A, Zheng J, Pflanz S, Frey  CR, Hesselgesser J, Halcomb RL , et al. Pharmacokinetic and 
Pharma codynamic Properties of GS -9620, a Novel TL R7 Agonist, Demonstrates 
ISG Induction without Detectable Serum Interferon at L ow Oral Doses. J 
Pharmacol Exp Ther 2013.
Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Aids Update 2016. Available 
at: http://www.unaids.org/en/resources/documents/2016/Global- AIDS-update -
2016. 31 May . 2016.
Kubicek WG, Anderson WD, Geber WF. Effects of hypoxia on the course of induced fever in 
dogs and monkey s. Am J Phy siol 1958;195 (3):601 -13.
Lanford RE, Guerra B, Chave z D, Giavedoni L, Hodara VL, Brask y KM, et al. GS -9620, an Oral 
Agonist of Toll -Like Receptor- 7, Induces Prolonged Suppression of Hepatitis B 
Virus in Chronically  Infected Chimpanzees. Gastroenterology  2013;144 (7):1508-
17 e10.
Li JZ, Etemad B, Ahmed H, Ag a E, Bosch RJ, Mellors JW, et al. The size of the expressed HIV 
reservoir predicts timing of viral rebound after treatment interruption. AIDS 
2016;30 (3):343 -53.
Lim SY, Osuna CE, Hraber PT, Hesselgesser J, Gerold JM, Barnes TL, et al. TL R7 agonists 
induce transient viremia and reduce the viral reservoir in SI V-infected rhesus 
macaques on antiretroviral therap y [Research Article]. Science translational 
medicine 2018;10:eaao452.
Mocroft A, Vella S, Benfield TL , Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of 
mortality  across Europe in patients infected with HIV- 1. EuroSIDA Study  Group. 
Lancet 1998;352 (9142):1725-30.
Palella FJ, Delaney  KM, Moorman AC, L oveless MO, Fuhrer J, Satten GA, et al. Declining 
Morbidity  and Mortalit y Among Patients Wit h Advanced Human 
Immunodeficiency  Virus I nfection. N Eng J Med 1998;338 (13):853-60.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 91 16 January 2019Pilaro AM, Green MD. Toxicologist's Review: Pegy lated interferon -a 2b for the Treatment of 
Chronic Hepatitis C I nfection (Biologics L icense Application # 99 -1488). Clinica l 
Pharmacology /Toxicology  Branch, Division of Clinical Trials Design and 
Analy sis, Center for Biologics Ev aluation and Research. December 19. 2000.
Schneider E, Whitmore S, Gly nn KM, Dominguez K, Mitsch A, McKenna MT. Revised 
surveillance case definitions for HIV infection among adults, adolescents, and 
children aged <18 months and for HIV infection and AIDS among children aged 
18 months to <13 y ears--United States, 2008. MMWR Recomm Rep 2008;57 
(RR- 10):1-12.
Sogaard OS, Graversen ME, L eth S, Olesen R, Brinkmann CR, Nissen SK, et al. The 
Depsipeptide Romidepsin Reverses HIV -1 Latency  In Vivo. PL oS pathogens 
2015;11 (9):e1005142.
Sterne J, Hernán M, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long -term effectiveness 
of potent antiretroviral therap y in preventing AIDS and death: a prospective 
cohort study . Lancet 2005;366 (9483):378-84.
U. S. Department of Health and Human Services (DHHS), Food and Drug Administration 
(FDA), Center for Drug Evaluation and Research (CDER). Guidance for Industry. 
Estimatin g the Maximum Safe Starting Dose in Initial Clinical Trials for 
Therapeutics in Adult Healthy  Volunteers . Rockville, MD. July , 2005.
Vial T, Descotes J. Clinical toxicity  of the interferons. Drug Saf 1994;10 (2):115 -50.
Vibholm L , Schleimann MH, Hojen JF, Benfield T, Offersen R, Rasmussen K, et al. Short -
Course Toll -Like Receptor 9 Agonist Treatment Impacts Innate Immunit y and 
Plasma Viremia in Individuals With Human I mmunodeficiency  Virus Infection. 
Clin I nfect Dis 2017;64 (12):1686-95.
GS-9620
Protocol GS -US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 92 16 January 201911. APPENDICES
Appendix 1. Investigator Signature Page
Appendix 2. Study Procedures Table
Appendix 3. Management of Clinical and Laboratory Adverse Events
Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 5. Pregnancy Precautions, Definition for Female of Childbea ring Potential, and 
Contraceptive Requirements
Appendix 6. Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines)
PPD
PPD
PPDGS-9620 
Protocol GS-US-382-1450 Final 
Gilead Sciences, Inc. Amendment 7 
Appendix 1. Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGEMENT 
A Phase 1 b, Randomized , Blinded , Placebo-Controlled Dose-Escalation Study of the Safety and 
Biological Activity of GS-9620 in HIV-I Infected, Virologically Suppres sed Adults 
GS-US-382 -1450, Amendment 7, 16 January 2019 
This protocol has been approved by Gilead Sciences , Inc. The following signature documents 
this approval. 
Medical Monitor 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices , and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Gilead Sciences, Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator Name (Print ed) Signanire 
Date Site Number 
CONFIDEN TIAL Page 93 16 January 2019 
GS-9620 
Protocol GS-US -382-1450 Final 
Gilead Sciences , Inc. Amendment 7 
Appendix 2. Study Procedures Table 
Study Procedures Table i Cohorts 1 to 3 
... .; . 5 = .: ... .. "' .=, en = 00: ,..; N t'"l or, \0 ... 
Q ... , 0 ... ... .. ... .. ... ... '"C Q ,_ "' "' "' "' "' "' '-' ,_ 0 0 0 0 0 = VJ ,,. Q., Q Q Q Q Q ta,;l ta,;l 
Post-Baseline study visits< 
-- Q0 :l ... - = -in r-- 0\ N in 0\ -t'"l \0 0\ t'"l or, r-- 0 t'"l r-- 0\ -r---t'"l or, 00 -Q 
Study I ' --t'"l in 00 ----N N N <') t'"l t'"l t'"l IO IO or, IO \Q \0 \0 r-- r-- r-- r-- Q0 - .... .... ... .... .... .... ... ;;,,, ;;,,, ;;,,, ..., ;;,,, ;'; ... ... ... ; ;'; ... ... Proced1ue "= 00: ci3~ "= <'= 00: 00: <'= 00: <'= 00: <'= 00: 00: 00: 00: "= Q Q Q Q Q Q Q Q Q Q Q Q Q 0 Q Q Q Q Q Q Q 0 Q Q Q Q 0 Q Q Q Q Q 
Informed X Consen t 
Reviewl/E X Criteria 
Medical History" X X X 
AEs and Con X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X Meds 
Complete X Physical Exame 
Symptom 
Directed X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Physical Examf 
12-LeadECG 
(petf01med supi X 
ne) 
Vital Signs X X X X X X X 
Weight X X X X 
Height X 
CONFIDENTIAL Page 94 16 January 2019 
GS-9620 
Protocol GS-US -382-1450 
Gilead Sciences , Inc. 
.. 
.!: .. 
"' = 0:: .. CQ .. cl.. .. 
<J .. 
(J"J Q. 
00 ...., • ..... Stndy I ' .... .... Proc .edm·e 0:: ,: 
Q Q 
Randomization X 
Plasma HIV-1 X RNA 
CD4+ cell count X 
Chem istry X profile 
Hematology X profile 
HBV/HCV X Serology 
Estimated GFR X 
Urinalysis X 
Senun X Pregnancy T estg 
Urine Pregnancy 
Tes~ 
Plasma GS-9620 
Intensive PKh 
Plasma ARV X Trough PKh 
CONFIDENTIAL ... .. ., 
'3 M ... 
"' 0 
Q 
--., 
:3 - -on .... °' M ...., on 00 .... ..... -..... M .... .... .... 2 2 ;;- = 0:: ,: = ,: ,: 
CQQ Q Q Q Q Q Q Q Q 
X X X X X X X X X 
X X X X X X 
X X X X 
X X X X X X 
X 
X X X X 
X X 
X X ...., • .. ., 
"' "' 0 0 
Q Q 
Post-Baseline study visits' 
on °' -...., \Q °' ...., on .... 0 ...., 
M M ...., ...., ...., ...., • • • on on 
> > 2 2 2 = ,: 
Q Q Q Q Q Q Q Q Q Q Q 
X X X X X X X X X X X 
X X X X X X 
X X X X 
X X X X X X 
X X X X 
X X 
Page 95 on \Q .. ., 
"' "' 0 0 
Q Q 
.... °' .... • .... -II) on \Q 10 \Q .... 
;;-> = Q Q Q Q Q Q 
X X X X X X 
X X X X 
X X X 
X X X X 
X X X 
X X ...., .... 
Q 
X 
X 
X on .... 
Q 
X Final 
Amendment7 
> 
"C = ... 
[/) ... Q 0 
"C Q 
(J"J 
laJ 
- 00 -0 .... 00 -;;-> ,: 
Q Q Q 
X X X X 
X X X 
X X X 
X X X 
X X 
X X X 
X X 
16 January 2019 
GS-9620 
Protoco l GS-US -382-1450 
Gilead Sciences , Inc. 
.. 
.!: .. 
"' = 0:: .. CQ .. cl.. .. 
<J .. 
(J"J Q. 
00 ...., • ..... Stndy I ' .... .... Proc .edm·e 0:: ,: 
Q Q 
TLR7 X genotyping 
Serum for 
cytokine / 
soluble 
biomarker 
studiesi 
Whole blood 
ISGmRNA; 
Cell associated 
HIV-I 
RNA/DNA with 
stored PBMCsi 
Plasma HIV-1 
RNA Single 
Copy Assay 
with stored 
plasmai 
PBMC -X ELISPOP 
Whole blood-
nll111tllle cell 
activation; 
CONFIDENTIAL ... .. ., 
'3 M ... 
"' 0 
Q 
--., 
:3 - -on .... °' M ...., on 00 .... ..... -..... M .... .... .... 2 2 ;;- = 0:: ,: = ,: ,: 
CQQ Q Q Q Q Q Q Q Q 
X X X X X X 
X X X X X X 
X X 
X X 
X X ...., • on .. ., .. 
"' "' "' 0 0 0 
Q Q Q 
Post-Baseline study visits' 
on °' -...., \Q °' ...., on .... 0 ...., .... 
M M ...., ...., ...., ...., • • • on on II) 
> > 2 2 2 ;;-= ,: 
Q Q Q Q Q Q Q Q Q Q Q Q 
X X X X X X X 
X X X X X X X 
X X 
X X 
X X 
Page 96 \Q ., 
"' 0 
Q 
°' .... • .... - on \Q 10 \Q .... 
> = Q Q Q Q Q 
X X X 
X X X 
X 
X 
X 
X ...., .... 
Q 
X 
X 
X 
X 
X on .... 
Q Fina l 
Amendment7 
> 
"C = ... 
[/) ... Q 0 
"C Q 
(J"J 
laJ 
- 00 -0 .... 00 -;;-> ,: 
Q Q Q 
X X X 
X X X 
X 
X 
X 
16 January 2019 
GS-9620 
Protocol GS-US -382-1450 
Gilead Sciences , Inc. Final 
Amendment7 
.. > 
.!: "C = .. ... 
"' ... [/) = 0:: M ...., • on \Q ... .. CQ ., 0 .. cl.. .. ... .. .. ., 
"C .. ., "' "' "' "' "' <J .. '3 0 0 0 0 0 
(J"J Q. Q Q Q Q Q 
Post-Baseline study visits' 
-- 00 ...., ., -• ..... :3 - -on .... °' M on °' -...., \Q °' ...., on .... 0 ...., .... °' .... • .... -...., on 00 -0 
Stndy I ' ...., on 00 .... ..... -..... M M M ...., ...., ...., ...., • • • on on II) on \Q 10 \Q .... .... .... .... 00 - .... .... .... .... .... 2 2 ;;- > > 2 2 2 ;;-> ;;-> Proc .edm·e 0:: ,: = 0:: ,: = ,: ,: = ,: = ,: 
Q Q CQQ Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q 
Whole blood -
flowFoxP3+ X X X 
Treg:i 
PBMC ICS for X X X X Tregi 
Review DLTs to 
confim1 dosing X X X X X 
can proceed 
In-Clinic X X X X X X Dosingi 
a Evaluation to be completed within 35 days prior to Pre-B aseline/Day -13 
b Subje.cts should be administered study chug after Baseline/Day 1 visit assessments (except for post-dose intensive PK) 
c All shidy visits are to be scheduled relative to the Baseline/Day 1 visit date. 
d Collect ART history for at least 12 months ; Pre-ARV viral set point , pre-ARV CD4 nadir and historical genotype will be collected if available 
e Urogenita l/anorectal exams may be pe1fom1ed at discretion of the Investigator 
f Symptom-directed physical examination as needed 
g Females of childbe aring potential only. Positive urine pregnancy tests will be confinned with a semm test at any visit. At End of Study visit (Day 101 ), urine pregnancy test 
only performed if not done within past 30 days. 
h Details of phannacokinetic blood sampling procedures and sample management for all PK samples in the study ·will be documented in the Phannacokine tic Sample 
Collection , Processing , Storage , and Shipment Manual. 
To be collected pre-dose on dosing days 
On dosing days , study dmg should be taken with approxinlately 240 mL of water on an empty stomach . Food will not be pe1mitted between at least 2 hours prior to and until 
2 hours after dosing. Aside from the 240 mL of water provided at dosing , water/liquids will not be pennitted from l hour prior to until 2 hours after dosing. If subjects eat 
prior to the 2 hour fasting period before study dmg dosing , no more than a light meal should be eaten (as described in the PK San1ple Collection , Proces sing, Storage , and 
Shipment Manual ). Q 
Q 
(J"J 
laJ 
CONFIDENTIAL Page 97 16 January 2019 
GS-9620 
Protocol GS-US -382-1450 
Gilead Sciences , Inc. 
Study Procedures Table (Cohort 4) 
., 
.5 .. ., "' ... = ,: -t ... ... "' 
r~ ... 
=-
-- 00 ..... ., -a-I ' N 
>, >, !J >, 
Study Procedm·e ,:: ,:: ,:: 
Q Q Q 
Infom1ed Consen t X 
Revie w I/E Criteria X 
Medical History" X X X 
AEs and Con Meds X X X X 
Complete Physical Exam• X 
Symptom Directed Physical X X X Exani 
12-LeadECG X (pe1fo1111ed supine ) 
Vital Signs X X 
Weight X X 
Height X 
Randomization X 
Plasma HIV-1 RNA X X X 
CD4 + cell count X X 
Chemi stry profile X X 
Hematology profile X X 
HBV/HCV Sero logy X 
CONFIDENTIAL N ..... ., ., 
"' "' '3 '3 
"' N °' \Q ..... 00 -N N M 
>, >, >, >, >, >, ,:: ,:: a ,:: a ,:: 
Q Q Q Q 
X X X X X X 
X X X X X X 
X X 
X X X X X X 
X X 
X X 
X X "' \Q r---., ... "' ., 
"' "' "' "' 0 0 
Q Q 
Post-Baseline stud y visits• 
M 0 r--- 00 -00 "' N 
"' "' "' \Q r--- r--- 00 °' >, >, >. >, J >, >, >, >, >, = ,: a ,: ,: a = Q Q Q Q Q 
X X X X X X X X X X 
X X X X X X X X X X 
X X X X 
X X X X X X X X X X 
X X X X X X X X 
X X X X X X X X 
X X X X X X X X 
Page 98 C 
00 °' - ., "' ., 
"' "' 0 0 
Q Q Q 
\Q ..... 0 r---
Q'\ 0 -M M 
°' ---->, >, >, >, >, J = = = a Q Q Q 
X X X X X X 
X X X X X X 
X X X 
X X X X X X 
X X X X 
X X X X 
X X X X Final 
Amendment7 
>, 
-0 = -rn ... Q 0 
-0 Q = (J) w w 
°' r---
N ..... "' -.... - >, >, >, = ,:: ,:: 
Q Q Q 
X X X X 
X X X X 
X X 
X X X X 
X X X 
X X X 
X X X 
16 January 2019 
GS-9620 
Protoco l GS-US -382-1450 
Gilead Sciences , Inc. 
Study Procedm·e 
Estimated GFR 
Urinalysis 
Senun Pregnancy T ese,; 
Urine Pregnancy Tese,; 
Plasma GS-9620 Intensive 
PKh 
TLR 7 genotyping 
Semm for cytokine / 
soluble biomarker studies 
Whole blood ISG mRNA 
Cell associated HIV-I 
RNA/DNA with stored 
PBMCs 
Plasma HIV-I RNA Single 
Copy Assay with stored 
plasma 
PBMC -ELISPOT 
Whole blood- immune cell 
activation 
Whole blood -flow FoxP3+ 
Treg 
Tcell ICS 
CONFIDENTIAL = .. .. .. 
<J 
00 
Q0 ...,. 
' ,., 
0:: 
Q 
X 
X 
X .. 
.5 .; 
"' ... 0:: .... ... .. "' .. 0 
Cl. Q 
---.... .. -= ' = ... ,., !J 0:: 
Q 
X 
X 
X 
X 
X 
)Ci 
xi 
xi 
xi 
X 
xi 
)Ci 
X N .... .. .. ., ., 
'3 '3 
in N a, 'D 
N .... Q0 -N M M ,., >, ,., ,., ,., ,., ,., 
0:: 0:: 0:: 0:: 0:: 0:: 0:: 
Q Q Q Q Q Q Q 
X X 
X X 
X 
X X X 
X X X 
X 
X 
X X ...,. in '° ,-.. .. ... .. .. 
"' "' "' "' 0 0 0 0 Q Q Q Q 
Post -Baseline study visits• 
.... 0 ,-.. Q0 ...,. .... Q0 in N ...,. V) in in '° ,-.. ,-.. Q0 0\ ,., ,., ,., ,., J ,., ,., ,., ,., ,., 
0:: 0:: 0:: 0:: 0:: 0:: 0:: 0:: 0:: 
Q Q Q Q Q Q Q Q Q 
X X X X X X X X 
X X X X 
)Ci X :x X 
)Ci X :x X 
)Ci :x 
)Ci :x 
)Ci X :x 
Xi 
Page 99 0 
00 0\ - .. .. .. 
"' "' "' 0 0 '3 Q Q 
'D .... 0 ,-.. 
0\ 0 .... M M 0\ .. .... .. - ,., ,., >, ,., ,., J 0:: 0:: 0:: 0:: = Q Q Q Q Q 
X X X X 
X X X 
)Ci :x 
xi :x 
xi 
xi 
)Ci :x 
Xi Fina l 
Amendment7 
,., 
-0 = ... 
00 ._ 
Q 0 
-0 Q = 00 
i:.. 
0\ ...,. ,-.. 
N .... in --- ,., ,., ,., = = = Q Q Q 
X X 
X X X 
X X 
X X X 
X X X 
X X 
X X 
X 
X 
X 
16 January 2019 
GS-9620 
Protoco l GS-US -382-1450 
Gilead Sciences, Inc. Final 
Amendment7 
.. ,., 
.5 -0 = .; ... 
"' ... 0 00 = 0:: .... N .... ...,. in '° ,-.. 00 0\ -._ .. ... .. .. .. ... .. .. .. .. .. 0 .. -0 .. .. "' ., ., "' "' "' "' "' "' "' <J .. 0 '3 '3 0 0 0 0 0 0 '3 = 00 Cl. Q Q Q Q Q Q Q i:.. 
Post-Baseline study visits• 
--- Q0 .... .. 'D .... 0 ,-.. 0\ ...,. ,-.. ...,. -= in N a, 'D .... 0 ,-.. Q0 ...,. .... Q0 in N 0\ 0 .... M M N .... in 
' ' = ... N .... Q0 -N M M ...,. V) in in '° ,-.. ,-.. Q0 0\ 0\ .. .... .. ---- ,., ,., !J ,., >, ,., ,., ,., ,., ,., ,., ,., ,., ,., J ,., ,., ,., ,., ,., ,., ,., >, ,., ,., J ,., ,., ,., 
Study Procedm·e 0:: 0:: 0:: 0:: 0:: 0:: 0:: 0:: 0:: 0:: 0:: 0:: 0:: 0:: 0:: 0:: 0:: 0:: 0:: 0:: 0:: 0:: = = = = Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q 
HIV reservoir mea slll"ement X X 
Future Biomarker Nirology X X analysis Blood Sample 
Revie w DL Ts to confinn X X X X X X X X X dosing can proceed 
In-Clinic Dosingi X X X X X X X X X X 
a Evaluation to be comple ted within 35 days prior to Pre-Ba seline/Day -13 
b Subjects shou ld be administered study drug after Baseline/Day 1 visit assessments (except for post-dose intensive PK) 
c All study visits are to be scheduled relative to the Baseline/Day l visit date 
d Collect ART history for at least 12 months ; Pre--ARV viral set point, pre-ARV CD4 nadir and historical genotype will be collected if available 
e Urogenital/anorectal exams may be perfonued at discretion of the Inve stigator 
f Symptom-directed physical examination as needed 
g Females of childbeati.ng potential only . Positive mine pregnancy tests will be confinued with a sel"lUll test at any visit. At End of Study visit (Day 157) , lll"ine pregnancy test 
only petformed if not done within past 30 days. 
h Detail s of pha1macokinetic blood sampling procedures and sampl e management for all PK samples in the study will be docmuented in the Phamiacokinetic Sample 
Collection , Processing , Storage , and Shipment Manual 
To be collected pre-dose on dosing days 
On dosing days , study dmg should be taken with approxiniately 240 mL of water on an empty stomach. Food will not be pemiitted between at least 2 hour s prior to and until 
2 hom·s after dosing. Aside from the 240 mL of water provided at dosing , water/liquids will not be pemiitted from l hour prior to until 2 holll"s after dosing. If subjects eat 
prior to the 2 hour fasting period before study drug dosing, no more than a light meal should be eaten (as described in the PK Satnple Collection , Proce ssing, Storage, and 
Shipment Manual) . Q 
Q 
00 
CONFIDENTIAL Page 100 16 January 2019 
GS-9620 
Protocol GS-US -382-1450 
Gilead Sciences , Inc. 
Study Procedures Table (Cohorts 5 to 9)3 
µ µ µ µ ... ... ... ... 
:g "' "' "' .: 0 0 0 
"' p.. p.. p.. p.. 
<': " -N r--- r---... ... ... ... "'" "' 
r~ 0: r'. ts r'. r'. 
"" ..., .!: 
"'! 1'. .: -M 
i~ > .. .. 
Study Procednn•• .. <': .. <': .. 
Q Q Q Q Q Q Q 
Infom1ed Consent X 
Review 1/E Criteria X 
Medical Histo1y X X X 
AEs and Con Meds X X X X X X X X 
Complete Physical X Examg 
Symptom Directed X X X X X X X Physical Examh 
12-LeadECG X (pe1fo1med supine) 
Vital Signs X X X 
Weight X X 
Height X 
Randomization X 
Stool sample for X microbiome analysisi 
VAS Questionnaire X 
Plasma HIV-1 RNA X X X X X X X 
CONFIDENTIAL µ ii, µ ... 0 ... 
"' 8 "' 0 0 p.. p., p.. 
N r---.,, N ... ... i; i; "' "' r'. ts ts 
M ... ..., .. , ..., .. .. "'1- > " <': .. " Q Q Q Q Q 
X X X X X 
X X X X X 
X X 
X 
X X X X X µ µ µ µ µ µ µ µ ... ... ... ... ... ... ... ... 
"' "' "' "' "' "' "' "' 0 0 0 0 0 0 0 0 p.. p.. p.. p., p.. p.. p., p.. 
r----... N r---... N r---... N r---... i; "' "' "' "' J:, J:, J:, ts ts r'. r'. r'. r'. ts r'. 
Post-Baseline study Yisit5• 
Ir) on Ir) Ir) 10 r--- r--- r--- Q0 Q0 a.. a.. 
> .. .. ; .. ; .. .. .. .. " <': e: .. Q Q Q Q Q Q Q Q Q Q Q Q 
X X X X X X X X X X X X 
X X X X X X X X X X X X 
X X X X 
X X 
X X X X X X X X X X X X 
Page 101 µ µ µ µ ... t; ... ... 
"' "' "' 0 0 0 0 p.. p.. ..... p.. - N r--- ... N r---... 
"' "' ts ts ts ts 
= = - -..... .... .... ..... ---- .. .. > .. .. <': .. .. .. 
Q Q Q Q Q Q 
X X X X X X X X X X X X 
X X 
X 
X X X X X X µ ... 
"' 0 p.. -
ts 
r4 -
Q 
X X 
X Final 
Amendment7 
µ µ .... .... 
"' "' in 0 0 p., p.. ..... 
N r--- 0 
1c' 'O Q >. 
c5 = 00 ts f;:;l i:.:i 
..... .., IO -.... - .. >. .. .. .. 
Q Q Q 
X X X X 
X X X X 
X X 
X X 
X X X X 
16 January 2019 
GS-9620 
Protoco l GS-US -382-1450 
Gilead Sciences , Inc. 
.. .. 
<.I 
rJ) 
1 
Study Procedm·e• 0:: 
Q 
CD4+ cell count 
CD8+ cell count , X CD4 /CD8 ratio and 
CD4% 
Chemistry profile X 
Hematology profile X 
HBV/HCV Serology X 
Estimated GFR X 
Urinalysis X 
U1ine Pregnancy Testi 
Serum Pregnancy Testi X 
Plasma GS-9620 
Intensive PKk 
Plasma ARTPKP X 
TLR 7 genotyping 
Semmfor 
cytokine /solub le 
biomarker studie s 
Whole blood ISG 
mRNA 
CONFIDENTIAL µ µ ... ... 
"' "' .:; 0 0 
"' p.. p.. = ... -N 'i .. 
"' .. 0 
Q. 0 6 Cl 
..., · = "J .:; 
"' = = Q i:: Q 0 
X 
X X"' 
X X"' 
X 
X xm 
X 
X X 
X 
xo X X 
X° X X µ µ µ iJ, µ ... ... ... 0 .... 
"' "' "' G "' 0 0 0 0 p.. p.. p.. Q. Q. 
r--- r--- N r---... N Q,I .. .. l;j l;j "' "' "' 0 0 0 6 0 6 Q 6 Cl 0 Cl 
-N N .., ,.., ..., ..,. 
; ; > > ;>-? = 0:: = Q 0 Q Q Q Q 0 Q 
X X X 
X X X 
X X X 
X X X 
X X X 
xn X" 
X 
X° X° 
xn X° µ µ µ µ µ µ µ µ ... ... ... .... ... .... .... ... 
"' "' "' "' "' "' "' 0 0 0 0 0 0 0 Q. Q. Q. Q. p.. Q. Q. Q. 
r---.. -N r---Q,I N r---.. N r---.. 
"' "' "' "' 0 0 0 0 d Q d Cl 6 Q 6 Cl 0 Cl 6 0 
Post-Baseline study ~isits• 
tr) on tr) tr) SQ .... .... r--- QC) QC) °' °' ;' ; ;>-; ; ; ; > 
0:: 0:: Q Q 0 0 Q Q Q Q Q Q 0 0 
X X X X X X X X 
X X X"' X X X"' X X X"' X X 
X X X"' X X X"' X X xm X X 
X X X"' X X X"' X X xm X X 
X X X X 
X X X 
xn xo X X X 
xn xo X X X 
Page 102 µ µ µ µ .... ... ... 
"' VJ "' 0 0 0 0 p.. Q. Q. p.. 
N r--- N r---... .. Q,I 
"' "' 0 0 d d Q d d Q 
-= ... -..... ..... -----.... 
;' ;>-;' ;' > 0:: = 0 0 Q 0 Q Q 
X X X 
xm X X"' X X 
xm X xm X X 
xm X xm X X 
X X 
xo 
xo µ ... 
"' 0 p.. -
d 
..... ~ -
Q 
X 
X Final 
Amendment7 
µ µ .... ... 
"' "' ... 0 0 rJ) Q. p.. .... 
N r--- 0 .... 
'O 0 >, 
8 = rJ) 
Cl l.l 
"" ... , '" ---;' ,, > 0:: = 0 0 Q 
X X X 
X"' X X X 
X"' X X X 
X X 
X"' X X X 
X X 
X X X X X X 
16 January 2019 
CCI
CCIGS-9620 
Protocol GS-US -382-1450 
Gilead Sciences , Inc. 
Study Procedm·e• 
Cell associated HIV -1 
RNA/DNA 
(CA VR/CA VD) with 
stored PBM Cs 
Plasma HIV-1 RNA 
Single Copy Assay 
with stored plasma 
PBMC -ELISPO'P 
Whole blood -
inunune cell activation 
Whole blood -flow 
FoxP3+Treg 
Tcell JCS; 
HIV -I Reservoir 
measurement ; 
Review DLTs to 
confinn dosing can 
proceed 
In-Clinic Dosing1 
I .. .. 
<.I 
rJ) 
""' 
0:: 
Q .:; 
"' = ... 'i .. 
"' .. 0 
Q. 0 
..., · = .:; 
"' = = Q c:c 
X" 
X° 
X 
X° 
X° 
X 
X 
X µ µ µ µ µ iJ, ... ... ... ... ... 0 
"' "' "' "' "' G 0 0 0 0 0 p.. p.. p.. p.. p.. Q. -N r--- r--- N r---... .. 
"' 0 0 
-N N .., ,.., 
> > > = 0:: = 0:: 0:: = 0:: 
Q 0 0 Q 0 Q 0 
X 
X 
X X 
X X X 
X X X 
b Evaluation to be completed within 35 days prior to Pre-Baseline/Day -13 µ µ µ µ µ µ µ µ .... ... ... ... .... ... .... .... 
"' "' "' "' "' "' "' 0 0 0 0 0 0 0 Q. Q. Q. Q. Q. p.. Q. Q. 
N r--- N r--- N r---.. N 
"' 0 
0 
Post-Baseline study ~isits• 
..,. tr) on tr) tr) SQ .... .... r--- QC) QC) ... 
0:: 0:: = 0:: 0:: = 0:: = = 0:: ,: 
Q Q 0 0 Q Q Q Q Q 0 Q 
X" X 
X" X 
X" X X 
X" 
X X X 
X X X 
C Subjects should be administered study dmg after Baseline/Day I visit assessments (except for post-dose intensive PK) 
CONFIDENTIAL Page 103 µ µ µ µ µ ... .... ... ... 
"' "' VJ "' 0 0 0 0 0 Q. p.. Q. Q. p.. 
r--- N r--- N r---
-= ... -..... 
°' °' ----- ... ... > 0:: 0:: 0:: 0:: = 0:: = Q 0 Q Q Q 0 0 
X X X X µ ... 
"' 0 p.. ... -
..... ..... ~ -
,: = Q 0 
X" 
X" 
X" X 
X" 
X 
X Final 
Amendment7 
µ µ .... ... 
"' "' ... 0 0 rJ) Q. p.. .... 
N 0 .... 
'O 0 = rJ) 
l.l 
"" ... , '" ---.... > 0:: 0:: = Q Q 0 
X X 
X X 
X 
X 
X 
X 
16 January 2019 
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 104 16 January 20 19d Dose 4 (Cohort 6 only )cannot occur until SEC completes review of the safety data from all subjects’ first three doses (GS-9620 10 mg dose). If the GS -9620 10mg dose is 
found to be safe, Dose 4 and subsequent Doses (5 -10) will escalat eto GS-9620 12 mg . If dose escalation is not approved by the SEC, subj ects will continue receiving 10 mg 
of GS -9620 or placebo from Doses 4 to 10
e All stu dy visits are to be scheduled relative to the Baseline/Day 1 visit date
f Collect ART history for at least 12 months; Pre -ARV viral set point, pre -ARV CD4 nadir and historical genotype will be collected if available
g Urogenital/anorectal exams may be performe d at discretion of the Investigator
h Symptom -directed physical examination as needed
j Females of childbearin g pot ential only. Positive urine pregnancy tests will be confirmed with a serum test at any visit. At End of Study visit , urine pregnancy test only 
performed if not done within past 30 days
k Details of pharmacokinetic blood sampling procedures and sample management for all PK samples in the study will be documented in the Pharmacokinetic Sample 
Collection, Processing, Storage, and Shipment Manual.
l In Cohort s 5and 6, , the study drug will be administered following an overnight fast.
 
m Cohorts 6 only
n Cohort 6 only,if dose escalation to 12mg is approved by SEC
o To be collected pre -dose on dosing days
p Cohorts 6 only required at Screening, Days 57 and Days 99
CCI
CCI
CCI
CCI
CCII 
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 105 16 January 20 19Appendix 3. Management of Clinical and Laboratory Adverse Events
Grade 1 
! 
May continue 
dosing at the 
discreti on of the 
investigat or Grade 2 
~----G~r_a_d_e_J ____ ~ I ~I---..---G_r_a_d_e_4 ____ 
I l 
Repeat lab to Repeat lab to 
confirm toxicity confirm toxicity 
grade grade 
1, 1, 
If confirmed: 
1. Withhold investigational medicinal products until Grade 2 
2. Restart all inves tigational medicinal products at full dose 
1, 1, 
If Grade 3 or 4 recurrence is confirmed following rechallenge 
with investigational medicinal product, discontinue all 
investigational medicina l products dosing permanently -If confirmed and 
possibly or probably 
related to 
inves tigation al 
medicinal products, 
discontinue 
investigation al 
medicinal products 
dosing permanently 
and follow at periodic 
intervals at least 
weekly until a return 
to baseline or is 
otherwise explained 
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 106 16 January 20 19Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Antiviral Toxicity Grading Scale 
Version : 01 April 2015
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hem oglobin
HIV POSITIVE
Adult and Pediatric 57 Days8.5to10.0 g/dL 
85 to 100 g/L7.5to 8.5g/dL 
75to85g/L6.5 to 7.5g/dL 
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 10.0 to10.9 g/dL
100to109g/L
OR
Any decrease from Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0 g/dL
90 to 100g/L
OR
Any decrease from Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Any decrease from Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94 g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95 to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1 –21 Days
(HIV POSITIVE OR
NEGATIVE )12.0 to 13.0 g/dL
120 to 130 g/L10.0 to 12.0 g/dL
100 to 120g/L9.0 to 10.0 g/dL
90 to 100g/L9.0g/dL
90g/L
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 107 16 January 20 19HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Absolute Neutrophil Count 
(ANC)
Adult and Pediatric, 
≥ 7 Months# 1000 to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00 to 1.30 GI/L 0.75 to 1.00 GI/L 0.50 to0.75 GI/L 0.50 GI/L
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
>13Years300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100to125 GI/L50,000 to 100,000/mm3
50to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 2500/mm31,500 to  2,000/mm31000 to 1,500/mm31000/mm3
2.00 GI/L to 2.50 GI/L 1.50 to 2.00 GI/L 1.00 to 1.50 GI/L 1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/d L 50mg/d L
1.00 to2.00 g/L 0.75 to 1.00 g/L 0.50 to 0.75 g/L 0.50 g/L
Hyperfibrinogenemia ULN to 600 mg/dL 600mg/dL — —
ULN to 6.0 g/L 6.0g/L — —
Fibrin Split Product 20 to 40 μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40 mg/L 40 to 50 mg/L 50 to 60mg/L 60mg/L
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN 
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 108 16 January 20 19HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
International Normalized Ratio 
of prothrombin time (INR)1.1 to 1.5 x ULN >1.5 to 2.0 x ULN >2.0 to 3.0 x ULN >3.0 x ULN
Activated Partial
Thromboplastin Time (APTT) 1.00 to 1.66 ULN 1.66 to 2.33 ULN 2.33 to 3.00 ULN 3.00 ULN
Methemoglobin 5.0to10.0% 10.0 to15.0% 15.0 to20.0% 20.0% 
# An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects. Please follow the Gilead convention of grading 
any resu lt within the LLN and ULN a 0.
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 109 16 January 20 19CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLN mEq/L 125 to 130mEq/L 121 to 125mEq/L 121 mEq/L
130 to <LLN mmol/L 125 to 130mmol/L 121 to 125mmol/L 121 mmol/L
Hypernatremia >ULN to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
>ULN to 150 mmol/L 150 to 154 mmol/L 154 to 159 mmol/L 159 mmol/L
Hypokalemia 
Adult and Pediatric
1 Year3.0 to <LLN mEq/L 2.5 to 3.0mEq/L 2.0 to 2.5mEq/L 2.0 mEq/L
3.0 to <LLN mmol/L 2.5 to 3.0mmol/L 2.0 to 2.5mmol/L 2.0 mmol/L
Infant <1 Year 3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L2.5 to 3.0mEq/L
2.5 to <3.0 mmolL2.0 to 2.5mEq/L
2.0 t o <2.5 mmolL2.0 mEq/L
<2.0 mmolL
Hyperkalemia 
Adult and Pediatric
1 Year5.6 to 6.0 mEq/L
5.6 to 6.0 mmol/L6.0 to 6.5 mEq/L
6.0 to 6.5 mmol /L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0 mEq/L
7.0 mmol/L
Infant <1 Year >ULN to 6.0 mEq/L
>ULN to 6.0 mmol/L> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol /L7.0 mEq/L
7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1Month55 to 64 mg/dL
3.03 to 3.58 mmol/L40 to 55mg/d L
2.20 to 3.03 mmol/L30 to 40mg/d L
1.64 to 2.20 mmol/L30 mg/dL
1.64 mmol/L
Infant, 1Month 50 to 54 mg/dL
2.8 to 3.0 mmol/L40 to 50mg/d L
2.2 to 2.8mmol/L30 to 40mg/d L
1.7 to 2.2mmol/L30 mg/dL
1.7 mmol/L
Hyperglycemia, Nonfasting 116to 160 mg/dL 160 to 250 mg/dL 250 to 500 mg/dL 500 mg/dL
6.42 to 8.91 mmol/L 8.91 to 13.90 mmol/L 13.90 to 27.79 mmol/L 27.79 mmol/L
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 mmol/L>250 to 500 mg/dL
>13.90 to 27.79 mmol/L>500 mg/dL
>27.79 mmol/L
Hypocalcemia 
(corrected for albumin if 
appropriate* )
Adult and Pediatric
2 Years7.8 <LLN mg/dL
1.94 to <LLN mmo l/L7.0 to 7.8 mg/dL
1.74 to 1.94 mmol/L6.1 to 7.0mg/dL
1.51 to 1.74 mmol/L6.1mg/d L
1.51 mmol/L
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 110 16 January 20 19CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Pediatric ≥7 days -2 Years 7.8 to 8.4 mg/dL
1.94 to 2.10 mmol/L7.0 to <7.8 mg/dL
1.74 to <1.94 mmolL6.1 to <7.0 mg/dL
1.51 to < 1.74 mmolL< 6.1 mg/d L
< 1.51 mmol/L
Infant, 7Days 6.5 to 7.5 mg/dL
1.61 to 1.88 mmol/L6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected 
for albumin if appropriate* )
Adult and Pediatric 
7Days>ULN to 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5 mg/dL
>ULN to 2.88 mmol/L 2.88 to 3.13 mmol/L 3.13 to 3.38 mmol/L 3.38 mmol/L
Infant, 7Days 11.5 to 12.4 mg/dL
2.86 to 3.10 mmol/L12.4 to 12.9 mg/dL
> 3.10 to 3.23 mmol/L12.9 to 13.5 mg/dL
> 3.23 to 3.38 mmol/L13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized) 3.0 mg/dL to LLN 2.5 to < 3.0 mg/dL 2.0 to 2.5 mg/dL 2.0 mg/dL
0.74 mmol/L to LLN 0.62 to 0.74 mmol/L 0.49 to 0.62 mmol/L 0.49 mmol/L
Hypercalcemia (ionized) ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0 mg/dL
ULN to 1.50 mmol/L 1.50 to 1.63 mmol/L 1.63 to 1.75 mmol/L 1.75 mmol/L
Hypomagnesemia 1.40 to <LLN mg/dL
1.2 to <LLN mEq/L1.04 to 1.40 mg/d L
0.9 to 1.2 mEq/L0.67 to 1.04 mg/dL
0.6 to 0.9 mEq/L0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmo l/L 0.43 to 0.58 mmol/L 0.28 to 0.43 mmol/L 0.28 mmol/L
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL
0.63 to LLN mmol/L1.5 to 2.0 mg/dL
0.47 to 0.63 mmol/L1.0 to 1.5 mg/dL
0.31 to 0.47 mmol/L1.0 mg/dL
0.31 mmol/L
Pediatric 1 Year– 14 Years 3.0 to <LLN mg/dL
0.96 to <LLN mmo l/L2.5 to 3.0 mg/dL
0.80 to < 0.96 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Pediatric 1Year 3.5 to <LLN mg/dL
1.12 to <LLN mmo l/L2.5 to 3.5mg/dL
0.80 to < 1.12 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 111 16 January 20 19CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyperbilirubinemia 
Adult and Pediatric 
>14Days1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN 
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0 mg/dL
> 513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Hyperuricemia >ULN to 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0 mg/dL
>ULN to 597 μmol/L 597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
Hypouricemia
Adult and Pediatric
≥ 1 year
Infant < 1 Year1.5 mg/dL to LLN
87 μmol/L to LLN1.0 to 1.5 mg/dL
57 to 87 μmol/L0.5 to 1.0 mg/dL
27 to 57 μmol/L0.5 mg/dL
27 μmol/L
N/A 1.0 mg/dl to <LLN -
57 μmol to <LLN0.5 to 1.0 mg/dL
27 to 57 μmol/L0.5 mg/dL
27 μmol/L
Creatinine** 1.50to 2.00 mg/dL
133to 177μmol/L2.00to 3.00 mg/dL
177to 26 5 μmol/L3.00 to 6. 00 mg/dL 
265to 530 μmol/L6.00 mg/dL
530 μ mol/L
Bicarbonate
Adult and Pediatric 
≥ 4 Years16.0 mEq/L to LLN 11.0 to 16.0 mEq/L 8.0 to 11.0 mEq/L 8.0 mEq/L
16.0 mmol/L to LLN 11.0 to 16.0 mmol/L 8.0 to 11.0 mmol/L 8.0 mmol/L
Pediatric < 4 Years NA 11.0 mEq /Lto <LLN 8.0 to 11.0 mEq/L 8.0 mEq/L
11.0 mmol/L to <LLN 8.0 to 11.0 mmol/L 8.0 mmol/L
Triglycerides
(Fasting)NA 500 to 750 mg/dL
5.64–8.47 mmol/L750 to 1200 mg/dL
8.47–13.55 mmol/L1200 mg/dL
13.55 mmol/L
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 112 16 January 20 19CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
LDL (Fasting)
Adult130 to 160 mg/dL >160 to 190 mg/dL > 190 mg/dL NA
3.35 to 4.15 mmol/L >4.15 to 4.92 mmol/L >4.92 mmol/L
LDL (Fasting)
Pediatric >2 to <18 years110 to 130 mg/dL >130 to 190 mg/dL > 190 mg/dL NA
2.84 to 3.37 mmol/L >3.37 to 4.92 mmol/L >4.92 mmol/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300 mg/dL NA
5.16 to 6.19 mmol/L 6.19 to 7.77 mmol/L 7.77 mmol/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/dL
5.15 to 7.77 mmol/L300 mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to 6.0 ULN 6.0 to 10.0 ULN 10.0 to 20.0 ULN 20.0 ULN
* Calcium should be corrected for albumin if albumin is < 4.0 g/dL
** An overlap between the Grade 1 scale and the Lab’s normal range for creatinine may res ult for Male subjects >70 yrs. Please follow the Gilead convention of grading any 
result within the LLN and ULN a 0.
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 113 16 January 20 19ENZYMES
Grade 1 Grade 2 Grade 3 Grade 4
AST (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
GGT 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin
Pediatrics <16 years 
≥ 16 years- 2.0 to LLN g/dL
20 to LLN g/L2.0 g/dL
20 g/LNA
3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 114 16 January 20 19URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hem aturia (Dipstick) 1 2 3-4+ NA
Hem aturia (Quantitative) 
See Note below
                              Females >ULN -10RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
                              Males 6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years200 to999 mg/24 h >999 to 1999 mg/24 h >1999 to3500 mg/24 h 3500 mg/24 h
Pediatric 3 Mo to 
<10Years201 to499 mg/m2/24h >499 to799 mg/m2/24 h >799 to1000 mg/m2/24 h 1000 mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Note s: 
 Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratorie s, toxicity grades will only be assigned to 
Dipstick Hematuria.
 With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigne d Grade 0.
 If the severity of a clinical AE could fall under either one of two grades (e.g., the se verity of an AE could be either Grade 2 or Grade 3 ), select the higher of the two grades for 
the AE.
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 115 16 January 20 19CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac Arrhythmia (general)
(By ECG or physical exam)Asymptomatic AND No 
intervention indicatedAsymptomatic AND Non -
urgent medical intervention 
indicatedSymptomatic, non -life-
threatening AND Non -
urgent medical intervention 
indicated Life-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac- ischemia/Infarction NA NA Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia Unstable angina OR Acute 
myocardial infarction
Hem orrhage (significant acute 
blood loss)NA Symptomatic AND No 
transfusion indicatedSymptomatic AND 
Transfusion of 2units 
packed RBCs (for children 
10cc/kg) indicated Life-threatening hypotension 
OR Transfusion of 2units 
packed RBCs indicated (for 
children 10cc/kg) indicated
Hypertension (with repeat 
testing at same visit)140– 159mmH g systolic 
OR 
90–99 mmHg diastolic159–179 mmHg systolic 
OR 
99–109 mmHg diastolic179mmHg systolic 
OR 
109mmHg diastolicLife-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization (other than 
ER visit) indicated
Pediatric 17Years (with 
repeat testing at same visit)NA 91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)Life-threatening consequences 
(eg, malignant hypertens ion) 
OR Hospitalization indicated 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial Effusion Asymptomatic, small 
effusion requiring no 
interventionAsymptomatic, moderate or 
larger effusion requiring no 
interventionEffusion with non -life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicatedLife-threatening consequences 
(eg, tamponade) OR Urgent 
intervention indicated
Prolonged PR Interval PR interval 
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV 
block OR Ventricular pause 
3.0 secCom plete AV block 
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 116 16 January 20 19CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Pediatric 16 Years 1st degree AV block
(PR > normal for age and 
rate)Type I 2nd degree AV block Type II 2nd degree AV 
block Com plete AV block
Prolonged QTc Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baselineAsymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baselineAsymptomatic, QTc interval 
0.50 sec OR Increase in 
interval 0.06 sec above 
baselineLife-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ven tricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc interval 
0.450 to 0.464 sec Asymptomatic, QTc interval 
0.465 to 0.479 sec Asymptomatic, QTc interval 
0.480 sec Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism NA Deep vein thrombosis AND 
No intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) Deep vein thrombosis AND 
Intervention indicated (eg , 
anticoagulation, lysis filter, 
invasive procedure) Embolic event (eg, pulmonary 
embolism, life -threatening 
thrombus) 
Vasovagal Episode (associated 
with a procedure of any kind)Present without loss of 
consciousness Present with transient loss of 
consciousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew  onset with symptoms 
OR Worsening symptomatic 
CHFLife-threatening CHF
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 117 16 January 20 19RESPIRATORY
Grade 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced to 
70% to 80%FEV1 or peak flow  50% to 69% FEV1 or peak flow  25% to 
49% Cyanosis OR FEV1 or peak flow  
25% OR Intubation
Dyspnea or Respiratory 
DistressDyspnea on exertion with no 
or minimal interference with 
usual social & functional 
activities Dyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activities Dyspnea at rest causing 
inability to perform usual 
social & functional activities Respiratory failure with 
ventilatory support indicated
Pediatric 14 Years Wheezing OR minimal 
increase in respiratory rate for 
ageNasal flaring OR Intercostal 
retractions OR Pulse oximetry 
90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%Respiratory failure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis OR 
Medical intervention indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in affected 
eye(s) 
Visual Changes (from 
baseline)Visual changes causing no or 
minimal interference with 
usual social & functional 
activitiesVisual changes causing greater 
than minimal interference with 
usual social & functional 
activitiesVisual changes causing 
inability to perform usual 
social & functional activitiesDisabling visual loss in affected 
eye(s)
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 118 16 January 20 19SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by 
study participant or 
caregiver (for disabled 
adults)Thinning or patchy hair loss 
detectable by health care 
providerCom plete hair loss NA
Cutaneous Reaction –Rash Localized macular rash Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions Diffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one siteExtensive or generalized 
bullous lesions OR 
Stevens -Johnson syndrome 
OR Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Toxic epidermal 
necrolysis (TEN)
Hyperpigmentation Slight or localized Marked or generalized NA NA
Hypopigmentation Slight or localized Marked or generalized NA NA
Pruritis (itching –no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)Itching causing no or 
minimal interference with 
usual social & functional 
activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing inability to 
perform usual social & 
functional activities NA
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 119 16 January 20 19GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetite w ithout 
decreased oral intakeLoss of appetite associated with 
decreased oral intake without 
significant weight loss Loss of appetite associated 
with significant weight loss Life-threatening consequences 
OR Aggressive intervention 
indicated [eg, tube feeding or 
total parenteral nutrition]
Ascites Asymptomatic Symptomatic AND Intervention 
indicated (eg, diuretics or 
therapeutic paracentesis)Symptomatic despite 
interventionLife-threatening consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening consequences 
(eg, sepsis or perforation) 
Constipation NA Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or 
enemas Obstipation with manual 
evacuation indicatedLife-threatening consequences 
(eg, obstruction)
Diarrhea 
Adult and Pediatric 
1YearTransient or intermittent 
episodes of unformed stools 
OR Increase of 3stools 
over baseline/24 hrPersistent episodes of unformed 
to watery stools OR Increase of 
4–6 stools over baseline per 
24hrs. Bloody diarrhea OR Increase 
of 7stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening consequences 
(eg, hypotensive shock)
Pediatric 1Year Liquid stools (more 
unformed than usual) but 
usual number of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive r ehydration 
indicated OR Hypotensive 
shock
Dysphagia -Odynophagia Symptomatic but able to eat 
usual dietSymptoms causing altered 
dietary intake without medical 
intervention indicatedSymptoms causing severely 
altered dietary intake with 
medical intervention indicatedLife-threatening reduction in 
oral intake
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 120 16 January 20 19GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, 
Dysphagia -OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerations Confluent pseudomembranes
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life -threatening 
consequences (eg, aspiration, 
choking)
Nausea Transient ( 24hours) or 
intermittent nausea with no 
or minimal interference with 
oral intakePersistent nausea resulting in 
decreased oral intake for 24 –48 
hoursPersistent nausea resulting in 
minimal oral intake for  48 
hours OR Aggressive 
rehydration indicated (eg, 
IVfluids)Life-threatening consequences 
(eg, hypotensive shock )
Pancreatitis NA Symptomatic AND 
Hospitalization not indicated 
(other than ER visit)Symptomatic AND 
Hospitalization indicated 
(other than ER visit)Life-threatening consequences 
(eg, sepsis, circulatory failure, 
hemorrhage)
Proctitis (functional-
symptomatic)
Also see Mucositis/ 
Stomatitis for Clinical 
ExamRectal discomfort AND No 
intervention indicatedSymptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicated Symp toms causing inability to 
perform usual social/ 
functional activities OR 
Operative intervention 
indicated Life-threatening consequences 
(eg, perforation)
Vom iting Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intakeFrequent episodes of vomiting 
with no or mild dehydrationPersistent vomiting resulting 
in orthostatic hypotension OR 
Aggressive rehydration 
indicatedLife-threatening consequences 
(eg, hypotensive shock)
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 121 16 January 20 19NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in Personality -
Behavior or in Mood (eg, 
agitation, anxiety, 
depression, mania, 
psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activities Alteration causing greater than 
minimal interference with 
usual so cial & functional 
activities Alteration causing inability to 
perform usual social & 
functional activities Behavior potentially harmful 
to self or others (eg, 
suicidal/homicidal ideation or 
attempt, acute psychosis) OR 
Causing inability to perform 
basic s elf-care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activitiesConfusion, memory 
impairm ent, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, OR 
coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usual 
social & functional activities Disabling ataxia causing 
inability to perform basic self -
care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) Disability cau sing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicatedDisability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part -time basis 
indicatedDisability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability to 
perform basic self -care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate 
for the setting Moderate developmental 
delay, either motor or 
cognitive, as determined by 
comparison with a 
developmental screening tool 
appropriate for the setting Severe developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting Developmental regression, 
either motor or cognitive, as 
determined b y comparison 
with a developmental 
screening tool appropriate for 
the setting
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 122 16 January 20 19NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference with 
usual social & functional 
activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesSymptoms causing inability to 
perform basic self -care 
functions OR Hospitalization 
indicated (other than ER visit) 
OR Headache with significant 
impairm ent of alertness or
other neurologic function 
Insomnia NA Difficulty sleeping causing 
greater than minimal 
interference with usual 
social/functional activitiesDifficulty sleeping causing 
inability to perform usual 
social & functional activitiesDisabling insomnia causing 
inability to perform basic self -
care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak -
ness causing no or minimal 
interference with usual 
social & functional activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perform usual 
social & functional activities Disabling muscle weakness 
causing inability to perform 
basic self -care f unctions OR 
Respiratory muscle weakness 
impairing ventilation
Neurosensory Alteration 
(including paresthesia and 
painful neuropathy)Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social &
functional activities Sensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activities Sensory alteration or 
paresthesia causing inability to 
perform usual social & 
functional activitiesDisabling sensory alteration or 
paresthesia causing inability to 
perform basic self -care 
functions
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are 
prolonged, repetitive (eg, 
status epilepticus), or difficult 
to control (eg, refractory 
epilepsy)
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 123 16 January 20 19NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (pre- existing) 
For Worsening of Existing 
Epilepsy the Grades Should 
Be Based on an Increase 
from Previous Level of 
Control to Any of These 
LevelsNA Increased frequency of pre-
existing seizures (non -
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorderChange in seizure character 
from baseline either in 
duration or quality (eg, 
severity or focality) Seizures of any kind that are 
prolonged, repetitive (eg, 
status epilepticus), or difficult 
to control (eg, refractory 
epilepsy)
Seizure 
–Pediatric 18 YearsSeizure, generalized onset 
with or without secondary 
generalization, lasting 
< 5minutes with < 24hours 
post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 5 –20 
minutes with 
< 24 hours post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes Seizure, generalized onset 
with or witho ut secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)NA Present NA NA
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activities Vertigo causing inability to 
perform usual social & 
functional activitiesDisabling vertigo causing 
inability to perform basic self -
care functions
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 124 16 January 20 19MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causing greater than 
minimal interference with usual 
social & functional activitiesJoint pain causing inability 
to perform usual social & 
functional activitiesDisabling joint pain causing 
inability to perform basic self -
care functions
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual 
social & functional activitiesStiffness or joint sw elling causing 
greater than minimal interference 
with usual social & functional 
activitiesStiffness or joint sw elling 
causing inability to perform 
usual social & functional 
activi tiesDisabling joint stiffness or 
swelling causing inability to 
perform basic self -care 
functions
Bone Mineral Loss BMD t -score or z- score
–2.5 to –1.0 BMD t -score or z- score –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Pediatric 21Years BMD z -score 
–2.5 to –1.0BMD z -score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater than 
minimal interference with usual 
social & functional activitiesMuscle pain causing 
inability to perform usual 
social & functional activitiesDisabling muscle pain causing 
inability to perform basic self -
care functions
Osteonecrosis NA Asymptomatic with radiographic 
findings AND No operative 
intervention indicatedSymptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicatedDisabling bone pain with 
radiographic findings causing 
inability to perform basic self -
care functions
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 125 16 January 20 19SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
Reaction Localized urticaria
(wheals) with no medical 
intervention indicatedLocalized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasmAcute anaphylaxis OR Life -
threatening bronchospasm OR 
laryngeal edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activities Symptoms causing inability to 
perform usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesIncapacitating fatigue/malaise 
symptoms causing inability to 
perform basic self -care 
functions
Fever (nonaxillary) 37.7C to 38.6 C
99.8Fto 101.5 F38.7C to 39.3 C
101.6 F to 102.8 F39.4C to 40.5 C
102.9 F to 104.9 F40.5C 
104.9 F
Pain-Indicate Body Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and MyalgiaPain causing no or 
minimal interference with 
usual social & functional 
activitiesPain causing greater than minimal 
interference with usual social & 
functional activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic self -
care functions OR 
Hospitalization (other than ER 
visit) indicated
Unintentional Weight 
LossNA 5% to 9% loss in body weight from 
baseline10% to 19% loss in body 
weight from baseline20% loss i n body weight 
from baseline OR Aggressive 
intervention indicated [eg, 
tube feeding or total parenteral 
nutrition]
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 126 16 January 20 19INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site Pain (pain 
without touching)
Or Tenderness (pain when 
area is touched) Pain/tenderness causing no 
or minimal limitation of use 
of limbPain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activitiesPain/tenderness causing 
inability to perform usual 
social & functional activitiesPain/tenderness causing inability
to perform basic self -care 
function OR Hospitalization 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15YearsErythema OR Induration
of 55cm to 9 9cm (or 
2581 cm2)Erythema OR Induration OR 
Edema 9cm any diameter 
(or 81cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (involving dermis and 
deeper tissue)
Pediatric 15Years Erythem a OR Induration 
OR Edema present but 
2.5cm diameterErythem a OR Induration 
OR Edema > 2.5cm 
diameter but < 50% surface 
area of the extrem ity 
segment (eg, upper 
arm/thigh)Erythem a OR Induration 
OR Edema involving 
50% surface area of the 
extremity segment (eg, 
upper arm/thigh) OR 
Ulcerat ion OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR 
DrainageNecrosis (involving dermis and 
deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching —no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 
48h treatment Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48h treatment Generalized itching causing 
inability to perfo rm usual 
social & functional activitiesNA
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 127 16 January 20 19ENDOCRINE/METABOLIC
Grade 1 Grade 2 Grade 3 Grade 4
Lipodystrophy (eg, back 
of neck, breasts, 
abdomen)Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious 
changes on casual visual 
inspectionNA
Diabetes Mellitus NA New  onset without need to initiate 
medication OR Modification of 
current meds to regain glucose 
controlNew  onset with initiation of 
indicated med OR Diabetes 
uncontrolled despite treatment 
modificationLife-threatening consequences 
(eg, ketoacidosis, 
hyperosmolar non -ketotic 
coma) 
Gynecomastia Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
Hyperthyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification Life-threatening consequences 
(eg, thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification Life-threatening consequences 
(eg, myxedema coma)
Lipoatrophy (eg, fat loss 
from the face, extremities, 
buttocks)Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 128 16 January 20 19GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding 
(IMB)Spotting observed by participant 
OR Minimal blood observed 
during clinical or colposcopic 
examIntermenstrual bleeding not 
greater in duration or amount 
than usual menstrual cycleIntermenstrual bleeding greater 
in duration or amount than usual 
menstrual cycleHem orrhage with life -
threatening hypotension OR 
Operative intervention 
indicated
Urinary Tract 
obstruction (eg, stone)NA Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunctionSigns or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing life -
threatening consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any other 
than HIV infection)Localized, no systemic antiμbial 
treatment indicated AND 
Symptoms causing no or 
minimal interference with usual 
social & functional activitiesSystemic antiμbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional activitiesSystemic antiμbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
interven tion (other than simple 
incision and drainage) indicatedLife-threatening 
consequences (eg, septic 
shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transportation, pursuing a hobby, e tc.
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 129 16 January 2019Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)
Pregnancy and Contraception Requirements for Males and Females of Childbearing 
Potential
The risks of treatment with GS-9620 during pregnancy  have not been evaluated in humans .
Please refer to the latest version of the investigator’s brochure for G S -9620 for the treatment of 
chronic hepatitis B virus and HIV -1 infection for additional informat ion. 
2)Definition of Female of Childbearing Potential
For the purposes of this study , a female subject of childbearing potential is a nonmenopausal
female who has not had a hy sterectom y, bilateral oophorectom y, or medically documented
ovarian failure. This definition includes a pubertal female who has not yet started menstruating. 
A woman who has had a tubal sterilization is considered to be of childbearing potential.
A female subject may  be considered menopausal in either of the following conditions:
Surgic al menopause: Appropriate medical documentation of prior complete bilateral
oophorectom y (ie, surgical removal of the ovaries and occurring at the age at which the
procedure was performed)
Spontaneous menopause: Permanent cessation of previously  occurring menses as a result of 
ovarian failure with documentation of hormonal deficiency  by a certified health care
provider. The worldwide mean age of spontaneo us menopause is 49.24 (SD1.73) years
A hormonal deficiency  should be properl y documented in the case of suspected spontaneous 
menopause as follows:
If age ≥54 years and with the absence of normal menses: serum follicle stimulating
hormone (FSH) level elevated to within the postmenopausal range based on the
laboratory  reference range where the hormonal assay is performed
If age <54 years and with the absence of normal menses: negative serum or urine 
human chorionic gonadotropin (hCG) with concurrently  elevated serum FSH level in the
postmenopausal range, depressed estradiol (E2) level in the postmenopausal ra nge, and
absent serum progesterone level, based on the laboratory  reference ranges where the
hormonal assay s are performed
3)Contraceptive Requirements
Male subjects and female subjects of childbearing potential who engage in heterosexual
intercourse must agree to utilize protocol specified methods of contraception from the 
screening/enrollment visit throughout the study  period and for 36days following the last dose of 
study  drug. Female stud y subjects who are not heterosexually active must provide periodi c 
confirmation of continued abstinence from heterosexual intercourse and regular pregnancy  
testing while taking GS -9620 or placebo. The investigator will counsel subjects on the protocol
specified method(s) for avoiding pregnancy  in case the subject choose s to engage in heterosexual 
intercourse.
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 130 16 January 2019Protocol specified contraceptive methods are as follows: (1) a combination of one hormonal
method and one barrier method; or (2) use of an intrauterine device (IUD) or tubal sterilization; 
seeAppendix Table 1. Acceptable hormonal methods include injectable progesterone, 
progesterone implants, combination oral contraceptives, transdermal contraceptive patch, and 
vaginal ring. A
n acceptable barrier method is the male condom. Female subjects must use a 
hormonal method if the partner has a vasectom y. If a subject has undergone tubal sterilization or
has had a Copper T 380A IUD or LNg 20 IUD inserted, no other contraception is needed .
If tubal sterilization is via the Essure procedure, verification of tubal blockage b y
hysterosalpingogram (HSP) must be performed approximately  3 months after microinsertion.
Prior to verification, Essure is not considered a reliable form of contraceptio n and the
contraception methods described below must be used. Female subjects who utilize hormonal
contraceptives as one of their birth control methods must have used the same method for at least 
3months before stud y dosing.
Female subjects of childbearin g potential must have a negative serum pregnancy  test at screening 
and a negative urine pregnancy  test at baseline (Day  1) prior to receiving the first dose of stud y 
drug. Lactating females must discontinue nursing before IMP administration.
Appendix Table 1. Protocol Specified Contraceptive Methods
Single Methods Combination Methods
Intrauterine Devices (IUDs)
Copper T 380A IUD
LNg 20 IUD
Tubal SterilizationEstrogen and Progesterone plus Barrier
Com bined oral contraceptives plus condom *
Transdermal patch plus condom *
Vaginal ring plus condom *
Implant plus condom *
Injection plus condom *
Partner’s vasectomy must be used w ith a hormon al method .
* (without spermicide and excluding lambskin)
The investigator will counsel all subjects on the most effective method(s) for avoiding pregnancy  
during the stud y. 
4)Additional Requirements for Male Subjects and Recommendations for Partners of 
Female Subjects
Male subjects must agree to use condoms (without spermicide and excluding lambskin) during 
heterosexual intercourse and avoid sperm donation while enrolled in the study  and for at least 
90days after administration of the last dose of study  drug .Partners of female subjects should be 
encouraged to us e condoms during heterosexual intercourse while enrolled in the study .
Use of condoms, with or without spermicide, has been proven to decrease the risk of
transmission of HIV and other sexually  transmitted diseases. The use of spermicide is not
recommended if the subject or subject’s partner is infected with HIV.
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 131 16 January 20195) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study , or if they  become pregnant within 30 days or 4 weeks of last study  drug dose. Subjects 
who become pregnant or who suspect that they  are pregnant during the study must report the 
information to the investigator and discontinue study  drug immediatel y.Subjects whose partner 
has become pregnant or suspects she is pregnant during the stud ymust report the information to 
the investigator. Instructions for reporting pregnancy , partner pregnancy , and pregnancy outcome 
are outlined in Section 7.7.2.1 .
GS-9620
Protocol GS –US-382-1450 Final
Gilead Sciences, Inc. Amendment 7
CONFIDENTIAL Page 132 16 January 2019Appendix 6. Definitions of Stage 3 Opportunistic Illnesses in HIV
(CDC Guidelines)
Candidiasis of bronchi, trachea, or lungs
Candidiasis of esophagus
Cervical canc er, invasive
Coccidioidomy cosis, disseminated or extrapulmonary
Cryptococcosis, extrapulmonary
Cryptosporidiosis, chronic intestinal ( 1month duration)
Cytomegalovirus disease (other than liver, spleen or nodes)
Cytomegalovirus retinitis (with loss of vi sion)
Encephalopath y, HIV-related
Herpes simplex: chronic ulcer(s) ( 1month duration); or bronchitis, pneumonitis or 
esophagitis
Histoplasmosis, disseminated or extrapulmonary
Isosporiasis, chronic intestinal ( 1month duration)
Kaposi’s sarcoma
Lym phom a, Burkitt’s (or equivalent term)
Lym phoma, immunoblastic (or equivalent term)
Lym phoma, primary , of brain
Mycobacterium avium complex or Myobacterium kansasii , disseminated or extrapulmonary
Mycobacterium tuberculosis , of any  site, pulmonary , disseminated or extrapulmonary
Mycobacterium , other species or unidentified species, disseminated or extrapulmonary
Pneumocy stis jirovecii (previously  known as “ Pneumocystis carinii ) pneumonia
Pneumonia, recurrent
Progressive multifocal leukoencephalopathy
Salmonella septicemia, recurrent
Toxoplasmosis of brain
Wasting sy ndrome attributed to HIV infection
CDC Stage -3-Defining Opportunistic I llnesses in HIV Infection - 2014 {Schneider 2008}